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Summary
v

T cells recognize a broad variety of antigens, including peptides, lipids and non-peptidic phos-
phorylated metabolites. Clarification of the rules rendering non-peptidic molecules immunogenic
is essential to understand and to influence the reactions of the immune system to this class of
substances in health and disease. Despite recent advances in research about immune responses
to non-peptidic compounds, important issues remain unanswered. Molecular mechanisms gov-
erning the immunogenicity of non-peptidic ligands such as their cell internalization, trafficking
within intracellular organelles, association with dedicated antigen-presenting molecules, induc-
tion of central and peripheral tolerance, and finally their role in autoimmune diseases as well as
in protection during infections are unknown to date.
The aims of this thesis were to assess some of the immunological functions and cell biological
rules governing the immunogenicity of non-peptidic antigens, with particular emphasis on cell
trafficking of non-peptidic antigens and antigen-presenting molecules. It focused on (i) the anti-
gen reactivity and presence of human invariant natural killer T (iNKT) cells in diseases, (ii) the
role of CD1a trafficking in lipid antigen presentation by this protein, and (iii) the requirements
of membrane translocation of phosphorylated mevalonate metabolites that stimulate human T
cell receptor (TCR) γδ cells.
With the development of alpha-galactosylceramide (αGC)-loaded soluble CD1d dimers, which
specifically interact with the TCR of iNKT cells, we have the perfect tool in our hands to perform
detailed studies on iNKT cells. Analysis of the iNKT cells in blood unveiled large differences
in their fluorescence intensity suggesting the presence of semi-invariant iNKT TCR with large
disparities in the affinity for the αGC-CD1d complex. Unexpectedly, established iNKT cell
clones showed no correlation between CD1d dimer-staining levels and αGC reactivity, indicat-
ing that additional mechanisms control responsiveness of iNKT cells, at least to this lipid antigen.
The identification of lipid antigens stimulating exclusively some desired functions in human
iNKT cells might lead to new medical therapies or vaccines. To screen a variety of synthetic
lipids for their capacity to activate iNKT cells, we devised an in vitro model based on plastic-
bound CD1d. Piperidinones, molecules with a ceramide- or sphingosine-like structure, revealed
that a single lipid tail is sufficient to form stimulatory complexes with CD1d. Interestingly,
piperidinones preferentially induce TH1-like cytokines, predicting a possible role as novel leader
molecules to functionally direct iNKT cell responses deployable in clinical therapies.
The balance of proinflammatory TH1 to regulatory TH2 cytokines is well-known to be decisive
for the outcome of many diseases. Atherosclerosis (ATH) is a chronic inflammatory disease char-
acterized by lipid accumulation in plaques. The disease is complicated by cardiovascular events
provoked by plaque rupture or erosion. Because inflammation participates in lesion progression
and rupture of plaques, the identification of its causes and of the culprit leukocyte populations
involved in plaque destabilization is crucial for effective prevention of cardiovascular events. We
used CD1d dimers to detect and characterize iNKT cells in ATH patients. We found that, in
human atherosclerotic lesions, the abundance of CD1d+ antigen-presenting cells (APC) and of
iNKT cells correlates with disease severity and activity. CD1d+ cells colonize advanced plaques
in symptomatic patients and are most abundant in plaques with concomitant signs of ectopic
neovascularization. In plaques, the frequency of iNKT cells among total T cells exceeds the
one in blood. After having successfully isolated iNKT cell lines from plaque tissue, we showed
that they promptly release proinflammatory cytokines upon lipid antigen stimulation and pro-
mote endothelial cell migration and microvascular sprout formation in vitro. This functional
proangiogenic activity is ascribed to interleukin-8 released by iNKT cells after lipid recognition.
These findings introduce iNKT cells as novel candidates to induce plaque neovascularization and
destabilization in human ATH. Targeting iNKT cells could lead to late stage ATH treatment.
vii
Another approach to understand the role of lipid-specific immune responses is to investigate
the molecular rules of lipid-CD1 complex formation. Lipids distribute, due to their physicochem-
ical properties or with the help of specific transporters and lipid transfer proteins, to different
intracellular compartments and membrane domains. Thus, it is advantageous for the immune
system to utilize multiple CD1 isoforms, each with a distinct trafficking pattern, to facilitate
sampling of lipid antigens localized in various membranes. Several studies have addressed traf-
ficking of CD1 isoforms. However, the molecular mechanisms are known in only a few cases.
We identified invariant chain (Ii) and lipid rafts as key regulators of CD1a organization on the
surface of APC and of its immunological function as antigen-presenting molecule. Colocalization
of CD1a with Ii is dependent on raft integrity and CD1a internalization is increased by Ii.
The localization of CD1a in lipid rafts is functionally relevant as raft disruption inhibits CD1a-
restricted antigen presentation.
Moreover, we found that CD1a is internalized independently of clathrin and dynamin and that
it follows a Rab22a- and adenosine diphosphate ribosylation factor (ARF) 6-dependent recycling
pathway, similar to other clathrin-independent cargo. Posttranslational S-acylation of the CD1a
cytoplasmic tail may occur but neither determines the rate of internalization nor recycling nor
its localization to detergent-resistant membrane microdomains. These findings place CD1a close
to major histocompatibility complex (MHC) class I in its trafficking routes although CD1a loads
lipids in recycling endosomes and not in the endoplasmic reticulum as MHC class I.
Strikingly, the glycolipid antigen sulfatide was found localized predominantly to early and re-
cycling endosomes where CD1a is located. Swapping the cytoplasmic tail of CD1a for the one of
CD1b and hence targeting the CD1a protein to the late endosomal and lysosomal compartments
decreases its capacity to present sulfatide and shortens the half-life of stimulatory complexes.
Thus, the physiological intracellular trafficking route of CD1a is critical for efficient presentation
of lipid antigens that traffic through the early endocytic and recycling pathways.
Intracellular trafficking of another class of non-peptidic antigens, namely the phosphorylated
metabolites which stimulate human TCR γδ cells expressing the Vγ9/Vδ2 heterodimer, was
examined. These T cells recognize a family of structurally related compounds produced in
the eukaryotic mevalonate and prokaryotic methylerythritol phosphate (MEP) pathways. The
endogenous self-ligands are generated within the cytoplasm and must cross the membrane in order
to associate with dedicated antigen-presenting molecules, which remain unknown at present.
Using an in vitro transport assay, we demonstrated that the multidrug resistance-associated
protein (MRP) 5 transporter is involved in membrane translocation of antigenic phosphorylated
metabolites. Confocal microscopy illustrated that MRP5 is located in membranes of both en-
doplasmic reticulum and early endosomes. Both the intracellular localization and active role in
antigen transport confer an immunological function to MRP5, resembling that of TAP (trans-
porter associated with antigen processing) transporters involved in peptide antigen translocation.
This indicates a similar strategy used for antigen presentation to TCR αβ and γδ T cells.
In conclusion, these studies have underlined the physiological relevance of T cells recogniz-
ing non-peptidic ligands and have revealed unanticipated molecular mechanisms controlling the
efficient presentation of such antigens.
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A Short History of Non-classical Immunology
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The scientific field examining the body’s defense or ‘immune’ (from medieval Latin immunis
meaning untouchable or tax-exempt) system is called immunology. It originated from microbi-
ology and medicine, especially from studies on the causes of immunity (resistance) to disease.
During the plague of Athens in 430 before Christ, Thucydides committed to writing the earliest
known mention of immunity in history. He noticed that persons having recovered from a previous
insult of the disease could nurse the sick without contracting the illness a second time.
More than a millennium later, in 1718, Lady Mary Wortley Montagu, the wife of the British
ambassador to Constantinople, observed the positive effects of variolation on the native Ottoman
population and had the technique performed on her own children. This is the first report, in her
“Turkish Embassy Letters”, of an archetype of a today’s vital immunological application namely
vaccination.
The principle of vaccination was first demonstrated in 1798 on the example of smallpox by
Edward Jenner. Since these first immunological trials on men the concept of immunology devel-
oped throughout the 19th and 20th centuries into a scientific theory. The work of Edward Jenner,
Jakob Henle, and Ignaz Semmelweis inspired the scientist of the first golden age of immunology
(1880-1910) to develop their theories. This era of Louis Pasteur, Robert Koch, Emil von Behring,
and Paul Ehrlich was boosted by the hunt for vaccines and thus immunology was closely linked
to microbiology.
Experiments with scorpion venom by Pierre-Louis Moreau de Maupertuis in the 18th century
where he observed that certain dogs and mice were immune to this venom and other observations
of acquired immunity were later exploited by Louis Pasteur in his development of vaccination and
his proposed germ theory of disease. Pasteur’s theory was in direct opposition to contemporary
theories of disease, such as the miasmatic theory (from Greek miasma meaning a noxious atmo-
sphere or influence). Only in 1981, when Robert Koch formulated his proofs, known as Koch’s
postulates and awarded a Nobel Prize in 1905, microorganisms were confirmed as a cause of
infectious diseases. Viruses were recognized as human pathogens in 1901 owing to the discovery
of the yellow fever virus by Walter Reed.
The second golden age of Immunology was preceded by and based on the discovery of antibodies
as by Paul Ehrlich (jointly awarded a Nobel Prize in 1908 with the founder of cellular immunology,
Elie Metchnikoff) who produced antibodies to the plant toxin ricin and formulated his side-chain
theory already around 1900 and by Jules Bordet who found antibodies to red blood cells. With
the proof by Karl Landsteiner that antibodies could be formed to recognize material that never
existed in nature, immunology was freed from its microbiology ties. Thus antibodies were the
advent of the second golden age of immunology (1955-1975) when nature’s defense of life began to
be unraveled. The second golden age initiated with the enunciation of the clonal selection theory
by Frank Macfarlane Burnet and peaked by the invention of the technique and the production
of the first monoclonal antibodies by Georges Köhler and César Milstein. Still it lasted till 1985
before the T cell receptor genes were identified. Slowly the dogma of the classical immune system
with its components (e.g. the innate and adaptive immunity) was built up.
In a protein world lipids were reduced to structural components of living matter mainly without
function especially in the sophisticated immune system. T cells specifically recognizing CD1
molecules were first described in 1989 [Porcelli et al. 1989] followed by further reports about alpha-
beta and gamma-delta T cells restricted to different CD1 molecules; still the antigen remained
elusive. Studies concluded that T cell responses to Mycobacterium tuberculosis were independent
of major histocompatibility complex molecules however they depended on CD1b expression by
antigen-presenting cells [Porcelli et al. 1992]. Nevertheless the nature of the antigen presented by
CD1 molecules was identified not until 1994 when mycolic acid from Mycobacterium tuberculosis
was proven the first lipid to be antigenic [Beckman et al. 1994]. Finally, when in 1997 the crystal
structure of the first CD1 (mouse CD1d1, corresponding to human CD1d) molecule was solved
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[Zeng et al. 1997], it revealed the mechanism by which lipids stimulate specific T cells.
In the last two decades non-classical components of the immune system were perceived and
during the very last decade started to be appreciated functionally [De Libero & Mori 2009 a].
To these components belong the CD1 molecules and the non-peptidic antigen-specific T cells.
In contrast to most classical components being highly polymorphic, the non-classical antigen-
presenting machinery seems to be less or even non-polymorphic. That fact is to open a whole
new world for vaccines and medical treatment because such a therapy could be applied to the
whole world’s population. Therefore clarification of how lipids become immunogenic and activate
T cells is crucial to guide and to influence the body’s defense mechanisms to its best by lipids
being designed for a desired function.
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Part I.
Introduction
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1. The immune system
The immune system of the body is built on three defense lines against infections and alterations
of self like cancer. The skin and other structural components of the body provide a first, physic-
ochemical barrier to invasion by pathogens and are able to isolate malignant cells in enclaves as
well as to exclaves. The second line of defense is provided by the innate immune system taking
immediate action whereas the third defense line, the adaptive immune system, is lagging few to
several days before the onset of a response.
Both the innate and the adaptive immune system contain so called humoral, acellular and cel-
lular integrants that depend on glycosylation [Arnold et al. 2007; Rudd et al. 2001]. Cells of the
innate system comprise macrophages and natural killer (NK) cells which rapidly kill their targets
upon encounter after engulfment or from outside, respectively. The complement system, a cas-
cade of proteins attacking invaders, is a major acellular innate defense mechanism and functions
in cooperation with antibodies mostly and most efficiently of the IgM subtype. In contrast to the
rather non-specific response of the innate, the adaptive immune system reacts highly specifically
by its major lymphocyte cells, the T and B cells. B cells originate from the bone marrow and
are the source of antibodies in the body. Conventional and unconventional T cells arise in the
thymus, where they are positively and negatively selected for their T cell receptor (TCR) to
establish restriction and avoid autoimmunity, respectively [Weinreich & Hogquist 2008]. Emigra-
tion from this developmental site is tightly controlled by molecules like the sphingolipid receptor
1 and the Krüppel-like transcription factor 2 [Carlson et al. 2006].
One major difference of the adaptive to the innate immune system is the establishment of
memory to react to a threat with high specificity in a faster manner - in hours rather than days
needed for a primary response. Memory is seen in the B and T cell-compartment [Mitchell 2008;
Rensing et al. 2009]. Nowadays, generation of memory is employed in medicine by vaccination
to protect humans before they get infected [Castellino et al. 2009].
Lately described unconventional T cells like the natural killer T (NKT) and γδ T cells seem to
phenotypically and functionally belong to both the innate and the adaptive immune system and
to be able to bridge between the two systems. These T cells are known to immediately respond
to pathogens and recently induction of glycolipid-specific memory T cells has been observed after
vaccination in cattle [Nguyen et al. 2009]. In combining the advantages of the innate and the
adaptive immune system by a fast and highly specific (memory) response, respectively, these cells
may be of crucial importance for the body’s immune defense. Still many aspects and mechanisms
by which these cells function are poorly understood and merit more scientific attention.
7

2. Non-peptidic molecules
2.1. Lipid evolution and repertoires
The abundance and diversity of lipids in microbes are not ignored by the immune system. Lipid-
reactive T cells complement and extend classical major histocompatibility complex (MHC)-
restricted peptide-specific T cells. The non-classical T cells provide the second, lipid-based arm
of the immune system that pathogens have to evade to be successful.
The lipidome of a single mammalian cell comprises more than a thousand different lipids [van
Meer 2005] and their mass equals the one of proteins in membranes. Most of them are built
by a polar head and hydrophobic tail(s). Their life-sustaining and thus most vital function for
a cell lies in a 3 nm hydrophobic boundary delimiting the environment. These membranes dy-
namically organize both across the lipid bilayer (lipid asymmetry) and in the lateral dimension
(lipid domains) [Somerharju et al. 2009]. Due to their intrinsic physical phase behavior and their
interactions with membrane proteins, they create unique compositions and multiple functionali-
ties of individual membranes of either compartments or even within a compartmental membrane
[van Meer et al. 2008].
By means of regulating anabolic and catabolic enzymes, of positioning translocases, and of
activating lipid transporters, cells can manipulate their lipidome. Cellular lipidomics [van Meer
2005] allocates a framework for understanding the role of lipids in time and space of a cell’s life.
Small genetic differences exist between higher mammalian species. Yet they are crucial and
the major known ones include the accumulation of subcutaneous fat, the growth of the brain
and the connectivity of neurons. All these achievements involve lipid metabolism, nevertheless
lipids are rarely mentioned in discussions about (human) evolution, because fat leaves no fossils
[Horrobin 1999]. Biochemistry of lipids and evolution are closely connected and will benefit from
recent advances in lipidomics even without historical traces.
The lipidomes of microbes can be similarly complex or relatively simple but have to fulfill the
same three general functions: energy storage, membrane matrix supply and signaling as first and
second messengers. Given the variety of lipids and their tightly regulated spatial and temporal
occurrence, it is not surprising that one can find lipids being specific for a cell or microbe or even
their (ephemeral) state (e.g. caused by viral infection or tumorigenesis). This fact is exploited
by the immune system to discriminate self from foreign or housekeeping from danger signals
emerging from the lipidome. Additionally, the discovery of new disease-related genes has proven
the importance of lipid-related proteins, such as lysosomal hydrolases, ATP-binding cassette
(ABC) transporters or lipid binding proteins in both lipid physiology [Kolter & Sandhoff 2009;
van Meer et al. 2008] and immune responses [De Libero & Mori 2006, 2009 a].
2.2. Lipid localization and metabolism
Glycerophospholipids (phosphatidylcholine, phosphatidylethanolamine, phosphatidylserine, phos-
phatidylinositol and phosphatidic acid) are the major structural lipids in eukaryotic membranes.
Their hydrophobic backbone is built of a diacylglycerol with saturated or cis-unsaturated fatty
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acyl chains of varying lengths. Another class of structural lipids are sphingolipids containing a
ceramide backbone [van Meer & Hoetzl 2009]. The major mammalian sphingolipids are sphin-
gomyelin and glycosphingolipids (mono-, di- or oligosaccharides) based on glucosylceramide and
occasionally galactosylceramide with saturated or trans-unsaturated acyl chains. Sterols provide
the majority of non-polar lipids of cell membranes with cholesterol predominating in mammals.
Hydrolysis of glycerolipids and sphingolipids is used to produce parallel series of messenger
lipids as lysophosphatidylcholine, lysophosphatidic acid, sphingosylphosphorylcholine, sphingo-
sine, and sphingosine-1-phosphate with only one aliphatic chain, that can readily leave mem-
branes and thereafter signal through related membrane receptors, and phosphatidic acid, dia-
cylglycerol, ceramide-1-phosphate, and ceramide, that remain in the membrane and can recruit
cytosolic proteins. Synthesis of structural lipids is spatially restricted inside eukaryotic cells.
Compartmentalized lipid metabolism is the first determinant of the unique local compositions
of organelles. When during evolution eukaryotes started to synthesize sphingolipids and sterols,
physical differences between these and the glycerophospholipids enabled cells to segregate lipids
within membranes. Secluding this event to a dedicated organelle, the Golgi, allowed creation of
membranes of different lipid composition, notably a thin, flexible endoplasmic reticulum (ER),
built of glycerolipids, and a robust plasma membrane containing at least 50% sphingolipids and
sterols. Besides sorting membrane proteins, sphingolipids obtained key positions in cell physiol-
ogy and signaling [van Meer & Hoetzl 2009].
The ER synthesizes the bulk of cellular lipids, structural (phospholipids and cholesterol) and
non-structural ones (triacylglycerol esters and the sphingolipid precursor ceramide). Specific
lipid biosynthetic enzymes are substantially enriched in mitochondria-associated membranes, a
ER subfraction, pointing to further subcompartmentalization of lipid synthesis in the ER. The
ER, situated at the beginning of the secretory pathway, displays low concentrations of sterols
and complex sphingolipids resulting in loose membrane packing. This permits efficient membrane
insertion and transport of newly synthesized lipids and proteins. The Golgi is specialized in sph-
ingolipid and glycosphingolipid synthesis, primarily destined for export to the plasma membrane.
The Golgi and its network constitute the logistic center of a cell, sorting lipids and proteins both
anterogradely and retrogradely. The production of sphingolipids may be linked to the vesicular
transport [Murphy et al. 2009; Zehmer et al. 2009] between different organelles through lipid
rafts. Secretory processes may be controlled by the local diacylglycerol levels that in turn are
regulated by the Golgi-specific cholinephosphotransferase. Plasma membranes, built to resist me-
chanical stress, are enriched in sphingolipids and sterols that grant packing at higher density than
glycerolipids. Even though the plasma membrane does not synthesize its own structural compo-
nents, it significantly participates in synthesis of total cellular sphingomyelin from ceramide by
a sphingomyelin synthase. The plasma membrane has important functions as mechanical bar-
rier and as signaling interface between intra- and extracellular space. Signaling involves many
lipid-synthesizing and -degrading reactions to drive the messenger cascades described for the
plasma membrane. Endosomal membranes of the endocytic pathway are similar to the plasma
membrane during their early stage, but upon maturation to late endosomes (LE) and internal
acidification, there is a decrease in sterols and phosphatidylserine versus a drastic increase in bis-
monoacylglycerophosphate. The latter works in multivesicular body formation, fusion processes
and sphingolipid hydrolysis. Differentially phosphorylated phosphoinositides identify endocytic
membranes and allow them to recruit cytosolic proteins involved in vesicle trafficking [Haucke
& Di Paolo 2007]. The overall amounts of signaling lipid mediators are negligible compared to
total membrane lipids, nevertheless they are crucial for cell functions. Topological and temporal
regulation of these signaling systems are largely unknown.
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Figure 2.1
Spatial lipid organization to form membrane asymmetry and domains. During the travel of
lipids from the endoplasmic reticulum through the Golgi, plasma membrane and endosomes,
intrinsic physicochemical properties and lipid transporters determine the phospholipid distribu-
tion across the bilayer leaflets. The ER membrane exhibits a widely symmetric lipid bilayer
due to intrinsic equilibration of phospholipids. In the Golgi, P4 ATPases (P4) translocate phos-
phatidylserine (PS) and phosphatidylethanolamine (PE) to the cytosolic side of the bilayer leaflet.
Sphingomyelin (SM) is formed by sphingomyelin synthase from ceramide (Cer) on the luminal
side. Neither phosphatidylcholine (PC) nor sphingomyelin are transported to the cytosolic face
but stay resident in the luminal leaflet. Asymmetry in the Golgi is achieved by specific transport
of phosphatidylserine and phosphatidylethanolamine as well as lack of transport of sphingomyelin
and phosphatidylcholine. During sphingomyelin synthesis, phosphatidylcholine is converted to
diacylglycerol (DAG), which freely diffuses across bilayers. Diacylglycerol can serve as a sub-
strate for the Golgi cholinephosphotransferase producing phosphatidylcholine. At the plasma
membrane, P4 ATPases transport phosphatidylserine and phosphatidylethanolamine to the cy-
tosolic face, with little or no transport of phosphatidylcholine or sphingomyelin under basal
conditions. This homeostatic equilibrium is sensitive to disruption by scramblase and/or by in-
hibition of P4 ATPases. Endosomes were shown to restrict phosphatidylcholine, sphingomyelin,
and glycosphingolipids (GSL) to the luminal leaflet without any specific transport mechanisms.
Adapted from [van Meer et al. 2008].
11
2. Non-peptidic molecules
Further organelles include multivesicular bodies, originating from inward budding of endo-
somes, and mitochondria, that have evolved from bacterial origin as they contain microbial
lipids [Griffiths 2007]. They synthesize large amounts of lipids like lysophosphatidic acid, phos-
phatidic acid, cardiolipin from phosphatidylglycerol, and phosphatidylethanolamine to be ex-
ported by decarboxylation of phosphatidylserine. Negatively charged lipids such as fatty acids,
phosphatidylglycerol, and phosphatidic acid can rapidly flip when their charge is neutralized by
low pH, but they can effectively be accumulated on one side of the membrane bilayer by a pH
gradient. In contrast to the ER bilayer, the Golgi, plasma, and endosomal membranes are asym-
metrically distributed with sphingomyelin and glycosphingolipids in the non-cytosolic (luminal)
leaflet and with phosphatidylserine and phosphatidylethanolamine in the cytosolic leaflet. This
asymmetrical distribution of lipids in membranes (see Figure 2.1, p.11) has important functional
consequences, in signaling, vesicule formation and traffic, and in keeping the identity of cellular
compartments. How this asymmetrical distribution impacts on lipid immunogenicity is not know
to date.
Translocation of lipids can occur by non-specific lipid transporters within membranes of high
phospholipid synthesis capacity. This transport appears to depend on membrane protein subset
and is adenosine triphosphate (ATP)-independent. This equilibration property is lost in non-ER
membranes of eukaryotes and in the outer membrane of prokaryotes, due to changes in lipid
and/or protein composition. On the other hand, glycolipid precursors for protein glycosylation
(oligosaccharides with a prenyldiphosphate backbone) are translocated from the cytosol across
the ER and the bacterial inner membranes by dedicated transporters.
Deletion of certain P4 ATPases not only affects lipid flipping from the non- to the cytosolic
hemileaflet but also blocks vesicular traffic, suggesting a role for lipid asymmetry in membrane
bending and vesicle budding. Other membrane-bound lipid transporters include ABC trans-
porters, that cardinally work in the opposite direction of P4 ATPases and moreover export lipids
by expelling them from the membrane rather than acting as flippases, and the plasma mem-
brane scramblase, which randomizes plasma membrane phospholipid distribution independently
of ATP. The nature of the scramblase is still poorly understood. For many ABC transporters,
specific pathologies have been genetically linked, but the subjacent mechanisms remain disputed
as do the substrates for the transporters.
2.3. Lipid cellular trafficking
Every organelle specifically contains some lipids that were produced elsewhere and acquired by
non-random transport mechanisms. The plasma membrane, endosomes and lysosomes depend
completely on lipid transport occurring by various mechanisms. The major membrane transport
pathway between cellular organelles is through the budding and fusion of membrane vesicles in
the secretory and endocytic pathways. Alternatively, lipids enter and leave organelles not con-
nected to the vesicular transport system, such as mitochondria and peroxisomes, with the help
of both soluble and membrane-bound proteins. After exit from the ER several lipids become
restricted to the exoplasmic leaflet of the bilayer, lose access to the cytosolic leaflet, and require
vesicle-mediated transport. Even the access to retrograde vesicles seems to be locked for certain
lipids preferentially trafficking in anterograde vesicles.
The lipid raft hypothesis proposes that preferential interactions between lipids generate do-
mains of specific lipid compositions to drive the sorting of membrane proteins [Sengupta et
al. 2007; Simons & Ikonen 1997; Yuyama et al. 2003]. Sphingolipids concentrate in rafts that
already exist in the ER membrane and persist throughout intracellular pathways, as single endo-
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somes show non-randomly distributed sphingolipids, indicative of domains with high sphingolipid
content. Lactosylceramide is preferentially endocytosed by caveolae and transported from the
endosomes to the Golgi. This indicates that the endocytic recycling system segregates lipids
by similar mechanisms to those of the secretory pathway. There are hints that lipid–lipid in-
teractions regulate the initial step of caveolar endocytosis. In general, both protein and lipid
assemblies on donor and acceptor membranes are important for membrane–membrane recogni-
tion and interactions that facilitate the non-vesicular lipid transfer processes. This combinatorial
recognition process has the intrinsic ability to provide spatial and temporal cues that constitute
a ‘chemical roadmap’ for vectorial lipid transport. Each membrane, each hemileaflet and each
segregated domain contains only a subset of the lipidome. The identification of these domains
and the elucidation of the relationships between physical state and function define the current
limits of our understanding. For example, phase separations may be driven by the loss of certain
lipid components together with the addition of new ones, as occurs in consequence of the activity
of lipid kinases, phosphatases and hydrolases during signaling reactions, or by changes in Ca2+
concentration, or by the aggregation of immune receptors [Sengupta et al. 2007]. Proteins can
show a clear preference for a particular lipid phase or even induce it. Most membrane-bound
peptides partition out of the liquid-ordered (raft) into liquid-disordered domains; exceptions are
peptides of the caveolin-1 scaffolding domain and at least some glycosylphosphatidylinositol-
anchored proteins.
2.4. Phosphorylated metabolites
The main source of phosphorylated metabolites in eukaryotes, plants, and archaea is the cy-
tosolic mevalonate pathway and its downstream products [Morita et al. 2007]. The alternative
2-C-methylerythritol 4-phosphate (MEP) pathway is used in most bacteria (with the exception
of gram-positive cocci), apicomplexan protozoa, and chloroplasts. HMG-CoA reductase, which
is the target of statin drugs and of negative feedback regulation by downstream products, is the
key regulatory enzyme of the mevalonate pathway and its MEP pathway ortholog Dxr [Gober
et al. 2003]. The enzyme farnesyl pyrophosphate (FPP) synthase represents the initial step to
the mevalonate pathway downstream compounds and converts isopentenyl pyrophosphate (IPP)
(and dimethylallyl pyrophosphate (DMAPP)) to geranyl and farnesyl pyrophosphate. FPP syn-
thase is inhibited by aminobisphosphonates and alkylamines [Das et al. 2001; Dunford et al. 2001;
Kunzmann et al. 2000; Thompson et al. 2006]. Loss of FPP and geranylgeranyl pyrophosphate
prevents membrane anchoring of many signaling proteins, causing signaling defects and in some
cases cell apoptosis.
2.5. Foreign and self non-peptidic antigens
Bacterial phosphorylated metabolites were the first antigens identified for TCR Vγ9/Vδ2 cells
and they were isolated from Mycobacterium tuberculosis lysates [De Libero 1997]. Later more
non-peptidic, low molecular weight compounds mostly containing an acid-labile pyrophosphate
group with various backbone structures were found stimulatory [Buerk et al. 1995; Constant
et al. 1994; Eberl et al. 2003; Tanaka et al. 1995].
Mycobacterium tuberculosis extracts were also instrumental in isolating the first CD1(b)-
restricted T cells [Porcelli et al. 1992]. The stimulatory antigens were later discovered to be
mycolic acids [Beckman et al. 1994]. CD1a-restricted antigens, such as didehydroxymycobactin
[Moody et al. 2004], and CD1c-restricted antigens, such as mannosyl phosphomycoketide [Moody
et al. 2000], were found in Mycobacterium tuberculosis sonicates, too. To date, mycobacte-
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riaceae and other microbes of the actinomycetales order are the most productive source of
group 1 CD1-presented antigens [Willcox et al. 2007]. Further CD1b-restricted antigens as
lipoarabinomannan [Sieling et al. 1995], a phosphatidylinositol mannoside, and 2-palmitoyl or
2-stearoyl-3-hydroxyphthioceranoyl-2’-sulfate-α-α’-d-trehalose (Ac2SGL) [Gilleron et al. 2004], a
mycobacterial diacylated sulfoglycolipid, have been found and are more closely related to group
2 CD1-presented antigens. Indeed, a synthetic phosphatidylinositol dimannoside has been co-
crystallized with mouse CD1d [Zajonc et al. 2006]. The most prominent structural feature of
CD1d-bound antigens, namely glycosphingolipids, seems to be their α-anomerically attached
sugar headgroup contrasting mammalian glycosphingolipids containing β linkages. In addition
to alpha-galactosylceramide, the archetype invariant natural killer T (iNKT) cell ligand, other
antigens as α-linked sphingolipids from Sphingomonas [Kinjo et al. 2005] and α-linked galacto-
syl diacylglycerol from Borrelia burgdorferi [Kinjo et al. 2006] were shown to activate iNKT cells.
Most non-peptide-specific T cells present a memory-like response after antigen encounter. This
has been ascribed to continuous, homeostatic TCR triggering by self antigens as IPP for γδ T
cells or the disputed isoglobotrihexosylceramide (iGb3) for iNKT cells. Additionally, self ligands
may be necessary for proper folding as well as stable assembly and trafficking of CD1 molecules.
Finally, autoimmune diseases like atherosclerosis (ATH) and multiple sclerosis may be connected
to T cells recognizing self non-peptidic compounds [De Libero & Mori 2007 a].
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On cells loaded with non-peptidic compounds antigen-presenting molecules (APM) allow crosstalk
with a variety of T cells.
3.1. CD1
Immunization of mice with human thymocytes led to the discovery of a highly specific antibody
recognizing 85% of the human thymic cell population [McMichael et al. 1979]. This antibody
(NA1/34) was later shown to bind CD1a of the CD1 proteins. These molecules are able to bind
and present lipid antigens to T cells.
3.1.1. CD1 evolution and morphology
The CD1 genes are highly conserved in mammalian species. Their existence has been known for
more than two decades [McMichael et al. 1979] but only during the last decade the functions
of CD1 proteins are being appreciated [Vincent et al. 2003]. CD1 proteins, even though being
structurally related to the MHC class I family, have evolved to bind and to present lipidic anti-
gens to T cells instead of peptides.
The human CD1 locus spans ≈ 175 kilobases on chromosome 1 and is paralogous to chro-
mosome 6 [Calabi & Milstein 1986]. The mouse CD1 locus, located on chromosome 3, is also
paralogous to the MHC locus on chromosome 17. In man, the CD1 genes encode five distinct
isoforms [Calabi & Milstein 2000] subdivided into group 1 (CD1a, CD1b and CD1c), group 2
(CD1d) and group 3 (CD1e) based on amino acid sequence similarity. Molecular phylogenetic
analysis of CD1 proteins from a variety of species representing several major mammalian orders
using comparison of gene sequences by alignment points to a common ancestor probably as early
as before the end of the Mesozoic era [Dascher & Brenner 2003]. In non-mammalian vertebrate
species existence of CD1 genes has not been evidenced so far, although not being extensively
searched for.
In addition to differences in sequence, there is a growing body of evidence that the group 1,
group 2 and group 3 CD1 isoforms also have distinct functions in the host immune system. The
group 1 CD1 (CD1a, CD1b, CD1c) proteins are more involved in presentation of foreign lipid
antigens, whereas group 2 (CD1d) recognize self-lipid antigens and play a more immunoregu-
latory role, although there could be some degree of overlap in these two functions. Hence, the
absence of group 1 CD1 genes in the mouse could have important consequences for evaluating
the contribution of CD1 antigen presentation in various human disease models.
The deletion of the group 1 CD1 genes from the mouse genome was first proposed by Brad-
bury and Milstein [Bradbury et al. 1990] and confirmed after completion of the mouse and human
genome sequencing [Dascher & Brenner 2003]. Compared with humans, who have single copies of
the five known CD1 isoforms, other species have variations in the number of CD1 genes, as well
as variations in the specific isoforms that are present in their genomes. The heterogeneity of the
CD1 gene family between species raises certain fundamental questions regarding the function of
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the individual isoforms. A conceptual breakthrough in understanding the potential role of the
various human CD1 isoforms (CD1a, -b, -c and -d) has emerged with the appreciation that each
isoform has a unique trafficking pattern through the endosomal system of antigen-presenting
cells (APC). Lack of certain CD1 genes in other species than human might be compensated for
by altered intracellular trafficking of the available CD1 isoforms leading to ‘functional’ homologs
of missing CD1 isoforms (‘traffic’ hypothesis [Dascher & Brenner 2003]). In line with this as-
sumption, mouse CD1d markedly colocalizes with lysosome-associated membrane glycoprotein
1 (LAMP-1), a marker for lysosomes and LE, whereas human CD1d does so only partially. Ac-
cording to the ‘traffic’ hypothesis, selective pressure gave rise to mutations in the cytoplasmic
tail changing the binding of adaptor proteins (AP) and thereby the trafficking pattern. Similar
convergent functional evolution can be seen for the guinea pig CD1b3 isoform that resembles
human CD1b in its sequence but human CD1a in its intracellular trafficking due to a single nu-
cleotide transition from the tyrosine in the tyrosine-based endosomal sorting motif to a cysteine
[Hiromatsu et al. 2002].
Selection pressure may not only change the cytoplasmic tail to broaden the compartment sur-
vey system of CD1 proteins but additionally act on the antigen binding groove to allow a larger
variety of antigens to be loaded and presented (‘groove’ hypothesis). This will increase a species’
fitness by the ability to present so far inaccessible antigens when encountering pathogens. This
has been confirmed by crystal structures of the CD1 isoforms revealing characteristic modifica-
tions of the antigen binding groove, as f.i. the extra tunnel (T’) or portal at the distal end of
the C’ pocket in human CD1b [Zajonc & Wilson 2007].
Evolutionary modifications to the CD1 gene family as assumed by the ‘traffic’ and ‘groove’
hypotheses could be simultaneous or temporally distinct incidents. A sequential scenario has
been favored, in which mutations of the cytoplasmic tail change the intracellular trafficking fol-
lowed by adaptation of the binding groove to the new environment (see Figure 3.1, p.17), because
selective pressure on the groove is depending on and exerted by differential lipid compositions
of the intracellular compartments. This is in accordance with the fact that optimal loading of
lipid antigens with longer acyl chains, which are actively sorted inside a cell based on the chain
length [Mukherjee et al. 1999], requires meeting of the CD1 molecules in LE [Moody et al. 2002,
2003].
Natural selection pressure shaping the immune system of the fittest to survive can be seen
in the evolution of APM genes by their sequences and by their crystallographic structures even
more conclusively.
The first solved crystal structure of CD1, namely mouse CD1d1 [Zeng et al. 1997], resembles
the one of MHC class I molecules and also associates with β2 microglobulin (β2m) by means of
conserved motifs in the α3 immunoglobulin like domain [Tysoe-Calnon et al. 1991]. Both CD1
and MHC class I molecules are anchored to the cell membranes by a transmembrane domain and
a cytoplasmic tail attached to the α3 heavy chain domain. In the membrane distal part of the
molecules, above the α3 domain and the β2m, two α helices (α1 and α2) lie atop a floor of six
anti-parallel β-pleated sheets. The main difference is seen in the antigen-binding site of MHC
class I and CD1 molecules with the shallow, rather hydrophilic groove of MHC class I compared
to the deep, hydrophobic groove of CD1. The several hydrophobic channels of the latter groove
allow binding of hydrophobic structures as the acyl chains of lipids.
CD1 molecules are found to have either two or four hydrophobic pockets termed A’, C’, F’,
and T’, with A’, C’, and F’ corresponding roughly to the eponymous MHC class I structure
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Figure 3.1
Evolutionary hypothesis of the human CD1 multigene family. A primordial CD1 (1) arises
by duplication and diversification from an MHC class I gene into a lipid-binding molecule with
the capacity to present the bound lipid to T cells and to traffic to some or all endosomal com-
partments. Gene duplications (2) occur creating multiple CD1 isoforms. Mutations in the
cytoplasmic tail (3) of different isoforms result in differential endosomal trafficking of the respec-
tive isoform (‘traffic’ hypothesis). Exposure to selected subparts of the endocytic system and
the prevailing physiological conditions in it as well as to quantitatively and qualitatively dis-
tinct subsets of lipids provide selective pressure to mutate the groove (4) for optimal binding of
lipid antigens (‘groove’ hypothesis). This optimized trafficking and lipid antigen binding confers
evolutionary advantage to the host. Adapted from [Dascher & Brenner 2003].
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counterparts [Moody et al. 2005]. T’ is a tunnel uniquely found in CD1b where it connects the
A’ and F’ pockets; additionally, CD1b has an extra opening portal at the end of the C’ channel
[Gadola et al. 2002 a]. Whereas the A’ and F’ pockets of CD1b are required for optimal antigen
presentation [Niazi et al. 2001], the role of the C’ pocket is not fully understood. Because the A’
and C’ pockets seem to be partially closed, the main lipid entry site is the F’ portal providing
access to the A’ and C’ channels as well. Ionizable residues in the F’ portal (of CD1b, CD1c,
and CD1d isoforms) might lead to pH-controlled partial unfolding of the α helices [Koch et al.
2005]. CD1a is lacking these residues as it does not travel to the late endosomal and lysosomal
compartments confirming a potential low pH-induced ‘lipid receptive’ state of the other CD1
isoforms. Furthermore, the F’ portal plays a crucial role in positioning the hydrophilic lipid
headgroups by a hydrogen bonding network. The sphingosine base of the antigen backbone
commonly binds to the F’ pockets leaving the acyl chain to adapt around a structural pole in the
A’ pocket. Even though the nature and existence of the four pockets varies among the isoforms,
the acyl chain length allowed is relatively similar with the exception of CD1b wherein longer
lipid chains can fit due to the T’ connected A’ and F’ channels. CD1a shows the shallowest and
smallest antigen-binding groove, whereas CD1b with its additional C’ and T’ channels attains
the largest cavity. CD1d has an intermediately sized total volume but CD1d and CD1b can bind
shorter lipid structures with the help of a ‘spacer’ lipid [Garcia-Alles et al. 2006; Wu et al. 2006;
Zajonc et al. 2005 b] filling the else empty space. To date, no crystal structure of CD1c has been
published and thus binding of antigens by CD1c is solely predictive. The more perpendicular
insertion of CD1-presented antigenic lipid, in contrast to the longitudinal orientation of peptides
on MHC molecules, exposes the lipid headgroup more towards the solvent and TCR.
3.1.2. CD1 tissue expression and cell distribution
Presentation of antigens by APM is not only temporally but also spatially controlled by tissue-
and cell-specific expression of e.g. CD1 proteins. In accordance with their function to present
lipids and glycolipids to T cells, the CD1a, CD1b, and CD1c proteins are expressed primarily on
APC [Dougan et al. 2007], including DC and B cells [Porcelli & Modlin 1999]; CD1d has a broader
distribution on lymphoid and myeloid lineage cells [Exley et al. 2000]. In the thymus, group 1
CD1 proteins (CD1a, CD1b and CD1c) are mainly expressed on CD4+CD8+ double-positive
(DP) cortical thymocytes and CD1d expression on thymocytes gradually decreases during de-
velopment with downregulation from cortical to medullary thymocytes and absence on naïve
peripheral T cells, albeit T cells retain the capacity to re-express CD1d upon activation [Exley
et al. 2000]. Furthermore, CD1a is used as an identification marker of Langerhans cells [Pena-
Cruz et al. 2001; Pena-Cruz et al. 2003].
CD1d is widely distributed also outside the hematopoietic system and its expression on
parenchymal (like hepatocytes, pancreatic, renal, and tonsillar cells) and endothelial cells (EC)
contrasts group 1 CD1 molecules [Dougan et al. 2007]. Especially high expression levels of CD1d
were found on vascular smooth muscle cells in all tissues [Canchis et al. 1993].
A major difference to MHC class II molecules exists as CD1 expression does change only
marginally upon dendritic cell (DC) maturation [Cao et al. 2002; Sugita et al. 1996; van der Wel
et al. 2003]. Therefore CD1-restricted antigens are efficiently presented by immature and mature
DC contrasting the enhanced peptide-MHC class II presentation of mature DC. Nevertheless,
upregulation of f.i. CD1d has been observed on hepatocytes after viral infection [Durante-
Mangoni et al. 2004; Tsuneyama et al. 1998].
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3.1.3. CD1 assembly, trafficking and loading
Akin their structure the assembly of CD1 proteins proceeds similarly to MHC class I molecules.
Directed to the ER lumen by mRNA-contained leader sequences, CD1 precursors are recognized
by the chaperones calnexin and calreticulin and thereafter ERp57 [Kang & Cresswell 2002 a].
β2m binding is the sine qua non for most MHC class I proteins to exit the ER but a fraction
of CD1d heavy chain is able to leave the ER without β2m. The CD1 isoforms appear to have
different requirements for ER exit as f.i. CD1b relies more on pairing with β2m. After for-
mation of the disulfide bonds in the heavy chain and finished glycosylation of the assembled
complex, MHC class I molecules become loaded with peptides translocated by the transporter
associated with antigen processing (TAP) transporter and facilitated by tapasin protein. Albeit
there is evidence that CD1 complexes are loaded with endogenous lipid ligands, proteins working
in analogy to TAP and tapasin have not been identified. The role in lipid CD1 loading of the
ER-located microsomal triglyceride transfer protein (MTTP), that has been reported necessary
for iNKT cell activation by CD1d [Brozovic et al. 2004; Dougan et al. 2005] and important for
all group 1 CD1 isoforms in antigen presentation [Kaser et al. 2008], remains controversial as
the mechanisms by which it affects exogenous antigen presentation and lysosomal recycling are
elusive.
After exit from the ER, CD1 proteins follow a direct secretory route [Briken et al. 2002].
Nevertheless subfractions of CD1 molecules can be deviated from this route by binding to other
molecules as proven for CD1d and invariant chain (Ii) and MHC class II [Jayawardena-Wolf
et al. 2001; Kang & Cresswell 2002 b]. Passing by the Golgi the CD1 proteins reach the plasma
membrane, maybe stabilized by endogenous lipids. Afterwards, they are differentially internal-
ized into the endocytic system [Moody & Porcelli 2003]. Why they are detouring via the plasma
membrane is still poorly understood. The prerequisite for CD1b, CD1c, and CD1d internalization
and trafficking is their tyrosine-based motif in the cytoplasmic tail, that allows binding of adap-
tor proteins (e.g. AP-2 for CD1b internalization) and sorting by the clathrin-dependent pathway
[Bonifacino & Traub 2003; Brigl & Brenner 2004]. Re-internalization seems to be a requirement
for efficient antigen presentation as tail-deleted mutants of CD1 proteins show functional defects
in T cell activation [Chiu et al. 2002; Jackman et al. 1998]. Without the tyrosine-based motif,
CD1a still enters the endocytic system but takes a clathrin-independent route [Barral et al. 2008].
Humans CD1a recycles from the plasma membrane mainly in early endosomes (EE) [Sugita
et al. 1999]. CD1b is routed through LE and lysosomes, residing in specialized lysosomes with
MHC class II (MIIC compartment) [Sugita et al. 1996]. Adaptor protein 3 (AP-3) helps targeting
proteins from sorting endosomes to lysosomes and has been found to bind to the cytoplasmic tail
of CD1b [Sugita et al. 2002] exerting its targeting function with this protein, too. Human CD1b
and mouse CD1d, being structurally the closest relatives, are located to LE and the lysosomal
compartments under steady state conditions. AP-3 is essential as its deficiency leads to plasma
membrane and early endosomal accumulation of CD1b as well as functional deficits including
developmental defects in the CD1d-restricted mouse iNKT cell population. CD1c surveys both
early and LE [Briken et al. 2000; Sugita et al. 2000 a] but due to the lack of AP-3 binding is
mostly barred from lysosomal compartments. For the same reasons, CD1d only partially local-
izes to lysosomes.
CD1a and CD1c found in the endocytic recycling compartment are known to re-access the
plasma membrane, and thus the cell surface for antigen presentation, in a adenosine diphosphate
ribosylation factor (ARF) 6-dependent manner through the slow recycling compartment similar
to MHC class I. Recycling mechanisms of CD1b and CD1d from LE and the lysosomal compart-
19
3. Antigen-presenting molecules (APM)
ments back to the cell surface are less well understood. As some lipids need lysosomal processing
to become immunogenic, immune evasion mechanisms invented by successful pathogens include
blocking of the lysosomal recycling pathway, f.i. reported for herpes simplex virus I [Yuan et al.
2006]. The broad intracellular survey system constructed by the diverse compartmental traffick-
ing of CD1 proteins tries to impede hiding of pathogens and their lipids [Moody & Porcelli 2003]
from the immune system [Sugita et al. 2000 b]. Alterations during infections in the self lipid
repertoire and its distribution [Mukherjee et al. 1999] are detected by the same means, namely
variations in CD1 isoform trafficking [Sugita et al. 2007].
As lipids are embedded in membranes, before they can be accessed by dedicated enzymes,
they must be extracted and made soluble. This is achieved by liftases and lipid-binding proteins
which reside within the endosomal compartments. Several common ER lipids have been found
associated with different CD1 isoforms [Cox et al. 2009; Garcia-Alles et al. 2006; Giabbai et al.
2005; Yuan et al. 2009]. ER-loading of endogenous lipids will overcome the energetically unfavor-
able empty hydrophobic cavities of the CD1 proteins and thus help in proper folding [Silk et al.
2008 b]. In some instances, endogenous spacer lipids are bound in order to fill the hydrophobic
cavities and thus reduce the space within CD1 pockets available for the simultaneous binding of
other lipids [Garcia-Alles et al. 2006; Wu et al. 2006; Zajonc et al. 2005 b]. Therefore, endogenous
lipids and so called spacer lipids are central to the production of functional CD1 proteins.
Mainly lysosomal enzymes like α-d-mannosidase, α-galactosidase, and α-hexosaminidase pro-
cess glycolipid antigens. The acidic environment participates in loading, by loosening the α
helices around the antigen binding groove of CD1 molecules, and processing by hydrolyzing
acid-sensitive chemical groups of the intact antigen, too. This has been strengthened by impact
of diverse lysosomal storage diseases on iNKT cell development and stimulation [Gadola et al.
2006 a; Schuemann et al. 2007]. CD1e, the fifth member of the human CD1 proteins and the only
one in group 3, stays intracellular and is slightly more polymorphic than its homologs. CD1e
is implicated in processing of large glycolipid compounds thus allowing their binding to CD1b
and formation of immunogenic complexes [de la Salle et al. 2005]. Whether CD1e has other im-
portant functions in lipid presentation remains to be investigated.
Lipid antigen processing has been reported for the headgroups but not for the tails so far.
Not all antigens need processing [Manolova et al. 2006; Shamshiev et al. 2000] as f.i. alpha-
galactosylceramide (αGC), the pan-iNKT cell activating glycosphingolipid, can be loaded onto
CD1d exogenously and even in cell-free in vitro plate-bound assays.
The removal of the lipid antigens out of the membrane [Schulze et al. 2009] and their transfer
into the antigen binding groove of CD1 proteins is assisted by a manifold of lipid transfer proteins
[De Libero & Mori 2005 b; Kolter & Sandhoff 2009] including CD1e, saposins and GM2-activator
protein [Kolter & Sandhoff 2005; Sandhoff & Kolter 2003]. The prosaposin is cleaved into four
functional saposins (A-D) with individual roles in lipid metabolism and lipid antigen loading.
They are involved in loading onto CD1b (saposin C) and mouse as well as human CD1d (saposin
B) [Kang & Cresswell 2004; Yuan et al. 2007; Zhou et al. 2004 b].
Due to the nature of non-peptidic antigens the presentation machinery is not only depending
on delivery by dedicated system from outside but also on intracellular proteins rendering the
antigens accessible for loading and/or processing by freeing them from membranes and vesicles
of self and foreign origin.
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3.2. The antigen-presenting molecule for isopentenyl
pyrophosphate and γδ T cells
Despite intense investigations the putative APM for TCR γδ cells remains mysterious. Attempts
to visualize the APM by fluorescently labeled or crosslinkable antigen failed as the modified
antigens lost activity. Blocking with antibodies to known APM like MHC class I/II or CD1 pro-
teins were not successful [Lang et al. 1995; Morita et al. 1995 a]. The hypothesis, that the TCR
γδ recognizes the antigen without the need of an APM, arose from the independence of antigen
processing by the APC but is unlikely as no TCR Vγ9/Vδ2 co-crystal with highly potent antigen
could be obtained and moreover TCR Vγ9/Vδ2 cells need cell-cell contact to be stimulated by
pyrophosphorylated antigens [Lang et al. 1995; Morita et al. 1995 a]. The requirement of cell-cell
contact does not prove the existence of an APM, but it could suggest the dependency on costim-
ulatory signals. Contradictory to such a dependency, the proliferative response of γδ T cells to
triggering with anti-CD3 alone was found equivalent to proliferation induced by anti-CD3 and
anti-CD28 [Hayes & Love 2002].
Furthermore, antibodies to the γδ TCR block T cell activation [Munk et al. 1990; Tanaka et al.
1994] and transfection of Vγ9/Vδ2 TCR can confer responsiveness onto a hitherto unresponsive
cell [Bukowski et al. 1995]. Therefore, it is more likely that a specific, antigen-loaded APM is
recognized by the TCR. The wide range of cell types that efficiently present phosphorylated
metabolites to γδ T cells points to a ubiquitous expression of such an APM, including even γδ
T cells, as they are able to activate themselves. Only human cells are capable of presenting the
stimulatory antigens to human Vγ9/Vδ2 T cells, while murine, hamster, and some monkey cell
lines are not.
The α subunit of the mitochondrial F1-ATPase was reported to be directly recognized by
the Vγ9/Vδ2 TCR aided by the presence of apolipoprotein A-1 in the media and this finding
was confirmed by soluble Vγ9/Vδ2 TCR binding to immobilized F1-ATPase in surface plasmon
resonance analysis [Scotet et al. 2005]. However, F1-ATPase is absent from some human APC
that are capable of presenting antigens to γδ T cells, thus challenging the claimed role of F1-
ATPase as APM for Vγ9/Vδ2 T cells.
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The identification of TCR γδ cells recognizing phosphorylated non-peptidic metabolite antigens
and of CD1-restricted TCR αβ cells reacting to lipid antigens [Porcelli et al. 1996], inspired a
large number of studies on non-peptide-specific T cells and promoted a new branch of modern
immunology that bridges innate and adaptive immunity. Two hallmark papers described CD1-
restricted TCR γδ and TCR αβ cells [Porcelli et al. 1989] and identified CD4+ T cells in MHC
class II-deficient mice [Cardell et al. 1995], which were later found to be CD1-restricted and
lipid-specific. CD1-restricted T cells have initially been linked to microbial infections [Park &
Bendelac 2000; Porcelli & Modlin 1999; Sieling et al. 2000] and mycobacterial lipids [Moody
et al. 2000].
4.1. αβ T cells
T cells restricted by group 1 CD1 molecules have been isolated and characterized. Due to lack
of tools allowing direct identification of group 1 CD1-restricted T cells, the knowledge about the
TCR repertoire, surface marker expression and modulation during diseases remains very limited.
A common TCR αβ interaction pattern with antigen complexes has only been proposed for CD1b
[Melian et al. 2000].
CD1d-restricted T cells were called natural killer T (NKT) cells because of their expression of
natural killer (NK) cell markers [Terabe & Berzofsky 2008]. The NK marker expression is not a
distinctive feature of NKT cells as some peptide-specific classical T cells are able to upregulate
these markers upon activation. Therefore, NKT cells were redefined by their CD1d-restriction
[Godfrey & Kronenberg 2004 a]. Two sets of NKT cells are able to recognize CD1d and are termed
type 1 and type 2 NKT cells. Type 1 NKT cells are defined by their invariant TCR Vα24-Jα18
chain in humans and Vα14-Jα18 chain in mice, as well named invariant NKT (iNKT) cells after
their TCR α-chain, whereas type 2 NKT cells use a more diverse TCR repertoire without any
bias in the Vα and Vβ chains.
4.1.1. iNKT cells
Type 1 NKT cells pair their invariant TCR Vα24-Jα18 mostly with TCR Vβ11 in humans and
with TCR Vβ8.2, 7 or 2 in mice. The term semi-invariant arose with the finding of a diverse
TCR β repertoire in mice [Matsuda et al. 2001] associated with the conserved Vα14 to Jα18
rearranged TCR α gene segments with a single N-nucleotide addition coding the third base of
a characteristic glycine. The frequency of this particular TCR considering the TCR α gene
segments should be around one in one million T cells. Astonishingly, iNKT cells are found in
the blood of mice with a frequency of ≈ 1% and in human peripheral blood mononuclear cells
(PBMC) of ≈ 0.1% and therefore three to four logs more often than expected (see [Godfrey &
Berzins 2007] Table 1). In 1997, a pan-activatory ligand for iNKT cells, the glycolipid αGC, was
found presented by CD1d [Kawano et al. 1997]. This ligand boosted the research on iNKT cells
tremendously by offering a tool to directly identify iNKT cells by αGC-loaded CD1d tetramers,
allowing pan-iNKT cell-expansion from total PBMC, clinical applications and iNKT cell-studies
in mouse models, as both mouse and human iNKT cells react to this glycosphingolipid. Ten
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years later, when the iNKT-αGC-CD1d co-crystal was solved, it became clear how the TCR of
iNKT cells interacts with the αGC-CD1d complex. The iNKT TCR docks longitudinally and
slightly laterally over the F’ pocket of CD1d. This is different from the diagonal binding of a
conventional αβ TCR which docks on the top of peptide-MHC complexes [Borg et al. 2007].
Another peculiarity of the iNKT TCR mode of binding is the fact that the αGC-TCR contact
is established solely by the TCR α-chain whereas the TCR β-chain contacts the CD1d molecule
without touching αGC [Wun et al. 2008]. On the other hand, both α- and β-chain of conventional
TCR make contacts with the peptide-antigen [Marrack et al. 2008; Rudolph et al. 2006; Wang &
Reinherz 2002]. The fact that most of the key residues contributing to the TCR-αGC-CD1d in-
teractions are conserved among species, explains the reported capacity of mouse CD1d to present
αGC to human iNKT cells and vice versa.
CD1d and Jα18 knockout mice were essential to address iNKT cell-development. Initial in-
vestigations revealed similarities and main differences to conventional T cells. iNKT cells and
conventional T cells emerge from DP thymocytes and share common precursors but the former
are positively selected by CD1d-expressing DP thymocytes and the latter on MHC class I and
II molecules of thymic epithelial cells [Gapin et al. 2001]. Two main models have been proposed
for iNKT cell development, namely the instructional and the precommitment model claiming
the TCR-dependence or -independence to become an iNKT cell (see [Kronenberg 2005] Figure
2), respectively. The selecting ligand remains controversial even though the self glycosphin-
golipid iGb3 has been suggested due to the decrease of 95% in the thymic NKT population in
β-hexosaminidase-B-deficient mice [Bendelac et al. 2007] and the inability of β-hexosaminidase-
B-deficient thymocytes to activate Vα14 NKT cell hybridomas [Zhou et al. 2004 a]. The absence
of iGb3 in the thymus [Speak et al. 2007] and a normal and functional iNKT cell compartment
in iGb3 synthase-deficient mice, which do not synthesize this glycolipid, [Porubsky et al. 2007]
argue against selection by iGb3. Thus the selecting ligand(s) remain unknown.
iNKT cells are activated several times during their thymic development and have to pass at
least two control points while progressing from a DP stage via four ‘immature’ stages, defined
by their CD24, CD44, DX5 and NK1.1 expression pattern, till they egress to the periphery (see
[Godfrey & Berzins 2007] Figure 3). The lately identified promyelocytic leukemia zinc-finger
(PLZF) transcription factor [Kovalovsky et al. 2008; Savage et al. 2008] seems limited in expres-
sion among immune cells to iNKT cells and is crucial for the acquirement of peripheral iNKT
characteristics (see [Gapin 2008] Figure 1). It appears at or just after positive selection of iNKT
cells and is found in human iNKT cells as well where it may have equal functions as the protein
is highly conserved.
Recent findings shed more light on the early stages of iNKT cell development during the
CD4−CD8− double-negative (DN) stage that can be subdivided into 4 sequential stages accord-
ing to the 4 possible permutations of CD25 and CD44 expression. During progression from DN3
to DN4 stage conventional T cells rearrange their TCR β-chain that, if productive, pairs with
the pre-TCR α-chain and permits progression to the DP stage. At this stage the TCR α-chain
locus rearranges and allows transcription of the TCR Vα-Jα-Cα chain. In contrast, iNKT DN4
cells express Vα14-Jα18 transcripts intracellularly, but no surface TCR. These cells are similar
in wild type (WT) and CD1d knockout mice and have the same potential to give rise to iNKT
cells when selected on WT thymocytes [Dashtsoodol et al. 2008].
Several lines of evidence, e.g. the activated phenotype of peripheral iNKT cells as well as the
lack of iNKT cells in Jα18-deficient mice (the Jα gene segments are contained in the CDR3α
contacting the antigen), indicate the presence of endogenous ligands for iNKT cells. The self
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glycosphingolipid iGb3 has been proposed as one endogenous ligand capable of inducing positive
selection of iNKT cells. However, subsequent studies have shown that mice without this lipid do
not have alterations in iNKT cells, thus suggesting that other ligands are responsible for positive
selection [Godfrey et al. 2004 b]. Several endogenous lipids may bind to CD1d [Giabbai et al.
2005; Zajonc et al. 2005 a], but their involvement in positive selection of iNKT cells has not been
proven.
Sulfatide, not activatory for human iNKT cells [Franchini et al. 2007], was observed to drive
human CD1d-restricted T cells to proliferate and release cytokines (our unpublished results).
The caveolar-enriched ganglioside monosialotetrahexosylganglioside (GM1) is another self lipid
able to bind to CD1d and compete with αGC (our unpublished observations).
Recent studies were trying to better describe CD1d-bound self-ligands using mass spectrometry
[Cox et al. 2009; Fox et al. 2009; Yuan et al. 2009]. These investigations showed that lysophos-
pholipids are stimulatory for human iNKT cells [Fox et al. 2009]. Even though a large quantity
of lipids, amongst them several linked to immune diseases, are associated with CD1d [Cox et
al. 2009], solely mono-acyl-lysophosphatidylcholine was antigenic towards iNKT cell clones and
total iNKT cells [Fox et al. 2009]. During trafficking through the cell, CD1d is loaded with
several ligands [Yuan et al. 2009], namely within the ER mainly with phosphatidylcholine, the
most abundant eukaryotic phospholipid; within LE with phosphatidylcholine, sphingomyelin, and
lysophospholipids; and possibly within the Golgi with sphingomyelin. Interestingly, autoreactive
human iNKT cells recognize CD1d molecules loaded with endogenous ligands even when CD1d
is engineered in order to avoid lysosomal trafficking, whereas mouse autoreactive iNKT cells re-
quire lysosomal routing of CD1d [Chen et al. 2007; Chiu et al. 1999; Chiu et al. 2002]. Whether
this is associated with different antigen specificity of human and mouse autoreactive iNKT cells
[De Libero & Mori 2009 a] remains to be investigated. The identification of the endogenous
stimulatory ligands [De Libero et al. 2009 b] is of major relevance as iNKT cells are important
regulatory T cells [Godfrey & Kronenberg 2004 a] and are also involved in autoimmunity and
cancer cell recognition and activation of innate immune cells [Cohen et al. 2009; Taniguchi et al.
2010].
4.1.2. NKT cells
Early studies in mice claimed a tissue-specific segregation and development of CD1d-dependent
and -independent NKT cells [Eberl et al. 1999]. The definition of NKT cells in this report
is in contradiction with the one used later defining all NKT cells as CD1d-dependent. The
cells described in that study could indeed be a diverse, NK marker-positive T cell population
developing extrathymically with a unknown restriction or maybe restricted by CD1d2, that is not
sufficient to drive NKT development [Chen et al. 1999] but could be involved in several disease
outcomes [Qian et al. 2010; Sakai et al. 2002].
A rare human CD8 memory NK marker-positive T cell-population, that was not CD1d-
restricted and possibly of extrathymic origin, was described to recruit innate immune cells upon
Fas engagement and to efficiently kill target cells [Giroux & Denis 2005].
In humans, TCR Vα24− NKT cells that recognized αGC in the context of CD1d were found
to be either CD8αβ- or CD4-positive [Gadola et al. 2002 b]. This could be explained by epitope
mimicry of αGC for certain NKT cells or be repugnant to the definition of iNKT cells but sup-
ports the instructive developmental model of TCR-antigen driven selection. The TCR Vα24−
cell population staining bright with αGC-loaded CD1d tetramers is TCR Vβ11+ whereas the
duller population shows a diverse TCR Vβ usage. This is in line with a model of one iNKT
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TCR crystal and two αGC-CD1d–specific Vβ11+ TCR crystals that show a similar mode of
recognition by all three TCR [Gadola et al. 2006 b].
Studies conducted in CD1d knockout and Jα18 knockout mice in some cases revealed dif-
ferent susceptibilities to infection, thus pointing to functionally distinct NKT and iNKT cell
populations, respectively [Tupin et al. 2007].
4.2. γδ T cells
γδ and αβ T cells arise from a common precursor in the thymus, but diverge into separate lin-
eages early in ontogeny [Hayes & Love 2007]. Differentiation along the γδ lineage likewise starts
at the immature DN stage, but lacks the pre-TCR, DP, and CD4/CD8 co-receptor single-positive
stages as well as a developmental extensive proliferation [Xiong & Raulet 2007]. Instead, most
γδ lineage cells remain DN, proliferate barely or not at all, and express the mature TCR γδ
complex [Taghon & Rothenberg 2008]. Still, signals transduced through the TCR are essential
in maintaining thymic γδ T cell differentiation and maturation [Hayday 2000].
Human TCR γδ cells use a limited repertoire of Vγ and Vδ with junctional diversity in their
chains [Carding & Egan 2002; Chien & Bonneville 2006], namely one of three major Vδ gene
segments (Vδ1, Vδ2, or Vδ3) and one of 6 different Vγ gene segments. As in mice, the combi-
nation of Vγ and Vδ segments in the TCR γδ heterodimer determines their tissue distribution
and antigen recognition pattern. The majority (50-80%) of human γδ T cells express a TCR
heterodimer composed of the Vγ9 and Vδ2 chains. Vγ9/Vδ2 T cells are unique to humans and
primates and represent 0.5 to 5% of the lymphocyte population among PBMC and are found in
tonsils and in spleen [Casorati et al. 1989], too. Intestinal TCR γδ cells preferentially pair Vδ1
and Vδ3 chains with members of the Vγ1 gene family [Carding & Egan 2002; De Libero et al.
1993].
Initially, TCR Vγ9/Vδ2 cells were characterized by their non-specific cytotoxicity against lym-
phomas and erythroleukemia cells that was later shown to depend on engagement of the TCR
[Bukowski et al. 1995]. Around the same time, the order of potency of several ligands stimulat-
ing diverse TCR Vγ9/Vδ2 cell clones was found constant [Buerk et al. 1995], suggesting a type
of antigen recognition different from that of TCR αβ cells interacting with peptide-MHC com-
plexes. This pan-activating potential and the fact that peripheral TCR Vγ9/Vδ2 cells present
a memory-like state responding immediately to antigenic challenges without apparent priming
[Tough & Sprent 1998] are still considered indirect evidences that γδ T cells are close to innate
immune cells.
A series of investigations have confirmed that all tested Vγ9/Vδ2 T cells recognize (E)-4-
hydroxy-3-methyl-but-2-enyl pyrophosphate (HMBPP), a small microbial compound that is a
natural intermediate of the MEP pathway of IPP biosynthesis in microbes [Eberl et al. 2003].
HMBPP is an essential metabolite in most pathogenic bacteria including Mycobacterium tuber-
culosis and malaria parasites. Certain bacterial species, such as Streptococcus, Staphylococcus,
and Borrelia, lack the MEP pathway and utilize the mevalonate pathway for IPP synthesis in-
stead. The Vγ9/Vδ2 TCR crystal structure confirmed the presence of a basic, positively charged
region in the binding groove that could directly interact with the negatively charged pyrophos-
phate moiety of the antigen [Allison et al. 2001]. This charge is essential for antigen recognition.
Indeed, site-directed mutagenesis of the positively charged lysine in the Jγ1.2 segment of the
CDR3γ to a negatively charged glutamate abrogated Vγ9/Vδ2 T cell stimulation by prenyl py-
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rophosphates as well as aminobisphosphonates and alkylamines, demonstrating that this basic
residue is necessary for recognition of all non-peptidic antigens [Miyagawa et al. 2001].
Vγ9/Vδ2 T cells are assumed to sense ‘danger’ signals of invading pathogens (e.g. in tubercu-
losis, salmonellosis, brucellosis, listeriosis, and malaria). This attributes γδ T cells an important
role in immunity to pathogens [Morita et al. 2000]. In addition, γδ T cells appear to have a
sentinel function by reacting to altered self as for instance against tumors. Recent studies have
shown that recognition of both infected cells and tumor cells is associated with changes in the
ubiquitous mevalonate pathway and with increased cellular levels of IPP [Gober et al. 2003;
Kistowska et al. 2008]. Therefore, the system has evolved to sense subtle modifications of the
vital mevalonate metabolic pathway.
γδ T cells may also contribute to the integrity of the epithelium during infection or injury
facilitating tissue healing [Jameson et al. 2002], thereby limiting the spread of pathogens within
the host [Havran et al. 1991]. In γδ T cells, TCR-mediated activation is complemented by ac-
tivating and inhibitory NK receptors, which modulate the response to different antigen doses
[Carena et al. 1997].
Unlike most αβ T cells, only a marginal fraction of circulating Vγ9/Vδ2 T cells express CCR7,
preventing them from entering lymph nodes. Instead, they express unique subsets of inflamma-
tory chemokine receptors which allow homing to sites of inflammation. γδ T cells rapidly upreg-
ulate CCR7 and B-cell costimulatory ligands (CD40L, OX40, CD70, and ICOS) upon activation
and help B cells to traffic to lymph nodes and to mature [Morita et al. 2007].
Similar to type 2 iNKT cells there exist non-Vδ2 T cells and alike they possess extensive
junctional diversity in their Vδ1 and Vδ3 TCR chains. Non-Vδ2 T cells are mostly localized
inside epithelial-rich (mucosal, intestinal and skin) tissues [Hayday & Tigelaar 2003]. Two cases
of Vδ1 T cells have been reported to be CD1d- [Russano et al. 2006] or CD1c-restricted [Spada
et al. 2000] under special circumstances such as during allergy or after expansion with mycobac-
terial extracts, respectively. Rare Vδ1 clones reactive to MHC, MHC-like [Groh et al. 1998], or
non-MHC molecules were established [Carding & Egan 2002; Thedrez et al. 2007] but neither
cognate interaction by surface plasmon resonance studies nor blocking of Vδ1 T cell-responses
by specific antibodies has been reported. These experiments suggest recognition of a new class of
conserved stress-induced antigens by non-Vδ2 T cells, which expand during infections with intra-
and extracellular bacteria as well as viruses. In most instances, Vδ1 expansion is not triggered
by stimuli derived from pathogens but instead follows recognition of endogenous gene products
presumably upregulated during infection. The endogenous antigens recognized by non-Vδ2 T
cells have not been characterized yet.
Despite recent advances in the γδ T cell field [Kronenberg & Havran 2007], many aspects of
γδ T cells and of their functions remain unknown.
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5. Materials
All external links given as URL were checked and working at the time the thesis was written.
The author of this thesis neither has influence on nor can be made responsible for potential
moving of the source location and for changes in content of the linked source.
Further information and hints about current protocols can be found in the 2nd edition of “T
cell protocols” edited by G. De Libero (http://dx.doi.org/10.1007/978-1-60327-527-9).
5.1. Antibodies
Whenever the isotype of an antibody is known it was listed as immunoglobulin (Ig) plus its class
and subclass.
Most antibodies were used for different applications as per manufacturer’s instructions and
tested in further experimental designs according to study needs. Most used procedures include
FACS (see section 7.8, p.47), CLSM (see section 7.6, p.46) and ELISA (see section 7.7, p.46).
For every type of experiment all used antibodies were carefully titrated to give optimal results
and least background.
Table 5.1 Antibodies, human
Specificity Clone Host Isotype Reference
β2m BBM.1 mouse IgG2b [Brodsky et al. 1979]
BirA peptide BIR1.4 mouse IgG2b
CD1a OKT6 mouse IgG1
CD1b BCD1b3.1 mouse IgG1, κ
CD1c F10/21A3 mouse IgG1
CD1d 42 mouse IgG1
CD1d 51 mouse IgG2b
CD1e 1-22 mouse IgG1
CD1e 20.6 mouse IgG1
continued on next page
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Specificity Clone Host Isotype Reference
CD3 OKT3 mouse IgG2a
CD3 S4.1 or 7D6 mouse IgG2a, κ
CD3 TR66 mouse IgG1
CD3 UCHT1 mouse IgG1
CD4 MT310 mouse IgG1, κ
CD4 RPA-T4 mouse IgG1, κ
CD4 S3.5 mouse IgG2a
CD8 3B5 mouse IgG2a
CD8 DK25 mouse IgG1, κ
CD8 LT8 mouse IgG1
CD25 BC96 mouse IgG1, κ
CD25 M-A251 mouse IgG1, κ
CD27 CLB-27/1 mouse IgG2a
CD27 LT-27 mouse IgG2a
CD27 M-T271 mouse IgG1, κ
CD39 A1 mouse IgG1
CD45 J33 mouse IgG1
CD45RA L48 mouse IgG1, κ
CD45RA MEM56 mouse IgG2b
CD69 CH/4 mouse IgG2a
CD69 L78 mouse IgG1
CD71 (TfR)
CD74 (Ii) LN-2 or B318 mouse IgG1
CD94 mouse
GM-CSF (capture) BVD2-23B6 rat IgG2a
GM-CSF (detection) BVD2-21C11 rat IgG2a
GM-CSF (capture) 6804 mouse IgG1
GM-CSF (detection) 3209 mouse IgG1
HLA DP B7/21.2 mouse IgG1, κ
HLA DQβ XIV 466.2 mouse
HLA DQ1 BT3/4 mouse
HLA DQ2 XIII 358.4 mouse
HLA DQw1 Genox 3.53 mouse IgG1 [Brodsky et al. 1980]
HLA DR 2/72 mouse
HLA DR D1.12 mouse IgG2a
HLA DR L227 mouse IgG1, κ [Lampson & Levy 1980]
continued on next page
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continued from previous page
Specificity Clone Host Isotype Reference
HLA DR L243 mouse IgG2a, κ [Lampson & Levy 1980]
HLA DRα DA6.147 mouse IgG1 [Guy et al. 1982]
HLA DR/DP/DQ IVA12 mouse IgG1, κ [Shaw et al. 1985]
HLA DR/DQ 9.3F10 mouse IgG2a [Van Voorhis et al. 1983]
IFN-γ (capture) HB8700 mouse IgG1
IFN-γ (detection) γ69-2GV mouse IgG1 [Gallati et al. 1987]
IL-4 (capture) 8D4-8 mouse IgG1
IL-4 (detection) MP4-25D2 rat IgG1
IL-4 (detection) 3H4
IL-4 (detection) 8F12 mouse IgG1
IL-8 (capture) JK8-1 mouse IgG1
IL-8 (detection) JK8-2 mouse IgG1
IL-17 (capture) 41809 mouse IgG2b
IL-17 (detection) goat polyclonal IgG
LAG-3 17B4 mouse IgG1
MHC class I W6/32 mouse IgG2a, κ
MRP5 C-17 goat polyclonal
MRP5 M5I-1 rat IgG2a
MRP5 P-20 goat polyclonal
NKG2D ON72 mouse IgG1
NKp30 Z25 mouse IgG1
NKp44 Z231 mouse IgG1
NKp46 BAB281 mouse IgG1
TCR Vα24 C15 mouse IgG1, κ
TCR Vβ11 C21 mouse IgG1, κ [Dellabona et al. 1994]
TCR Vγ9 B3 mouse IgG1
TCR Vδ2 4G6 mouse IgG1
TNF-α (capture) MAb1 mouse IgG1
TNF-α (detection) MAb11 mouse IgG1
TNF-α (capture) 357-101-4 mouse IgG1
TNF-α (detection) 2-179-E11 mouse IgG1
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Table 5.2 Antibodies, mouse
Specificity Clone Host Isotype Reference
IFN-γ (capture) R4-6A2 rat IgG1
IFN-γ (detection) XMG1.2 rat IgG1
IL-2 (capture) JES6-1A12 rat IgG2a
IL-2 (detection) JES6-5H4 rat IgG2b
IL-4 (capture) 11B11 rat IgG1
IL-4 (detection) BVD6-24G2 rat IgG1
5.2. Cell lines and clones
Table 5.3 Cell lines, human
Name Type Reference
A-375 malignant melanoma [Giard et al. 1973]
C1R B lymphoblastoma [Storkus et al. 1989]
HeLa negroid cervix epitheloid carcinoma [Scherer & Hoogasian 1954]
HL-60 caucasian promyelocytic leukemia [Collins et al. 1977]
HMEC-1 dermal microvascular endothelial cell line [Ades et al. 1992]
K-562 caucasian chronic myelogenous leukemia [Lozzio & Lozzio 1975]
Molt-4 acute T lymphoblastic leukemia [Minowada et al. 1972]
T2 lymphoblastoma [Salter et al. 1985]
THP-1 monocytic leukemia [Tsuchiya et al. 1980]
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Table 5.4 Cell lines, mouse
Name Type Reference
CTLL-2 IL-2 dependent C57BL/6 T lymphoblast [Gillis & Smith 1977]
J558 BALB/c plasmacytoma [Weigert et al. 1970]
P3X63Ag8 BALB/c plasmacytoma [Koehler & Milstein 1975]
P3X63Ag8.653 BALB/c plasmacytoma [Kearney et al. 1979]
All cell lines in the laboratory were tested upon receipt and at regular intervals thereafter in
accordance with institutional guidelines (see appendix SOP mycoplasma, p.199).
Table 5.5 Clones, human
Name Type Restriction Specificity Reference
BG clones iNKT CD1d [Franchini et al. 2007]
DS1B9c αβT CD1c Sulfatide [Shamshiev et al. 2002]
DS1C9b αβT CD1b Sulfatide [Shamshiev et al. 2002]
DS2C13a αβT CD1a Sulfatide [Shamshiev et al. 2002]
G2B9 γδT HMBPP, IPP [Casorati et al. 1989]
GG33a αβT CD1b GM1 [Shamshiev et al. 1999]
JS7 iNKT CD1d [Xia et al. 2006]
JS63 iNKT CD1d [Xia et al. 2006]
K34A6.2 αβT CD1a Sulfatide [Shamshiev et al. 2002]
K34B9.1 αβT CD1a Sulfatide [Shamshiev et al. 2002]
S17d αβT CD1d Sulfatide
S33d αβT CD1d Sulfatide
S38d αβT CD1d Sulfatide
SaGC lines iNKT CD1d [Kyriakakis et al. 2009]
VM-D5 iNKT CD1d
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Table 5.6 Hybridomas, mouse
Name Type Restriction Specificity Reference
FF4 iNKT CD1d [Schuemann et al. 2007]
FF5 iNKT CD1d [Schuemann et al. 2007]
FF13 iNKT CD1d [Schuemann et al. 2007]
All clones and hybridomas mentioned above were established in the laboratory. These cells were
tested after establishment and periodically thereafter in accordance with institutional guidelines
(see appendix SOP mycoplasma, p.199).
5.3. Compounds
Table 5.7 Compounds
Name Class APM i Responder Reference
α-galactosylceramide (KRN7000) GSL ii CD1d iNKT [Kobayashi et al. 1995]
α-sulfatide GSL CD1d iNKT [Franchini et al. 2007]
7-aza- and 7-thiasphingosines SL iii CD1d [Mathew et al. 2009 c]
C-analogue of sulfatide GSL CD1a [Modica et al. 2006]
KRN7000 S-glycoside analogue GSL CD1d [Rajan et al. 2009]
Sphingolipid analogues SL CD1d [Mathew et al. 2009 b]
i Antigen-presenting molecule(s)
ii Glycosphingolipid
iii Sphingolipid
The compounds in (see Table 5.7, p.36) were synthesized and/or purified by collaborators and
generously provided for mutual studies or projects.
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5.4. Cytokines and chemokines
Human GM-CSF is produced from J558 cells transfected with the human GM-CSF gene (clone
36.17, pMCK-gpt-hGMCSF) in FCSM (see section 5.6.1, p.39) with 50 µM β-mercaptoethanol
after selection in FCSM with 50 µM β-mercaptoethanol plus 5 µg/ml mycophenolic acid and
125 µg/ml xanthine and tested in a classical sandwich ELISA (see section 7.7, p.46) against
commercial recombinant human GM-CSF standard.
The most prominent of the interleukins (IL) affecting T cells, human IL-2 is produced from
J558 cells transfected with the human IL-2 gene (clone 2, pMCK-gpt-hIL2) in FCSM with 50 µM
β-mercaptoethanol after selection in FCSM with 50 µM β-mercaptoethanol plus 5 µg/ml my-
cophenolic acid and 125 µg/ml xanthine and tested on CTLL-2 cells against commercial recom-
binant human IL-2 standard.
Human IL-4 is produced from P3X63Ag8.653 cells transfected with the human IL-4 gene in
FCSM with 50 µM β-mercaptoethanol after selection in FCSM with 50 µM β-mercaptoethanol
plus 5 µg/ml mycophenolic acid and 125 µg/ml xanthine and tested against commercial recom-
binant human IL-4 standard in a sandwich ELISA.
Human IL-6 is produced from P3X63Ag8.653 cells transfected with the human IL-6 gene (clone
X6310-46, BCMGSneo-hIL-6) in FCSM with 50 µM β-mercaptoethanol after selection in FCSM
with 50 µM β-mercaptoethanol plus 5 µg/ml mycophenolic acid and 125 µg/ml xanthine and
tested against commercial recombinant human IL-6 standard in ELISA.
All cytokine-containing media were filtered through Stericup GP Express Plus 0.45 µm mem-
brane filters (Millipore, Zug, Switzerland), tested, aliquotted and stored at -20 ◦C.
Human IL-8 (BioLegend, San Diego, California, USA), IL-17 (R&D Systems, Abingdon,
United Kingdom), IFN-γ (BD Biosciences, Allschwil, Switzerland or PeproTech, London, United
Kingdom or Bender MedSystems, Vienna, Austria) and TNF-α (PeproTech or ImmunoKontact,
AMS Biotechnology, Bioggio Lugano, Switzerland) were bought from commercial suppliers.
All commercial cytokines were tested, stocked at the needed concentrations (e.g. 1 µg/ml for
ELISA) and stored at -70 ◦C.
5.5. DIMER
For preparation of soluble recombinant human CD1d, a strategy similar to the one introduced to
obtain soluble recombinant human CD1b [Garcia-Alles et al. 2006] was developed. The cloning
was adapted from published methods [Manolova et al. 2003, 2006]. Shortly, human CD1d cDNA,
devoid of the transmembrane and cytoplasmic coding sequence, was amplified from C1R-hCD1d
cells [Brossay et al. 1998], that express the full-length protein, using the 5’hCD1d-XhoI and
3’hCD1d-P-ClaI primer pair and the Advantage R© HF 2 DNA polymerase (Clontech, Takara Bio
Europe, Saint-Germain-en-Laye, France).
Human CD1D amplification primers
5’ - CTC GAG ATA TGG GGT GCC TGC TG - 3’ (5’hCD1d-XhoI)
5’ - TTA TCG ATA GGC CCA CCC CAG TAG AGG AC - 3’ (3’hCD1d-P-ClaI)
The product was cloned into pCR2.1-TOPO (Invitrogen, Basel, Switzerland) and sequenced.
The XhoI/ClaI fragment was ligated into pBluescript-Bir [Nowbakht et al. 2005], a pBluescript II
KS+ (Stratagene, Agilent Technologies, Basel, Switzerland) based vector containing a fragment
encoding the #85 BirA peptide tag (GGGLNDIFEAQKIEWHE) [Schatz 1993]. The soluble
human CD1d-birA fusion product was excised by XhoI/NotI digestion and subcloned into the
eukaryotic cDNA expression vector BCMGSneo [Karasuyama et al. 1990]. The final construct was
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super-transfected by electroporation into J558 cells expressing human β2m with a hygromycin
resistance gene [Nowbakht et al. 2005]. After double-selection with hygromycin B and G418
(both Calbiochem, Merck, Nottingham, United Kingdom), cells were cloned, picked according
to expression, expanded and frozen. The amino acid sequence of soluble CD1d is as follows.
Soluble recombinant birA-tagged human CD1d including the leader sequence i
[MGCLLFLLLWALLQAWGSA]iiE VPQRLFPLRC LQISSFANSSWTRTDGLAWL
GELQTHSWSN DSDTVRSLKP WSQGTFSDQQ WETLQHIFRV YRSSFTRDVK
EFAKMLRLSY PLELQVSAGC EVHPGNASNN FFHVAFQGKD ILSFQGTSWE
PTQEAPLWVN LAIQVLNQDKWTRETVQWLL NGTCPQFVSG LLESGKSELK
KQVKPKAWLS RGPSPGPGRL LLVCHVSGFY PKPVWVKWMRGEQEQQGTQP
GDILPNADET WYLRATLDVV AGEAAGLSCR VKHSSLEGQD IVLYWGG[PID
KL]iii[GGGLNDIF EAQKIEWHE]iv
For every production of soluble recombinant human CD1d, cells were double-selected with
hygromycin B and G418 for two weeks, adapted to and then cultured under low serum growth
conditions (see subsection 5.6.1, p.39). Soluble birA-tagged CD1d was purified similarly to
reported protocols [Garcia-Alles et al. 2006]. Briefly, harvested supernatants were precipitated
in 40% ammonium sulfate and dialyzed against phosphate buffered saline (PBS). Soluble human
CD1d was purified from total proteins by isoelectric focusing (IEF) in a RotoforTM preparative
IEF cell (Bio-Rad, Reinach, Switzerland) with 1.5% Bio-Lyte 5/8 Ampholyte (Bio-Rad).
Table 5.8 Soluble recombinant birA-tagged human CD1 proteins
protein Uniprot amino acids molecular weight isoelectric point v
CD1a P06126 302 34.6 kDa 5.87
CD1b P29016 302 33.5 kDa 5.21
CD1c P29017 302 34.1 kDa 5.55
CD1d P15813 300 34.0 kDa 6.21
BSA P02769 607 69.3 kDa 5.82
v calculations by http://www.expasy.ch/tools/pi_tool.html (with birA peptides; without leader peptides,
β2m) and glycosylation
IEF fractions were tested by Western blotting with the BIR1.4 monoclonal antibody (mAb)
and pooled. The pooled fractions were dialyzed against PBS, stocked and stored at -70 ◦C until
use. IEF was primarily performed to eliminate bovine serum albumin (BSA) and other proteins
of no interest contained in cell culture supernatants.
For preparation of the DIMER, IEF-purified soluble recombinant birA-tagged CD1d was loaded
with molar excess of the antigen of interest for 45 min at room temperature (RT) before addition
of twofold molar excess of BIR1.4 mAb for another 15 min at RT. DIMER were used immediately
or stored at 4 ◦C. They remained stable for more than one year after preparation.
i 319 amino acids including leader and BirA target peptides
ii Amino acids of the leader peptide are given bold
iii Amino acids added for in-frame cloning are given bold and blue
iv Biotinylation substrate peptide consensus sequence is given bold and red
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5.6.1. Media basis
All media were prepared in RPMI 1640 (Gibco, Invitrogen, Basel, Switzerland) with 100 µM
non-essential amino acids, 1 mM sodium pyruvate, 100 µg/ml kanamycin, 2 mM GlutaMAXTM-I
(all Gibco) and filtered through Stericup GP Express Plus 0.22 µm membrane filters (Millipore).
Fetal calf serum medium
The fetal calf serum medium (FCSM) was prepared by addition of 10% fetal calf serum (Gibco)
to the basic medium.
Human serum medium
The human serum medium (HSM) is composed of basic medium with 100 U/ml human IL-2 and
5% AB-positive human serum (Blutspendezentrum SRK beider Basel, Basel, Switzerland).
5.6.2. Buffers
ELISA blocking solution
Released cytokines were measured by ELISA in sterile filtered PBS plus 10 mg/ml bovine serum
albumin (PAA, Cölbe, Germany or Sigma-Aldrich, Basel, Switzerland) and 0.05% Tween-20
(Sigma-Aldrich).
ELISA washing solution
The ELISA plates were washed with PBS and 0.05% Tween-20. The ELISA washing solution
was prepared as 10x stock from PBS powder (AppliChem, Darmstadt, Germany) and diluted in
MilliQ water before use.
Erythrocyte lyzing buffer
Erythrocyte lysis was done in PBS containing 174 mM ammonium chloride (NH4Cl), 10 mM
potassium bicarbonate (KHCO3), 0.1 mM Na2EDTA, and 10 mM sodium azide (NaN3).
FACS buffer
Surface staining of cells was performed in PBS supplemented with 0.5% human albumin (kind
gift of the Swiss Red Cross) and 0.02% sodium azide (NaN3).
MACS buffer
Isolation of cell populations by magnetic-activated cell sorting (MACS) used a sterile filtered
buffer composed of 2 mM ethylenediaminetetraacetate (EDTA) and 0.5% bovine serum albumin
in PBS.
Saponin buffer
Intracellular staining of fixed cells was achieved by permeabilizing the cells in PBS containing
0.5% (v/v) human albumin and 0.02% (v/v) sodium azide (NaN3) plus 0.1% (w/v) saponin
(from Quillaja bark, Sigma-Aldrich).
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5.7. Primers
5.7.1. Mycoplasma
A standard operating protocol (SOP) for detection of mycoplasma has been developed (see ap-
pendix SOP mycoplasma, p.199) for the Department of Biomedicine, University Hospital Basel.
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6.1. Cloning, cells
Isolation of iNKT cell clones from PBMC of healthy donors [Franchini et al. 2007] was described
before. The general procedure for cloning T cells from PBMC is as follows. Use fresh HSM
and 5× 105 irradiated feeders per ml plus 1 µg/ml phytohemagglutinin final. Instead of phyto-
hemagglutinin T cell specific antigens can be used. In the case of cloning with a specific antigen
the amount of human IL-2 should be reduced to suboptimal doses e.g. 5 to 10 U/ml until cells
start blasting. The amounts of medium are calculated for one threefold dilution series to plate
1 Terasaki plate (Nunc, Thermo Fisher Scientific, Roskilde, Denmark) with 10 cells per well (10
cells in 20 µl matching 500 cells per ml, e.g. 4 to 12 ml) and 2 Terasaki plates with 3 cells per
well (3 cells in 20 µl matching 150 cells per ml, e.g. 4 to 9 ml) and 4 Terasaki plates with 1 cell
per well (1 cell in 20 µl matching 50 cells per ml, e.g. 4 to 9 ml) and 10 Terasaki plates with 0.3
cell per well (0.3 cell in 20 µl matching 15 cells per ml, e.g. 4 to 9 ml). Dilution series are plated
with a special cloning tool and plates are placed in a cell culture incubator (see section 6.6,
p.43) as soon as possible to avoid medium evaporation and thereby drying out of the cells. The
cloning is left untouched for 3 to 4 d before checking for contamination. Then the cloning is kept
unattended until day 12 to 14 before growing clones are counted and thereof the plating efficiency
is computed. Expanding clones are picked from the lowest starting cell per well concentration
upwards and transferred to 96-well plates. Once 2 96-wells are full, screening for desired clones
is initiated. All clones should be named as follows. The first or two leading letters indicate the
source or donor, the next letter is given by the antigen used if any, the following letter is assigned
according to the plating dilution of the clone (A meaning 0.3 cell per well, B meaning 1 cell per
well, C meaning 3 cells per well, and D meaning 10 cells per well), and thereupon clones are
numbered increasingly.
6.2. Cloning, lines
Use restimulation protocol to expand lines from different sources. Phytohemagglutinin may be
changed for T cell specific antigens at will. Antigen-specific cell expansion should be conducted
under suboptimal doses of human IL-2 (5 to 10 U/ml) for the first days until blasts become visible.
Thereafter human IL-2 should be added at the optimal dose of 100 U/ml as the advantage of the
blasts will not be overtaken by other human IL-2 receptor expressing cells anymore.
6.3. Cytospin
Cells were collected and washed twice in cold PBS. Fixation of cells with paraformaldehyde
(PFA) was performed as optional step in some cases. Cells were diluted to 0.5 to 1× 106
per ml to reach 1 to 2× 105 cells per spot of 200 µl. Cells were spun on appropriate glass
slides (gelatine/chromalaun- or polylysine-coated) for 8 min at 800 revolutions per minute (rpm)
(134 g) with fast acceleration. Cell spots were air dried completely. Acetone fixation of cells
was performed as optional step in some cases. Cytospins were frozen at -70 ◦C until use. After
thawing slides were dried at 25 ◦C completely (only if they were not fixed yet) before proceeding
to re-naturing, possible fixation, and staining.
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6.4. Depletion and enrichment
6.4.1. Isolation of lymphocytes from tissue
Collagenase-assisted release of lymphocytes from fresh tissue
Collagenase-assisted release of lymphocytes from fresh tissue was performed in accordance with
previously established protocols [De Libero et al. 1993] using some modifications. Tissue was
kept in PBS at RT until initiation of cell isolation procedures. The biopsy was transferred to a
Petri dish containing cold PBS, cells were gently scraped off the tissue surface with a scalpel and
retained. The remaining tissue was cut to tiny pieces and, after extensive washing, transferred
to a conical tube for digestion. The digestion to access tissue penetrating lymphocytes was
performed in HSM (see section 5.6.1, p.39) plus 20 µg/ml gentamycin (Gibco), 20 µg/ml ciproxin
(Bayer, Zürich, Switzerland), and 2.5 µg/ml fungizone (Gibco) including 400 U/ml collagenase
type IV (Sigma-Aldrich) and 500 U/ml benzonase nuclease or 2 mg/ml deoxyribonuclease type
I (Sigma-Aldrich). Scraped and collagenase-freed cells were pooled and separated from debris
by Ficoll density gradient centrifugation if desired. Release of lymphocytes from fresh arterial
tissue obtained during thrombo-endarterectomy was performed as described above. Isolated
arterial-resident lymphocytes were maintained in HSM (see section 5.6.1, p.39).
Expansion of tissue-isolated lymphocytes
Tissue cell isolates were subjected to two rounds of stimulation with dendritic cells obtained as
described [Shamshiev et al. 2000] plus the desired antigen - for iNKT cells 100 ng/ml αGC (kind
gift of Kirin Breweries, Tokyo, Japan) was used as first choice - in the presence of anti-MHC
class I and anti-MHC class II mAb (W6/32 and L243, both from ATCC) to avoid activation
of MHC-restricted alloreactive T cells. The expanded plaque tissue cells were assessed for the
presence of the cells of interest by multicolor flow cytometry (see section 7.8, p.47) and antigen
presentation assays.
6.4.2. Isolation of peripheral blood mononuclear cells (PBMC)
A SOP for isolation of PBMC (see appendix SOP PBMC, p.195) was developed for our collabora-
tors at the Cantonal Hospital Luzern. Importantly, all components were handled and complete
isolation was performed at RT to assure optimal density of Ficoll. Shortly, for 1 buffy coat
being approximately 50 ml tenfold concentrated blood, five 50 ml conical tubes were filled with
15 ml Ficoll (Lymphoprep, Axon Lab, Baden-Dättwil, Switzerland) each and equilibrated for a
few minutes. Three times diluted blood (in PBS) was cautiously layered on top of the Ficoll.
Tubes were centrifuged 20 min at 25 ◦C and 2000 rpm (836 g) without brake. White PBMC-
rings were collected to 5 new 50 ml conical tube. PBMC were washed in PBS, to eliminate part
of the platelets and thrombocytes, and pooled to 1 conical tube. Cells were counted using a
hundredfold dilution. A recovery of 2× 108 to 1× 109 of PBMC from 1 buffy coat is expected.
CD14-positive monocytes from PBMC
PBMC were labeled with CD14 MicroBeads and passed over a MACS cell separation column or
through the autoMACS Separator (all components of Miltenyi, Bergisch Gladbach, Germany)
according to the manufacturer’s instructions.
Monocytes can be gained, albeit less pure, by adhesion enrichment from PBMC. Therefore
PBMC were plated in flasks and after 2 to 3 h non-adherent cells were discarded and adherent
cells were washed carefully before further usage.
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6.5. Fixation
Dendritic cells (DC) from PBMC The medium used to generate dendritic cells (DC) was
FCSM with addition of 10% (50 ng/ml) human GM-CSF and 8% (1000 U/ml) human IL-4. DC
differentiation was checked after three to five days by surface loss of CD14 and increase or gain
of antigen-presenting molecules (e.g. CD1 and MHC) as well as costimulatory molecules (e.g.
CD80 and CD86).
Maturation of DC DC were matured by culturing in DC medium (see section 6.4.2, p.43)
plus addition of 1 µg/ml LPS (E.coli, Calbiochem) and 1 ng/ml recombinant human TNF-α
(PeproTech) for one to two days.
6.5. Fixation
Glutaraldehyde fixation
Cells were washed in PBS to get rid of serum proteins before fixation. Cells were resuspended
in 2 to 4 ml with no more than 3× 106 cells per ml in a 15 ml conical tube. For larger volumes a
50 ml conical tube was used. During cell washes 0.1% glutaraldehyde (Sigma-Aldrich) in PBS was
prepared. Glutaraldehyde was handled under nitrogen (N2) and in the dark whenever possible.
Resuspended cells were being gently vortexed while pouring 1 volume of 0.1% glutaraldehyde
to 1 volume of cells. After no more than 20 s of glutaraldehyde fixation 4 ml 200 mM L-lysine
were added immediately. The solution was continuously vortexed until its color appeared yellow.
Cells were washed repeatedly in 10% FCSM. Cells were re-counted to control for death due to
the fixation procedure.
Paraformaldehyde (PFA) fixation
To diminish serum proteins, cells were washed in PBS. Cells were resuspended at 2× 106 cells
per ml roughly. During cell washes the stock of 4% paraformaldehyde (PFA) (Merck) in PBS was
thawed. 4% PFA stock was prepared from powder as follows. PBS was alkalified with one one-
hundredth volume 5 N sodium hydroxide (NaOH) to allow solubilization of PFA, PFA powder
was added and mixed until solution appeared clear. The PFA solution was acidified with 5 N
hydrogen chloride (HCl) until pH reaches 7-7.5 on pH-stripes. Aliquotted stocks were stored at
-20 ◦C. While pouring 1 volume of 4% PFA to 1 volume of cells, resuspended cells were gently
vortexed. PFA-fixing cells were incubated 20 min at RT with occasional shaking to avoid settling
and clumping of cells. Fixation was stopped by addition of 200 mM L-lysine. Cells were washed
in 10% FCSM and re-counted to exclude dead cells occurring from fixation.
6.6. Maintenance
Cells were grown in a carbon dioxide (CO2) cell culture incubator (HERAcell cell culture incu-
bator, Heraeus, Hanau, Germany) at 37 ◦C, 5% CO2, and with more than 95% relative humidity.
6.6.1. Freezing
Cells were collected from cell culture plastic, washed once in PBS, resuspended in 90% fetal calf
serum 10% dimethyl sulfoxide (DMSO), and aliquotted to CryoTubesTM (Nunc, Thermo Fisher
Scientific). CryoTubes were placed in a styrofoam box at -70 ◦C to allow for optimal freezing at
-1 ◦C/min. After one to three days, cells were transferred to liquid nitrogen (N2).
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6.6.2. Restimulation
T cell lines and clones were regularly restimulated with feeders and phytohemagglutinin (Remel,
Thermo Fischer Scientific, Lenexa, Kansas, USA). Restimulation was done in less than 4 d old
HSM supplemented with 1× 106 per ml 3000 cGy (rad) irradiated PBMC as feeders and 2 µg/ml
phytohemagglutinin. 24-well plates with T cells ranging from 2× 105 to 2× 106 in 1 ml were
mixed with 1 ml of restimulation medium. Intervals of at least 2 weeks before proceeding to a
subsequent restimulation were kept.
6.6.3. Thawing
The freezing tube was taken from liquid nitrogen via dry-ice and placed into a 37 ◦C water bath
until only a small piece of ice was left. Cells were pipetted to a 15 ml conical tube containing
2 ml PBS and once 6 ml PBS were added dropwise while gently shaking the tube. Thawed cells
were centrifuged 7 min at 1000 rpm (209 g) and 15 ◦C. The supernatant was discarded and the
tube was scratched to loosen the pellet. Once 8 ml PBS were added slowly shaking the tube
concurrently. Cells were spun 7 min at 1000 rpm (209 g) and 15 ◦C in a bench top centrifuge.
The supernatant was discarded and the tube scratched to loosen pellet. Cells were plated into
an appropriate number of 6-well or 24-well plates.
6.7. Sorting
Cells and controls were stained in PBS containing 0.1% human albumin and 2 mM EDTA
if staining was not affected. DNA intercalating agents such as propidium iodide (PI) or 7-
aminoactinomycin D (7AAD) were avoided because of their detrimental effects on cells. 20 µg/ml
gentamycin (Gibco) was used additively to prevent contaminations. All stained cells and controls
plus single stains for compensation were collected through a cell strainer (sieve of nylon mesh
to retain cell clumps) to FCSM-coated polypropylene tubes for sorting. The volume was not to
deceed 800 µl and cell densities had to range from 1 to 3× 107 cells per ml. Sorted cells were
collected in FCSM-coated tubes containing a bottom layer of FCSM plus gentamycin.
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7. Immunological techniques
7.1. Antigen presentation assay
All types of antigen presentation assays described below were performed as cell-free stimulation
assays by replacing the presenting cells with plate-bound antigen-presenting molecules either as
monomers, dimers or multimers.
7.1.1. Antigen presentation assay, chase
Presenting cells (2.5× 104 per well) were pulsed for 1 h with sonicated antigen at 37 ◦C in 10%
FCSM (see section 5.6.1, p.39), washed, and chased for different time periods before addition of
T cells at the same time point (1× 105 per well). The supernatants were harvested after 24 or
48 h and released cytokines were measured by ELISA (see section 7.7, p.46).
7.1.2. Antigen presentation assay, competition
Presenting cells (2.5× 104 per well) in 10% FCSM (see section 5.6.1, p.39) were incubated during
the whole assay at 37 ◦C with sonicated antigen (at the indicated concentrations). Competing
compounds were given several hours in advance of αGC. T cells (7.5× 104 per well) were added
30 min after addition of αGC. Supernatants were harvested after 24 or 48 h and cytokine release
was assessed by ELISA.
7.1.3. Antigen presentation assay, pulse
Presenting cells (2.5× 104 per well) in 10% FCSM (see section 5.6.1, p.39) were pulsed for the
indicated time periods with sonicated antigen at 37 ◦C. Presenting cells were washed extensively
and T cells were added (1× 105 per well). The supernatants were harvested after 24 or 48 h and
released cytokines were measured by ELISA.
7.1.4. Antigen presentation assay, standard
Presenting cells (2.5× 104 per well) in 10% FCSM (see section 5.6.1, p.39) were pulsed for 1 h
and incubated during the whole assay, at 37 ◦C, with sonicated antigen. After 60 min, T cells
were added (1× 105 per well). The supernatants were harvested after 24 or 48 h and released
cytokines were measured by ELISA.
7.2. Cell tracing and tracking
Washed cells and dyes were prepared in warm medium. Cells were left for 5 min to take up 0.1 µM
carboxyfluorescein succinimidyl ester (CFSE) in a cell culture incubator (see section 6.6, p.43) at
37 ◦C or with 1 µg/ml 4’,6-diamidino-2-phenylindole dihydrochloride (DAPI) (Sigma-Aldrich) or
Hoechst (e.g. 33342, Sigma-Aldrich) for 30 min. The labeling was stopped by addition of warm
PBS containing 5% human albumin to absorb the dye. Labeled cells were washed in warm PBS
before usage.
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7.3. Co-culture assay
Labeled cells of interest were placed on top of a feeder cell layer or APC and given five to seven
days until analysis of co-culture effects by appropriate means.
7.4. Cytotoxicity assay
Compounds to be tested were sonicated for 5 min in a Elmasonic X-tra 150 H sonicator (Elma,
Singen, Germany) at 150 Hz 37 ◦C and incubated overnight at increasing doses with cells. The
next day, cells were labeled with 5 µg/ml PI (Sigma-Aldrich) or 7AAD (Invitrogen). Cell death,
measuring PI or 7AAD uptake into the cells, was assessed by fluorescence-activated cell sorting
(FACS) (see section 7.8, p.47) on a CYANTM ADP (Beckman Coulter, Nyon, Switzerland). The
median lethal concentration (LC50) were calculated for tested compounds.
7.5. Immunoprecipitation
Immunoprecipitation of proteins was performed on protein G sepharose beads (GE Healthcare,
Otelfingen, Switzerland). Washed cells (more than 1× 106 per immunoprecipitation) were lyzed
by repeated freeze-thaw cycles or a suiting detergent (Triton-X100, Brij98, etc.) containing lysis
buffer with proteinase inhibitor cocktail and 1 mM phenylmethylsulfonyl fluoride for 1 h on ice.
1 volume of 100 mM Tris pH 7.2 was added to lyzed pellets. One tenth volume of washed protein
G sepharose beads was added for preclearing the lysate and rotated 1 h overhead on a wheel
at RT. Lysate supernatant was transferred and incubated with 10 µg antibody in a maximal
total volume of 500 µl overnight on an overhead rotating wheel at 4 ◦C. One tenth volume of
washed protein G sepharose beads was added for immunoprecipitating the lysate and placed for
3 h on an overhead rotating wheel at 4 ◦C. Beads were precipitated by centrifugation and the
immunoprecipitation was washed twice before Western blotting.
7.6. Confocal laser scanning microscopy (CLSM)
Fresh-frozen, OCT-embedded tissue sections or cells, either grown or fixed and cytospun or
cytospun on polylysine-coated slides, were fixed in 2% PFA at RT or 100% acetone -20 ◦C. In
case of future use non- or fixed preparations were frozen at -70 ◦C. After fixation cells were
permeabilized in saponin buffer (see section 5.6.2, p.39). Blocking was done with CAS block
(Invitrogen) and possibly appropriate non-immune immunoglobulins. Samples were stained with
antibodies against the marker of interest followed by a final nuclear counterstain (e.g. DAPI,
Hoechst or PI). Slides were mounted in fluorescence mounting medium (Dako, Beckman Coulter),
sealed with nail polish and stored at 4 ◦C until analysis. Analyses were performed on a Zeiss
LSM510 or LSM710 confocal laser scanning microscope (Carl Zeiss, Feldbach, Switzerland).
7.7. Enzyme-linked immunosorbent assay (ELISA)
MaxiSorpTM ELISA plates (Nunc, Thermo Fisher Scientific) were coated with capture mAb
diluted in PBS overnight at 4 ◦C. The plate was blocked with ELISA blocking solution and
incubated with the supernatants of the antigen presentation assays. Detection was performed
with the biotinylated partner mAb in ELISA blocking solution. Streptavidin-horseradish peroxi-
dase (Zymed, Invitrogen, Basel, Switzerland) with o-Phenylenediamine dihydrochloride (Sigma-
Aldrich, according to the manufacturer’s instructions) as substrate were used to develop the
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7.8. Fluorescence-activated cell sorting (FACS)
ELISA. The reaction was stopped by adding half a volume of 10% (v/v) sulphuric acid (Sigma-
Aldrich). Opitcal densities of the developed wells were read in a SpectraMax R© 190 spectropho-
tometer at 490 nm (Molecular Devices, Sunnyvale, California, USA) and converted to concentra-
tions expressed as mean pg/ml ± standard deviation (SD) of triplicates or quadruplicates using
the SoftMax Pro 5 program (Molecular Devices) by comparison to recombinant standards.
7.8. Fluorescence-activated cell sorting (FACS)
Fixed or non-fixed cells were plated to a 96-well U-bottom plate. Fixed cells were processed in
saponin buffer (see section 5.6.2, p.39) for intracytoplasmic staining at RT whereas living cells
were handled on ice with FACS buffer (see section 5.6.2, p.39).
Fluorescent labels were chosen according to the expression of the markers of interest. Weak
markers were given bright labels and strong markers were given duller labels. In multicolor anal-
ysis channels of the flow cytometer were chosen to minimize spectral overlap of the fluorochromes
used.
Antibodies (see section 5.1, p.31) were used in general in the range of 0.2 to 20 µg/ml. Titra-
tions of all used antibodies were performed on appropriate target cells to achieve optimal staining
to background (signal to noise) ratios.
Cells were acquired on a CYAN ADP flow cytometer (Dako, Beckman Coulter), and events
were gated to exclude non-viable cells on the basis of light scatter and PI or 7AAD incorporation
as well as on pulse-width of the forward scatter signal to include only single living cells.
7.9. Fluorescence microscopy
Cells were treated as for confocal laser scanning microscopy (see section 7.6, p.46) but analyzed
on a Olympus BX61 fluorescence microscope (Olympus, Volketswil, Switzerland).
7.10. Proliferation assay
7.10.1. Thymidine uptake
Was replaced by CFSE (see subsection 7.10.2, p.47) whenever possible.
7.10.2. Carboxyfluorescein succinimidyl ester (CFSE)
Cells were marked with CFSE (see section 7.2, p.45) and activated or subjected to a co-culture
assay (see section 7.3, p.46) with stimulatory cells. Antigen was added to assess antigen-specific
proliferation of a population of interest.
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8. Molecular techniques
8.1. Genomic deoxyribonucleic acid (gDNA) preparation
DNA was extracted from 1 to 2× 106 cells, left in culture for more than 1 week after thawing, with
NucleoSpin Blood (Macherey-Nagel, Oensingen, Switzerland) as per manufacturer’s protocol
(see appendix SOP mycoplasma, p.199). Eluted DNA was stored correspondent to NucleoSpin
Blood recommendations (e.g. -20 ◦C).
8.2. Electrophoresis
8.2.1. Agarose gel electrophoresis
For all screening or test PCR products a 1% agarose gel was run and digital pictures were taken
while exposing the intercalating ethidium bromide to ultraviolet light.
8.3. Polymerase chain reaction (PCR)
For all screenings or tests primers were selected and a standard cycling program was established
to be run with Taq polymerase (see appendix SOP mycoplasma, p.199).
8.4. Vesicle uptake studies
Blood was drawn from healthy donors into heparinized syringes and immediately processed.
One-step inside-out membrane vesicles (OSV) were prepared as previously described [Wu et al.
2005]. ATP-dependent transport of radioactive substrates into OSV was measured by a rapid
filtration technique. For 3H guanosine 3’,5’-cyclic monophosphate (cGMP) control and 3H IPP or
14C IPP (all ARC, St. Louis, Missouri, USA) uptake studies, OSV were used in a buffered system
(55 µl total volume) containing 1 mM ATP, 10 mM MgCl2, 10 mM creatine phosphate, 100 µg/ml
creatine phosphokinase (all Sigma-Aldrich), 10 mM Tris−HCl (pH 7.4) and 3.3 µM radioactive
substrate. After 60 min at 37 ◦C incubation, 1 ml of ice-cold 10 mM Tris−HCl (pH 7.4) was added
and thereof 0.5 ml was filtered through 3% (w/v) bovine serum albumin soaked polyvinylidene
fluoride filters (Millipore, 0.22 µm pore size). The filters were rinsed three times with 2 ml
10 mM Tris-HCl (pH 7.4) and the radio-labeled substrate retained on the filter was determined
by liquid scintillation counting in Pico-FluorTM 15 scintillation liquid (Perkin Elmer, Waltham,
Massachusetts, USA). Obtained radioactivity values were expressed as counts per minute (cpm).
ATP-dependent uptake is the difference in tracer retention on the filter with ATP-γ-S (a non-
hydrolyzable ATP analogue, Sigma-Aldrich) in the presence of the ATP regenerating system
(10 mM creatine phosphate, 100 µg/ml creatine phosphokinase), compared to values obtained
with ATP.
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9. Patients and healthy donors
All investigations with human subjects and tissues were approved by the regional ethical review
boards and were performed in accordance with institutional guidelines.
9.1. Atherosclerosis patient cohort from Cantonal Hospital Luzern
Cells and plasma of a random cohort of 350 persons seeing a doctor for manifold reasons were
collected in compliance with the SOP for isolation of PBMC (see appendix SOP PBMC, p.195)
developed for our collaborators at the cardiology unit of the Cantonal Hospital Luzern.
Table 9.1 Clinical characteristics of the Lucerne patients
Group i 1 2 3 6
Individuals (67) (96) (192) (81)
Continuous variables ii
Age iii 69 ± 10 (67) 58 ± 11 (96) 62 ± 9 (192) 54 ± 12 (81)
BMI iv 26.1 ± 4.4 (66) 27.0 ± 4.1 (95) 26.6 ± 4.1 (188) 26.9 ± 3.9 (80)
Leuk v 6.9 ± 2.6 (67) 7.7 ± 3.6 (94) 6.7 ± 2.6 (187) 6.0 ± 2.3 (79)
LDL vi 1.9 ± 0.8 (48) 2.8 ± 1.0 (83) 2.4 ± 1.1 (185) 2.7 ± 1.0 (76)
HDL vi 1.1 ± 0.4 (48) 1.2 ± 0.4 (87) 1.3 ± 0.6 (188) 1.4 ± 0.5 (79)
Tgl vi 1.3 ± 1.0 (48) 1.3 ± 1.1 (87) 1.3 ± 1.0 (187) 1.2 ± 1.3 (79)
Chol vi 3.9 ± 1.0 (50) 4.9 ± 1.3 (88) 4.5 ± 1.2 (188) 4.8 ± 1.1 (79)
continued on next page
i 1: Scheduled for vascular surgery (histologically proven PAD/CerebroVD), 2: Acute CAD (ACS included
unstable AP), 3: Chronic CAD (relevant coronary stenosis), 6: No significant coronary atherosclerosis (but
endothelial dysfunction, small vessel disease, coronary sclerosis)
ii All continuous variables are given as median ± SD (individuals measured)
iii Given in years
iv Body mass index given in kg/m2
v Leukocyte count given in 1× 109/l
vi Low-density lipoprotein (LDL), high-density lipoprotein (HDL), triglyceride (Tgl) and total cholesterol (Chol)
given in mmol/l
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continued from previous page
Group i 1 2 3 6
Individuals (67) (96) (192) (81)
Categorical variables vii
Male gender 53 (67) 75 (96) 143 (192) 42 (81)
Diabetes 11 (67) 12 (96) 37 (192) 7 (81)
Hypercholesterolemia 40 (67) 59 (96) 142 (192) 36 (81)
Hypertension 54 (67) 46 (96) 124 (192) 33 (81)
Smoker 52 (67) 57 (96) 107 (192) 30 (81)
Family history 19 (67) 33 (96) 67 (192) 32 (81)
CAD viii 21 (29) 92 (96) 185 (191) 7 (81)
PAD ix 28 (67) 1 (96) 12 (192) 3 (81)
CVI x 21 (67) 4 (96) 7 (192) 1 (81)
COPD xi 12 (67) 3 (96) 8 (192) 3 (81)
Aneurysm 23 (67) 1 (96) 3 (192) 0 (81)
ACBP xii 8 (67) 2 (96) 3 (192) 0 (81)
Collagenosis 2 (67) 1 (96) 3 (192) 2 (81)
PAT xiii elevated 21 (61) 14 (85) 51 (177) 35 (79)
TCFA xiv 1 (1) 20 (23) 64 (92) 5 (36)
i 1: Scheduled for vascular surgery (histologically proven PAD/CerebroVD), 2: Acute CAD (ACS included
unstable AP), 3: Chronic CAD (relevant coronary stenosis), 6: No significant coronary atherosclerosis (but
endothelial dysfunction, small vessel disease, coronary sclerosis)
vii All categorical variables are given as number (individuals measured)
viii Coronary artery disease (CAD) or atherosclerotic heart disease
ix Peripheral vascular disease (PVD), also known as peripheral artery disease (PAD) or peripheral artery
occlusive disease (PAOD)
x Cerebrovascular insult (CVI) or stroke
xi Chronic obstructive pulmonary disease (COPD)
xii Aorto-coronary bypass graft (ACBP)
xiii Peripheral artery tonometry (PAT), non-invasive endothelial function measurement (score<1.7 abnormal,
score>2.0 normal (means good endothelial function))
xiv Thin-capped-fibro-atheroma (TCFA) refers to a special form of plaque composition which is prone to rupture
Additionally, clinical parameters were assessed by our collaborators whenever possible and
after having obtained written consent from the examined subject. Data collected were basic
information (e.g. body measures, sex, race, etc.), reasons of hospitalization, risk factors (e.g.
diabetes, hypercholesterolemia, hypertension, smoking, family history, etc.), manifestations of
ATH, comorbidities, actual/former drug therapy, laboratory blood test results, angiographic
parameters, flow measurements and intravascular ultrasound (IVUS) of the left/right coronary
artery, of the left anterior descending artery and of the circumflex artery.
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9.2. Atherosclerosis patients from Cantonal Hospital Bruderholz
9.2. Atherosclerosis patients from Cantonal Hospital Bruderholz
Table 9.2 Clinical characteristics of the Bruderholz patients
Cardiovascular events No Yes P value
Individuals (n = 27) (n = 22)
Cardiovascular risk factors
Diabetes mellitus i 1 (4) 10 (45) <0.001
Hypercholesterolemia i 2 (7) 7 (32) 0.03
Arterial hypertension i 6 (22) 11 (50) 0.04
Smoking i 5 (18) 7 (32) 0.35
Male sex i 13 (48) 11 (50) 0.90
Age ii 74 ± 14 79 ± 9 0.12
Body mass index iii 23 ± 6 28 ± 6 0.01
History of cardiovascular disease
Coronary heart disease i,iv 0 (0) 21 (95) <0.001
Cerebrovascular disease i,v 0 (0) 8 (36) <0.001
Arterial occlusive disease i,vi 0 (0) 8 (36) <0.001
Infection at death i,vii 11 (41) 10 (45) 0.80
Autopsy viii 20 ± 12 24 ± 9 0.28
i Number (%)
ii Mean years ± SD
iii Mean kg/m2± SD
iv Myocardial infarction, angina pectoris with myocardial ischemia, revascularization
v Cerebrovascular ischemic stroke, transient ischemic attack, revascularization
vi Symptomatic peripheral arterial occlusive disease, symptomatic aortic aneurysm, revascularization
vii Infection at death was defined by the presence of two or more of the following criteria: body temperature
>38 ◦C, C-reactive protein >5× 104 mg/ml, neutrophils (band forms) >10%, positive blood cultures
viii Mean hours after death ± SD
Arterial ring segments were obtained during autopsy from deceased patients who were treated
for a broad variety of medical conditions at the department of general medicine of the academic
medical center Cantonal Hospital Bruderholz [Kyriakakis et al. 2009].
9.3. Healthy donor cohort from Blutspende beider Basel
Buffy coats were received fresh after preparation by the unit in charge of the University Hospital
Basel, Blutspende beider Basel, and cells were immediately prepared as described above (see
subsection 6.4.2, p.42). The overall time required from the donation of blood to a purified
PBMC population was no more than 6 h.
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10. Software and statistical analyses
10.1. CLSM software
10.1.1. ImageJ
ImageJ was developed for Image processing and analysis in Java http://rsbweb.nih.gov/ij/.
Images were loaded into ImageJ [Rasband 1997–2009] and visualized using HiLo LUT for back-
ground correction (thresholding). Images were quantified by the Intensity Correlation Analysis
(ICA) [Li et al. 2004] and Colocalisation Thresholds (CT) [Costes et al. 2004] plugins. At least
four complete images containing more than 8 single cells without region of interest (ROI) se-
lection were used to calculate Mander’s Colocalization Coefficients for channel 1 (M1: e.g. red
overlapping with green) and channel 2 (M2: e.g. green overlapping with red) and the Intensity
Correlation Quotient (ICQ: random staining ICQ ≈ 0, segregated staining 0 > ICQ ≥ −0.5, de-
pendent staining 0 < ICQ ≤ +0.5). Colocalized pixels were calculated using the Colocalization
Highlighter (CH) plugin with the median channel thresholds of channel 1 and channel 2 of all
images of a specific marker established by the CT plugin and the results are shown as binary
image.
For channels containing autofluorescence, a median filter with 1 pixel size was applied if stated.
For 3D-reconstruction overlapping Z-stacks were acquired and processed with 5 or 10 degree angle
increment with interpolation. Scale bars of 10 µm were placed in images if not denoted otherwise.
Final assembly of the images was done with the ImageJ internal montage plugin.
For every project adequate macros were developed and applied to the images of choice to
guarantee unbiased and equal processing. Standardized batch runs were performed on selected
sets of dimension-matched images.
10.1.2. Imaris
http://www.bitplane.com/
10.1.3. ZEN
http://www.zeiss.com/c12567be0045acf1/Contents-Frame/3f3821b370efc91cc125734c002fb38c/
10.2. FACS software
10.2.1. FCS Express
http://www.denovosoftware.com/site/FCSExpress.shtml/
FCS Express was used to create publication grade flow cytometry plots based on the pre-
analysis done in Summit and exported as jpg-file.
10.2.2. FlowJo
http://www.flowjo.com/
For analyses needing batch processing, fcs-files with stored compensation performed in Summit
were subjected to further evaluation with FlowJo.
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10.2.3. Summit
The Summit software was developed by Dako and used to acquire FCS-files on a CYAN ADP
flow cytometer.
FCS-files were analyzed using the Summit software and if applicable compensation was per-
formed with single stains of used fluorochromes. Cells of interest were chosen according to their
forward- and side-scatter profile and further gated on pulsewidth versus a dead cell exclusion
dye to only include single living cells in the analysis.
10.3. Fluorescence microscopy software
10.3.1. cellP
The Olympus cellP software (http://www.olympus.de/microscopy/35_cell_P.htm/) was used
for image acquisition on an Olympus BX61 fluorescence microscope.
10.4. Graphic software
10.4.1. GIMP
GIMP is the GNU Image Manipulation Program. Further information can be found at http:
//www.gimp.org/.
10.5. Line art software
10.5.1. GraphPad Prism
GraphPad Prism was used for basic biostatistics, curve fitting and scientific graphing, especially
line art. For further information on GraphPad Prism visit http://www.graphpad.com/prism/
Prism.htm/.
10.6. Statistical software
10.6.1. GraphPad Prism
See the subsection on GraphPad Prism in the line art section above for information on the
program.
10.6.2. R
R is a free software environment for statistical computing and graphics and was used for more
complex statistical data evaluation not available within the GraphPad Prism Software. For
further information on the R package visit http://www.r-project.org/.
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11. CD1-DIMER, a T cell envision tool
Historically, it has been a challenge to directly identify T cells for their speci-
ficities. T cell receptor (TCR) affinity is intrinsic to its amino acid sequence and
three-dimensional structure but generally is low. A solution to stain for the TCR
was first reported using multimerization of peptide-major histocompatibility com-
plex (MHC) molecules thereby augmenting the avidity by multiple simultaneous in-
teractions. Later, CD1d tetramers were employed to detect invariant natural killer
T (iNKT) cells. Firstly, every presenting molecule needs to be identically loaded;
ensured when handling a synthetic antigen, but ligand preparations from tissue are
hardly pure enough to fulfill the criteria. Secondly, the usually low fluorescence in-
tensity hinders an unambiguous identification of positive cells. The CD4 and CD8
co-receptors, providing a substantial part of the binding energy for peptide-MHC, do
not interact with CD1d and therefore can be neglected when staining iNKT cells.
To circumvent these drawbacks, CD1d was engineered to be dimerized and poten-
tially multimerized on polymers at will. Visualizing iNKT cells in peripheral blood
by alpha-galactosylceramide (αGC)-CD1d dimers instead of tetramers unveiled huge
differences in fluorescence intensity. Two populations, defined as dull and bright, were
sorted and cloned to assess possible functional dependencies. More than eighty iNKT
cell clones were phenotypically and functionally examined. Comparative analyses did
neither show correlation to half maximal activation by αGC nor any activatory, in-
hibitory and costimulatory molecules. Considering that a co-receptor for iNKT cells
has not been identified so far and the invariance of the TCR alpha chain, the TCR
beta chain should dominate the T cell specificity. More recent structural data con-
firmed the importance of the TCR beta chain sitting on top of the F’ pocket of CD1d
that can induce conformational changes in CD1d when loaded with different types of
antigens.
Peptide-MHC tetramer-induced activation requires T cell co- and receptor binding
but not co-stimulation; αGC-CD1d dimer-induced activation needs TCR triggering
only. As to this singular prerequisite, activation with plastic-bound antigen-loaded
CD1d dimers was performed. Chemically designed and synthesized piperidinones un-
expectedly revealed that a single lipid tail is sufficient to form stimulatory complexes
with CD1d and to induce cytokine release by iNKT cells. All active piperidinones
preferentially induce TH1-like cytokines, whereas the TH2 prototype cytokine IL-4 is
released to a lesser extent. As both classes of cytokines are detected after αGC stimu-
lation, the TH1-bias has to be imputed to the type of lipid-CD1d complexes formed by
the piperidinones. TH1-responses have been associated with prolonged TCR engage-
ment, hence piperidinones might form complexes with CD1d that are binding with
high affinity to the TCR of iNKT cells. Structural fine-tuning of piperidinones may
lead to new, unique biological properties deployable in vaccination and anti-tumor
therapies.
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Comprehension of the biological roles of T cells had been hampered by the lack of tools to
determine the frequency and phenotype of antigen-specific T cells. Up to recently, antigen-
specific T lymphocytes had been identified mainly by functional assays as cytokine secretion,
cytotoxic activity or proliferation — usually performed after culture of the cells in vitro. Over
the past years, the development of tetrameric peptide-loaded major histocompatibility complex
(MHC) class-I complexes has radically altered the way of monitoring T cells and their responses.
In order for a T cell to react to the peptide or lipid antigen to which it is specific, it has to sense
the antigen in the context of the antigen-presenting molecule (APM) complex, MHC or CD1,
respectively. Even though being specific, T cell receptors (TCR) are known to have low affinities
for their cognate antigen-APM counterparts, with combined fast dissociation rates and short half-
lives in the range of a few seconds. The interactions between TCR and monomeric antigen-APM
are therefore too labile to be exploited to effectively label T cells. But joining multiple APM
molecules into one complex greatly enhances binding stability. In a hallmark paper [Altman
et al. 1996], a first solution, how to stain T cells for their specificities, was introduced for MHC-
restricted peptide-specific T cells. To approach the need for multivalency, multimers of MHC
molecules were designed to overcome the low affinity of a single TCR by increasing the overall
avidity of the interaction by multiple concomitant bindings. Therefore biotinylated soluble MHC
monomers were bound to (fluorochrome-conjugated) streptavidin, having four biotin binding
sites, and thereby converted to tetravalent structures. The resulting MHC tetramers remain the
most widely used reagents to detect antigen-specific CD4+ and CD8+ T cells by flow cytometry
[Altman & Davis 2003; Bakker & Schumacher 2005; James et al. 2009; Wooldridge et al. 2009].
Typically, MHC class I tetramers are formed by refolding soluble recombinant MHC class I
heavy chain and β2 microglobulin (β2m) obtained from bacterial inclusion bodies in the presence
of a single peptide. While this approach is successful in yielding homogeneously loaded MHC
class I molecules, attempts to refold CD1 molecules by this method have failed. That failure may
be due to the larger amount of hydrophobic amino acids in CD1 than MHC class I molecules,
needed to bind glycolipid antigens. Lately, two protocols were described for the generation of
CD1d tetramers. One is based on CD1d molecules derived from insect cells [Benlagha et al. 2000;
Matsuda et al. 2000], while the other is based on denatured CD1d molecules that are refolded in
vitro by oxidative chromatography [Karadimitris et al. 2001].
CD1d tetramer staining assays were initially reported for mouse invariant natural killer T
(iNKT) cells [Gumperz et al. 2000; Matsuda et al. 2000] with some cross-reactivity to in vitro
alpha-galactosylceramide (αGC)-expanded human iNKT cells [Benlagha et al. 2000]. A similar
strategy successfully identified human iNKT cells by a tetramerized αGC-loaded engineered
human β2m-CD1d-Fc fusion protein [Gumperz et al. 2002] in fresh peripheral blood mononuclear
cells (PBMC). Akin technologies are currently used to detect the presence of iNKT cells in mouse
and man.
Contrasting reports found that several lipid antigens could tightly bind (i.e. with a slow
dissociation rate) to mouse CD1d as read out by T cell hybridomas [Benlagha et al. 2000] or
found a very rapid off rate with a half-life of αGC-CD1d complexes in the order of 7 s to 3 min
by plasmon resonance [Naidenko et al. 1999]. That contradiction may be related to technical
issues associated with BIAcore technology and/or the use of a biotinylated form of αGC with
potentially changed CD1d1 binding properties.
While only CD1d fusion proteins were used in tetramer-based staining assays, we devised a
system based on CD1d molecules, naturally (non-covalently) bound to β2m, that are tagged to be
dimerized by an anti-tag mAb and that can be loaded by the antigen of interest (see section 5.5,
p.37). The final construct (see Figure 11.1, p.62) was designed to avoid any conformational or
structural constraints that could be introduced by fusion protein approaches and, therefore was
designed to allow for conformational changes in the CD1d protein upon antigen binding, exposure
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Figure 11.1
Alpha-galactosylceramide-loaded human CD1d DIMER. Soluble recombinant human CD1d is
loaded with the archetype iNKT-ligand αGC and dimerized with the BIR1.4 mAb specific for
the birA-tag engineered at the C-terminal end of the CD1d protein.
to different environmental pH or TCR interaction. Our β2m-associated soluble recombinant
human CD1d loaded with αGC and dimerized with the tag-specific BIR1.4 mAb is referred to
as DIMER.
As loaded monomers of CD1d are not able to stain iNKT cell clones (data not shown), dimer-
ization was carefully controlled by diluting the BIR1.4 mAb against CD1d. The testing demon-
strated the expected sensibility of the system to the ratio of CD1d to BIR1.4 (see Figure 11.2
(A), p.63). In order to establish the sensitivity of the novel system an antigen titration was
performed using the iNKT cell antigen αGC, starting from a molar ratio of one to roughly two
hundred of CD1d to αGC (see Figure 11.2 (B), p.63). The required amounts of antigen for
reliable and optimal staining by the DIMER was assessed on the iNKT cell clone JS7. By di-
luting the first plateau concentration of αGC six times by twofold the JS7 population shifted to
background MFI levels as seen by FACS analysis (see Figure 11.2 (B), p.63). Molar excess of
the candidate antigen is of critical importance especially for low affinity ligands as the available
amount of antigen for loading remains deceptive due to lipid behavior in aqueous solution (inter
alia micellization).
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Figure 11.2
Establishing the DIMER system. (A) Titration of BIR1.4 mAb against αGC-loaded monomers
and subsequent staining of the iNKT cell clone JS7 showed that the sensibility changes in a
fourfold span around the optimum with a reduction in MFI to half by increasing or decreasing
the BIR1.4 concentration by twofold. (B) In the region of a five to fifty molar ratio of αGC
to CD1d (10-100 αGC to BIR1.4) the DIMER staining rises from substantially different from
background to plateau.
Every batch of DIMER was carefully tested and analyzed before usage to assure identical con-
ditions of this crucial tool. Higher order multimers (trimers, tetramers, pentamers, ‘dextramers’
and polymers) will have longer interaction half-lives at the cell surface under staining conditions
around the zero point. However, when staining at physiological temperatures or RT, multimers
are swiftly internalized [Whelan et al. 1999]. Under the latter conditions, a potential advantage
of prolonged multimer dwell times is outbalanced by cellular uptake. Utilizing the DIMER mul-
timerized on dextran could abate the requirement of highly pure antigen, therefore tests were
conducted on selected iNKT cell clones showing different levels of DIMER staining. The effect
of dextran-DIMER multimers is valid over a broad range of staining intensities and furthermore
under limiting amounts of antigen the MFI can be augmented as much as 80-fold compared
to the DIMER (data not shown). Therefore and in addition because the CD1d molecules may
already be loaded by lipids during production and purification, it is likely that the dextran-
DIMER multimers could be used for staining even mixtures of antigens or tissue sample lipid
preparations.
11.1. Clonal brightness
Comparing the DIMER staining of a cohort of iNKT cell clones to their surface expression of
total TCR (by means of anti-CD3 mAb) or of the TCR variable chain regions (by anti-TCR
Vα24 and anti-TCR Vβ11 mAb), we repeatedly noticed a discrepancy between TCR or TCR
variable chain expression and DIMER staining (see Table 11.1, p.64).
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Table 11.1 Clonal brightness (MFI)
iNKT cell clone CD3 TCR Vα24 TCR Vβ11 DIMER
JS7 90 583 673 172
JS11 63 379 487 104
JS63 78 392 698 284
LMP-D9 60 340 422 104
VM-D5 50 340 422 453
Moreover, the clone with the lowest surface expression of the TCR showed the most intense
labeling by DIMER. All murine iNKT cell hybridomas contain a characteristic single N region
nucleotide addition at the V-J junction of their TCR Vα14 chain to preserve the glycine and
aspartate at residues 93 and 94, respectively [Behar et al. 1999]. The human TCR Vα24 to Jα18
junction contains the entire Jα18 gene segment except for two cytosines immediately after the
heptamer recombination signal and thus is created by deletion of two bases without N region
additions [Porcelli et al. 1993]. Therefore, a varying contribution of the TCR α-chain can be
excluded and the diverse (DIMER) staining could possibly be explained by a co-receptor being
differentially expressed on the clones or by a vast contribution of the TCR β-chain as well as its
P- and N-nucleotides to the total binding footprint. Mouse iNKT cells preferentially use several
TCR Vβ genes (e.g. Vβ8.2 or less frequently Vβ7 or rarely Vβ2) for their TCR Vα14 chain,
whereas human iNKT cells pair their TCR Vα24 mostly with the Vβ11 chain; other TCR Vβ
chains are hardly ever found on mouse and human iNKT cells.
This led us to derive αGC-expanded lines from PBMC of several healthy donors, to sort them
for dull or bright DIMER staining (see Figure 11.3, p.65) and to clone the sorted populations.
The clones are named according to their origin Buffy coat-derived αGC-expanded from a plating
with 0.3 cell per well (A) or with one cell per well (B). In addition, the more than eighty clones
are numbered for their DIMER MFI (f.i. BGA1 or BGB24) with 1 being the dullest and 89 being
the brightest clone (see Figure 11.5, p.66). The dull sorted iNKT cells seemed to be minimally
more efficient than bright sorted ones (see Figure 11.4, p.66). Reanalysis by DIMER staining
of the BG clones confirmed the reliability of the DIMER technique as most of the dull sorted
clones stayed duller than the bright sorted clones (see Figure 11.5, p.66).
The BG clones did not show any restraints in expression of CD4 and CD8 as their phenotypes
included double-negative (DN), CD4+ and CD8+ cells. Only one clone (CD8+) was TCR Vα24-
and Vβ11-negative but it could not be stained by the DIMER [Behar & Cardell 2000].
Whereas TCR Vα24 significantly (P=0.0175) correlated with TCR Vβ11 (data not shown),
as expected, neither TCR-chain could be directly linked to DIMER staining. When comparing
the quotients DIMER divided by TCR Vα24 and DIMER divided by TCR Vβ11 the correlation
was highly significant (P<0.0001) (see Figure 11.6, p.67). This fact seems to point to a sole
contribution of the TCR chains to the antigen recognition, nevertheless a contribution of a to
date unknown co-receptor can not virtually be excluded. No direct correlation could be seen
between the classical TCR co-receptor molecules CD4 or CD8 and DIMER staining. A skewed
picture became obvious when the DIMER staining was subdivided into dull, intermediate and
bright. Dull clones tend to express CD8, on the other hand bright clones contained more CD4-
positive ones than dull (and intermediate) clones. DN clones were found in all DIMER intensity
populations (see Figure 11.7, p.67).
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Figure 11.3
Sorting of dull and bright DIMER-positive iNKT cells from PBMC. PBMC were stained for
CD3, TCR Vα24, TCR Vβ11 and DIMER. Cells were consecutively gated on pulsewidth and
propidium iodide (PI) (not shown), forward (FSC) and side scatter (SSC), and CD3. Then
TCR Vα24 was plotted against TCR Vβ11 and FSC against DIMER. Both ways to visualize
iNKT cells showed 6-7% of total T cells presented an iNKT cell phenotype after αGC expansion.
Percentages are given of total acquired cells.
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Figure 11.4
Plating efficiency of the BG clones. Over-
all plating efficiency was very high with two
to three cells per well giving a clone. The
dull sorted iNKT cells (filled diamonds) were
slightly more effective than the bright sorted
ones (empty diamonds). The dotted line
shows the 37% cut-off.
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Figure 11.5
Clonal brightness. Reanalysis by DIMER staining of the BG clones confirmed the reliability of
the technique and led to the naming of the BG clones according to DIMER MFI ranking with 1
given to the dullest and 89 to the brightest clone. MFI of dull sorted clones are plotted as filled
bars on the left and MFI of bright sorted clones as open bars on the right.
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Figure 11.6
Correlation of the TCR alpha- and beta-chain with the DIMER. The MFI values of DIMER,
TCR Vα24, TCR Vβ11 and quotients thereof are plotted for all BG clones. P values for (Spear-
man nonparametric) correlation analyses are not significant except P<0.0001 for the graph on
the right.
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Figure 11.7
Relation of the classical CD4 and CD8 co-receptors to the DIMER. CD4 is plotted versus CD8
for three subdivisions of DIMER MFI, namely clones staining below 600, from 600 to 1000 and
over 1000 (dot plots from left to right).
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Neither CD4 nor CD8 do interact or partner with CD1d, at least not around the epitopes of
the mAb used, as no inhibition of DIMER was observed (data not shown). Because iNKT cells,
as implied by their name, express natural killer (NK) markers like natural cytotoxicity receptors
(NCR), it was checked for their presence and the expression of killer cell immunoglobulin-like
receptors (KIR) as well as for the surface levels of killer cell lectin-like receptors (KLR). Exam-
ining the sorted lines showed that a minor percentage of total cells was positive for the NCR
NKp30, NKp44 and NKp46 (0.88%, 0.56% and 0.97% of the dull line versus 0.22%, 0.40% and
0.19% of the bright line respectively). The KLR NKG2D, one major activatory receptor on NK
cells, was more widely expressed with 29.13% of the dull- and 23.35% of the bright-sorted cells
being positive. Further investigations, including CD94 and CD161, on the lines and on the BG
clones did not reveal significant association of either or both markers with dull or bright DIMER
staining (data not shown). Altogether these data led us to revise the hypothesis from ‘dull and
bright sees the antigen the same way and the staining difference is due to a co-receptor’ to the
hypothesis ‘dull and bright sees the antigen in different ways due to differences in (the variable
and joining regions of) the β-chain’. A hint to confirm the latter hypothesis came from DIMER
blocking experiments performed on the dullest and on the brightest BG clone. Blocking by a
anti-TCR Vα24 required two times more mAb for the brightest compared to the dullest clone,
whereas five times or six times more mAb was necessary for anti-TCR Vβ21 or anti-CD1d mAb
(see Table 11.2, p.68), respectively.
Table 11.2 DIMER blocking - 50% blocking concentration ( µg/ml)
mAb epitope on BGA1 BGA89 fold difference
C15 Vα24 0.095 0.18 1.9
C21 Vβ11 0.450 2.15 4.8
42 CD1d 3.250 20.00 6.2
Conclusively, different variable and joining regions of the TCR β-chain may make up antigen
specificity even though the participation of a to date unknown co-receptor can not be formally
ruled out. Investigations to correlate DIMER staining with cytokine profiles or release or ac-
tivation thresholds were not conclusive so far; even taking into account the surface molecule
fingerprints of the iNKT cells. If iNKT cells predominantly play their innate or adaptive skills
might be depending on the type of APC and/or the environment where they become activated
in and has to be investigated in future.
More recent findings revealed the αGC-CD1d structure [Koch et al. 2005], the structure and
binding kinetics of three different human αGC-CD1d-specific TCR [Gadola et al. 2006 b] and the
influence on the affinity of iNKT TCR and the threshold of iNKT cell activation by the length of
lipids bound to human CD1d molecules [McCarthy et al. 2007]. The architecture of CD1 proteins
has been reviewed [Zajonc & Wilson 2007] and the crystal structures of lipid-CD1 complexes dis-
close differences in the mode of presentation of lipids by the CD1 isoforms. Whereas group 1,
especially CD1a and CD1b, anchors the lipid backbone inside the hydrophobic binding grooves
(‘lipid anchoring’), group 2 CD1d positions the polar ligand headgroup(s) through a precise
hydrogen-bonding network in well-defined orientation at the T cell recognition interface (‘head-
group positioning’). Even more important is the occurrence of small conformational changes in
the CD1d protein upon binding of αGC due to increased polar interactions with the αl and α2
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helices that line the antigen binding groove [Silk et al. 2008 b]. Additional fragmentary electron
density data indicates that the binding groove of non-lipid-bound CD1d may be partially occu-
pied by some small-molecule species to overcome the inherent lability of CD1d molecules. What
becomes readily visible in the absence of a crystal lattice, where CD1d molecules lacking bound
αGC are unstable. Comparison of the filled and empty CD1d showed several structural dispari-
ties arising primarily from alterations in side-chain conformations to fill vacant space [Koch et al.
2005]. These modelings provide the basis for a scheme of ligand-induced changes in the APM
(performed on human CD1d and αGC and some analogues). The model predicts how the length
of the lipid tail(s), in particular inside the F’ cavity, propagates structural changes to the TCR
recognition interface [McCarthy et al. 2007]. Furthermore, that might explain how nonglycosidic
CD1d lipid ligands activate human and murine iNKT cells [Silk et al. 2008 a] without engaging
the hydrogen-bonding network that is formed between the CD1d α helices and the headgroups
of e.g. glycosidic antigens.
Although earlier studies tried to explain the interaction of iNKT TCR to antigen-loaded CD1d
by iNKT TCR sequence analysis [Kawano et al. 1999] or site-directed mutagenesis of CD1d
[Burdin et al. 2000], conclusive and surprising insights were only reached by the groundbreaking
iNKT TCR αGC-CD1d co-crystal [Borg et al. 2007] and an iNKT TCR αGC-CD1d contact
interaction analysis [Wun et al. 2008]. Most earlier studies focused on the complementarity
determining region (CDR)3 of the TCR β-chain as it is supposed to contain the most diversity
due to the fact that it is located in the V-D-J joint [Danska et al. 1990; Saada et al. 2007]. Alanine
substitution analysis revealed that the Tyr48 and Tyr50 located in the CDR2β contributed the
most in the interaction of the TCR β-chain by binding to the α1 helix of CD1d (in addition
to Asn53 and Glu56) but only one residue, Tyr103, in the CDR3β chain negligibly added to
the interaction by binding to the α2 helix [Wun et al. 2008]. The CDR2β loop is positioned
directly over the F’ pocket in the CD1d as seen in the co-crystal [Borg et al. 2007]. That may
explain how the TCR can sense different lipid tail lengths through structural propagation by
F’ pocket occupation [McCarthy et al. 2007]. From the inverse point of view, that is in line
with our findings that a series of more than eighty iNKT cell clones are able to demonstrate an
amazing range of DIMER MFI for the very same antigen-CD1d complex, namely CD1d loaded
by αGC (see Figure 11.5, p.66). These structural data have already been successfully integrated
to design functionally enhanced lipid activators of iNKT cells and will continue to be integrated
for design of other chemotherapeutic agents or immunostimulatory compounds for a variety of
immune-mediated diseases.
One major difference is the role of the co-receptors CD4 and CD8 in peptide-MHC versus lipid-
CD1 multimer systems. As the importance of CD4 and CD8 is well documented for peptide-MHC
interactions with TCR [Mallaun et al. 2008; Palmer & Naeher 2009; Rudolph et al. 2006; Wang
& Reinherz 2002], a co-receptor for CD1 molecules has not been found to date and CD1-reactive
T cells have an unrestrained pattern of co-receptor expression comprising CD4 or CD8 or neither
one. Because for CD1-restricted TCR the major interaction partner is the CD1 molecule and
to a marginal part the lipid antigen [Borg et al. 2007; Wun et al. 2008], secondary factors as
temperature can have even more dramatic effects on staining than those reported for MHC-
restricted TCR [Whelan et al. 1999]. Predictions how temperature will affect all systems remain
unreliable, therefore it is advisable to control the effects of temperature on each individual system.
Tetramers of peptide-MHC, which are thought to engage three different TCR, are more than
sufficient for most staining applications [Wooldridge et al. 2009]; in many cases, a simple peptide-
MHC dimer is effective. Conclusively, multimerization of the DIMER on dextran does not
abolish the property of the DIMER to sense the affinity of the a clonal TCR to αGC but
tremendously increases the avidity (data not shown). High molecular weight dextran polymers
have an osmotic pressure effect during the staining procedure when used at high concentrations;
69
11. CD1-DIMER, a T cell envision tool
that can easily be circumvented or at least ameliorated by dilution. Avoiding an osmotic pressure
effect is of importance when staining PBMC, as shifts in the forward and side scatter profile
would complicate the identification of desired populations. Further perspectives include the
establishment of an enhanced multimer system tested for a wide range of lipid antigens that
will be of great value as diagnostic tool to detect rare lipid-specific and CD1d-restricted T cell
populations in patients with different types of diseases.
Tetramers are as well used to examine the activation requirements of T cells. However, the
possibility of antigen transfer from soluble antigen-APM complexes to APM molecules on the
surface of the T cells themselves, or other cells in the assay, can not be ignored. Therefore
systems are developed to exclude at least influences from third party cells other than T cells.
One prerequisite was the realization that cross-linking cell surface TCR and CD8 with soluble
peptide-MHC class I tetrameric complexes produces a pattern of early tyrosine phosphorylation
that resembles the one induced by antigen-pulsed APC [Purbhoo et al. 2001]. Moreover, co-
stimulation signals from other molecules such as CD28 are not obligatory for T cell activation
by tetramers. Cross-linking with anti-CD3 is known to produce a different intracellular signaling
pattern. Even if CD8 is not required for tetramer binding, experiments in mice have confirmed
the necessity of CD8 binding for tetramer-induced activation.
Tetramer activation of T cells can be attained at over 1000-fold lower concentrations of tetramer
than required to visualize even small shifts in MFI in FACS experiments [Wooldridge et al.
2009]. The remarkable sensitivity of antigen-APM multimer-induced T cell activation is in turn
demonstrated by such faint shifts that may correspond to only a few engaged tetramers per
T cell. In addition to trigger a normal pattern of T cell signaling cascades, tetramer activation
results in lytic granule as well as a full range of cytokine and chemokine release and the induction
of various cell surface activation markers.
After the establishment of DIMER staining by FACS, we were also interested in the iNKT cell
response upon antigen encounter. Most prominent might be the distinction of type 1 helper T
cells (TH1) and type 2 helper T cells (TH2), the type preponderantly induced by the immune
system is in many cases critically important for the outcome of a disease or infection. As iNKT
cells unlike classical αβ T cells present an activated phenotype and do not require any priming
to release large amounts of cytokines, further confirmed by data of tetramer-activated classical
T cells, we thought of using the DIMER immobilized on plastic and loaded with the antigen of
interest as stimulant.
After successful establishment of a standard protocol to activate iNKT cells by plate-bound
CD1d loaded with αGC using the same engineered CD1d molecules as in DIMER staining, diverse
chemically synthesized compounds were investigated in order to find new lipids stimulating iNKT
cells. Thanks to a fruitful collaboration with a group of chemists, a whole series of compounds
was accessible that were designed to test the role of the antigen headgroup and acyl chains
in iNKT cell activation. These studies were published [Mathew et al. 2009 a; Mathew et al.
2009 b,c; Rajan et al. 2009] and their biological aspects are summarized in the subsequent four
chapters. Before assessing several structural features of iNKT cell-ligands, antigenicity of a new
αGC analogue was examined.
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11.2. N-acetyl-2-amino-2-deoxy-α-galactosyl
1-thio-7-oxaceramide, a new α-galactosylceramide analogue
The N -acetyl-2-amino-2-deoxy-α-d-galactopyranosyl 1-thio-7-oxaceramide (see Table 11.3 (1),
p.71) was synthesized [Rajan et al. 2009] by substituting a 7-oxasphingosine triflate with α-
d-N -acetyl-1-thiogalactosamine. The triflate was obtained from an azide and the thiol was
prepared according to a known procedure from α-d-galactosamine hydrochloride. As compared
to ceramide, 1 is neither a substrate of ceramide kinase, consistent with the absence of the C(1)-
OH group, nor an inhibitor of ceramide phosphorylation by ceramide kinase. While it partially
displaced CD1d-bound lipids, it failed to stimulate iNKT cells when presented by human CD1d-
transfected cells. These results suggest that it binds weakly to recombinant CD1d, but does not
form immunogenic complexes with CD1d.
Table 11.3 Structure of a new galactosaminide αGC analogue
Number Name Structure
1
N -acetyl-2-amino-2-deoxy-α-d-
galactopyranosyl
1-thio-7-oxaceramide
Several α-d-galactopyranosyl ceramides [Brodesser et al. 2003; Radin 2003; Shimamura et al.
2007; Tan & Chen 2003; Vankar & Schmidt 2000], especially KRN-7000 [Miyamoto et al. 2001;
Morita et al. 1995 b], OCH [Franck & Tsuji 2006; Murata et al. 2005; Ndonye et al. 2005], and
RCAI-61 i [Tashiro et al. 2008], incorporating phytosphingosine or sphingosine moieties, pos-
sess important biological properties [Bendelac et al. 2007; Godfrey & Berzins 2007; Kronenberg
2005; Tupin et al. 2007], comprising immunostimulating [Barbieri et al. 2004; Costantino et al.
2002; Yang et al. 2004] and antitumor activities [Bleicher & Cabot 2002; Cuvillier 2002; Gul-
bins & Grassme 2002; Kawase et al. 2002; Maceyka et al. 2002; Obeid et al. 1993; Pettus et al.
2002; Shikata et al. 2003]. Several analogues of these α-d-galactopyranosides were synthesized,
and they also display notable biological activities [Franck & Tsuji 2006; Yang et al. 2004] (see
[Rajan et al. 2009] for further references). The synthesis and evaluation of a thioglycoside ana-
logue of KRN7000 has recently been published [Dere & Zhu 2008], prompting us to report our
results on the synthesis and evaluation of 1. Replacing the galactosyl by an N -acetyl-2-amino-
2-deoxygalactosyl moiety was thought to contribute to elucidating the effect of C(2)-OH of the
glycon on TCR recognition, while the S–glycosyl bond will confer stability against chemical and
enzymatic cleavage [Driguez 2001]. 7-oxasphingosines behave similarly to ceramides, and allow to
independently modify the headgroup and lipid moiety of sphingosine, an advantage that has since
been realized using olefin metathesis [Nussbaumer 2008; Yamamoto et al. 2006]. Conceivably, 1
may be obtained either by glycosidation [Pachamuthu & Schmidt 2006] of a 1-thioceramide or of
a 1-thiosphingosine, or by nucleophilic substitution by an N -acetyl α-d-galactopyr-anosyl thiol of
a ceramide possessing a leaving group at C(1) and preferentially a non-participating neighboring
group, such as an N3 substituent [Herzner et al. 2000]. We opted for the second strategy, assum-
ing that nucleophilic substitution will prevail over single electron transfer from the thiolate to
i OCH is a truncated and RCAI-61 the 6’-O-methyl analogue of KRN7000
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Figure 11.8
Binding to CD1d and failure to activate iNKT cells. (A) N -acetyl-2-amino-2-deoxy-α-d-
galactopyranosyl 1-thio-7-oxaceramide (1) was tested for its capacity to prevent binding of αGC
to plate-bound CD1d and subsequent T cell response to αGC. Supernatants were taken and
released GM-CSF and IL-4 (data not shown) were measured by ELISA and expressed as pg/ml
± SD of triplicates. Weak but significant competition of 1 with αGC was seen as compared
to complete inhibition of αGC by ganglioside monosialic acid (GM1) used as control competi-
tor. (B) In contrast, 1 (open diamonds) failed to activate iNKT cells when titrated on CD1d
transfectants and compared to αGC (closed diamonds). Supernatants were assessed for release
of IL-4, IFN-γ and TNF-α giving similar results.
the N3 group, and reported on the synthesis of 1 and the results of its evaluation as substrate of
ceramide kinase [Spiegel & Milstien 2007] and as T cell-stimulatory antigen [Staros et al. 1978].
The galactosaminide 1 is neither cytotoxic to APC nor to iNKT cells at the tested dosage
(up to 20 µg/ml), as assessed by flow cytometry (data not shown). First, binding to human
CD1d and displacement of the strong agonist αGC was investigated. CD1d was attached to the
plastic and incubated with 1 at molar excess over αGC, first with the former and then with
the latter one. 1 partially reduced the activation of iNKT cells by αGC (see Figure 11.8 (A),
p.72), indicating a weak capacity to prevent binding of αGC to CD1d under these experimental
conditions. Next, 1 was investigated for stimulation of iNKT cells when presented by living
APC. Different APC were used to exclude cell type-specific effects. In all experiments, there was
no activation of iNKT cells (see Figure 11.8 (B), p.72). Lack of iNKT cell stimulatory potential
may be ascribed to the replacement of the OH group at C(2) of the glycon by the acetamido
group. Replacement of OH at C(2) of the glycon with an NH2 group also abolishes iNKT cell
activation [Miyamoto et al. 2001]. The OH group at C(2) establishes H-bonding with two amino
acids (R95 and G96) on the α-chain of iNKT TCR [Borg et al. 2007] that is mandatory for T cell
activation, as shown by the CD1d:αGC binding footprint for the NKT TCR [Wun et al. 2008].
The observed weak displacement capacity may be attributed to the different constitution and
rigidity of the oxasphingosine moiety as compared to the phytosphingosine moiety of αGC. The
different structure of oxasphingosine might impair the interaction between 1 and the CD1d F’
pocket, and influence the position of the sugar head, preventing an optimal interaction with the
TCR.
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11.3. Sphingolipid analogues based on 7-oxasphingosine and
7-oxaceramide
Table 11.4 New sphingolipid analogues based on 7-oxasphingosine/-oxaceramide
7-oxasphingosine/-oxaceramide analogues with a modified C(1)-OH or amide moiety
The analogues 7–9 i of 7-oxaceramide and 7-oxasphingosine were synthesized from the known
azidosphingosine 21. The 1,4-disubstituted 1,2,3-triazole analogues 10–16 of ceramides were
synthesized by the click reaction of the known azide 24 (see Table 11.4, p.73). None of the
analogues 7–15 was active as inhibitor of sphingosine kinase type 1 and of acid sphingomyelinase,
whereas 16 is a weak inhibitor of sphingosine kinase type 1. Triazoles 10, 11, and 15 did not
inhibit ceramide phosphorylation by ceramide kinase, and none of 7, 8, and 10–15 activated
iNKT cell clones when presented by human CD1d-transfected APC or by plate-bound human
CD1d [Rovina et al. 2006]. Triazoles 14 and 15 prevent binding of αGC to plate-bound human
CD1d and subsequent T cell response to αGC. Only 15 reduced activation by αGC significantly
and independently of the cytokine measured (see Figure 11.9, p.75).
The ability of sphingolipids and glycosphingolipids to modulate apoptosis [Brodesser et al.
2003; Cuvillier 2002; Gulbins & Grassme 2002; Maceyka et al. 2002; Obeid et al. 1993; Padron
2006; Shikata et al. 2003] and immune responses [Barbieri et al. 2004; Costantino et al. 2002;
Pettus et al. 2002; Plettenburg et al. 2002; Wu et al. 2008; Yang et al. 2004] is likely to depend on
specific receptor interactions with both the polar headgroup and the lipid tails of the sphingosine
and fatty acid moieties. The exploration of these interactions is based on crystal-structure
analyses of receptors in complex with the lipids [Koch et al. 2005; Snook et al. 2006], and on the
synthesis and biological evaluation of analogues [Delgado et al. 2006; Julina et al. 2004; Li et al.
2002].
1,2,3-Triazoles are non-hydrolyzable bioisosters of amides [Brik et al. 2005; Kolb & Sharpless
2003], readily obtained by the click reaction [Appendino et al. 2007; Bock et al. 2006; Brik et
al. 2005; Finn et al. 2008; Kolb & Sharpless 2003; Moses & Moorhouse 2007; Rostovtsev et al.
i Note that the compound numbers in this section refer to [Mathew et al. 2009 b]
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2002]. They mimic geometric and electronic features of a configurationally biased amide bond,
and participate in dipole–dipole interactions [Appendino et al. 2007; Gajewski et al. 2007] and
H-bonding. They may act as H-bond acceptors and as (weak) donors, depending on their substi-
tution. In 1,4-disubstituted 1,2,3-triazoles, N(2) and N(3) exhibit H-bond accepting properties,
whereas the strong dipole moment of triazole causes the polarization of H-C(5) that may act as a
weak H-bond donor [Horne et al. 2004; Palmer et al. 1974; Purcell & Singer 1967] (see [Mathew
et al. 2009 b] for further references). The triazole ring of the envisaged analogues 10–16 [Mathew
et al. 2009 b] orients the acyl chain in a way that prevents a parallel orientation with the alkyl
chain of the sphingosine moiety, and its polar substituents may serve as H-bond acceptors in a po-
sition differing from the C−O group of the C(2)-acylamino chain. These features are of interest,
as the crystal structure of αGC bound to the human and mouse CD1d receptor shows that the
two alkyl chains diverge from each other [Koch et al. 2005], suggesting that the configuration of
the amide moiety, besides its H-bond-acceptor and -donor properties, plays an important role in
interacting with receptors. The triazoles should be readily available from the known azide inter-
mediate in the synthesis of 7-oxaceramide [Rajan et al. 2004]. After the synthesis of the triazoles
10–16 was completed, a synthesis of related ceramides [Kim et al. 2007] and O-glycosides [Lee
et al. 2007] that stimulated cytokine production, comparable to the one of αGC, and exhibited
a stronger TH2 cytokine response was published. Biological properties for which we considered
testing these analogues comprise T cell suppression [Savage et al. 2006], and the interaction with
sphingosine and ceramide kinases, and with acid sphingomyelinase [Baumruker & Prieschl 2002].
Compounds 7, 8, and 10–15 did neither show any activatory capacity on iNKT cell clones
when presented by human CD1d-transfected APC nor by plate-bound human CD1d (data not
shown). None of the compounds proved cytotoxic for APC or iNKT cells at tested doses (up to
20 µg/ml), as assessed by flow cytometry (data not shown). Lack of stimulatory activity may
not exclude the capacity of these compounds to bind to CD1d. This was investigated using
a competition assay to evaluate the capacity of the compounds to prevent binding of αGC to
CD1d and, thus, to prevent T cell activation. Only compound 15 was able to compete, although
this competition was only achieved at 15-fold molar excess over αGC (see Figure 11.9, p.75).
In additional experiments, we investigated whether 15 was capable of competing with αGC in
living cells. In contrast to the strong inhibition seen in the plate-bound assay, 15 was incapable
of reducing T cell activation at all tested doses of αGC (data not shown).
This unexpected discrepancy between plate-bound and living cell competition assays might
be explained with the instability of the thioamide moiety of 15 inside living cells. To test the
stability of the thioamide 15, we performed plate-bound assays at pH 4 and 7. At pH 4, an
increase in cytokine release as compared to pH 7 was seen, and a partial degradation of 15 was
thus assumed (see Figure 11.10, p.75). In living cells, 15 requires trafficking to lysosomes, where
lipid antigens are loaded onto CD1d molecules [Jayawardena-Wolf et al. 2001]. Therefore, it is
tempting to speculate that the acidic late-endosomal microenvironment affects the stability of
15.
74
11.3. Sphingolipid analogues based on 7-oxasphingosine and 7-oxaceramide
0 2000 4000 6000
no competitor
triazole cer 15
triazole cer 14
MeOH
**
IL-4 / (pg/ml)
A B
0 1000 2000 3000
no competitor
triazole cer 15
triazole cer 14
MeOH
*
GM-CSF / (pg/ml)
Figure 11.9
Competition of triazoles with alpha-galactosylceramide. Ceramide analogues 14 and 15 were
tested for their capacity to prevent binding of αGC to plate-bound human CD1d and subsequent
T cell response to αGC. Supernatants were taken and released IL-4 (A) and GM-CSF (B) were
measured by ELISA and expressed as pg/ml ± SD of duplicates. Only 15 was significantly
reducing activation by αGC independently of the cytokine measured (**: P<0.01; *: P<0.05).
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Figure 11.10
A triazole with sensitivity to low pH. A competition experiment was performed at pH 4 or 7.
Supernatants were taken and released IL-4 (A) and GM-CSF (B) were measured by ELISA, and
expressed as pg/ml ± SD of duplicates. At pH 4, triazole 15 shows less competition than at pH
7, independently of the cytokine measured (*: P<0.05).
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11.4. 7-aza- and 7-thiasphingosines
Table 11.5 Structures of 7-aza- and 7-thiasphingosines
The trifluoroacetamide 24, the 7-thiasphingosine 5, the sulfone 6 and the 7-azasphingosine 7
The synthesis of 7-oxasphingosine (3 i) and 7-oxaceramide (4) was improved [Mathew et al.
2009 b] by starting from the 4-methoxybenzyl-protected d-galactal 9. The sphingosine ana-
logues 5–7 and 24 were synthesized via the azido alcohol 13 (see Table 11.5, p.76). The 7-
thiasphingosine 5 is a poorer substrate for both isoforms of sphingosine kinase than sphingosine,
but showed a slight preference for sphingosine kinase type 2. The sulfone 6 and the 7-aza com-
pounds 7 and 24 were not phosphorylated by either type 1 or type 2, and none of 5–7 and 24
activated iNKT cell clones when presented by CD1d-transfected APC or by plate-bound CD1d.
Only 7 and 24 associated with plastic-bound recombinant CD1d and prevented stimulation of
iNKT cells by αGC in plate-bound activation assays (see Figure 11.11, p.77).
Sphingolipids are structural components of the cell and exert multiple functions in cell sig-
naling, including the role of d-erythro-sphingosine and ceramide in the regulation of apoptosis
[Brodesser et al. 2003; Cuvillier 2002; Gulbins & Grassme 2002; Maceyka et al. 2002; Obeid
et al. 1993; Pettus et al. 2002; Shikata et al. 2003], and the role of sphingosine-1-phosphate and
ceramide in immune responses [Barbieri et al. 2004; Costantino et al. 2002; Padron 2006; Plet-
tenburg et al. 2002; Wu et al. 2008; Yang et al. 2004]. These functions are thought to depend on
specific interactions between receptors, and both the lipid tail (two tails for ceramide) and the
polar headgroup of sphingosine and ceramide [Delgado et al. 2006]. We began exploring these
interactions by synthesizing and evaluating analogues, and so far reported on modifications of
the polar headgroup and on the replacement of the C(7)H2 group by an O-atom, as in 3 and 4,
a replacement that did not appear to affect the tested biological properties [Rajan et al. 2004].
This may be different for analogues where the C(7)H2 group is replaced by bulkier, more polar,
or charged groups, and we considered the 7-thia and 7-aza analogues 5–7 of interest.
We now describe the modified synthesis of 7-oxasphingosine and 7-oxaceramide, the synthesis of
7-thia- and 7-azasphingosines, and the evaluation of these analogues as substrates of sphingosine
kinases, as CD1d ligands, and as activators of iNKT cells. The results clearly show that the
electronic environment and/or nature of the groups near C(7) of sphingosine do have an effect
i Note that the compound numbers in this section refer to [Mathew et al. 2009 c]
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Figure 11.11
Competition of azasphingosines with alpha-galactosylceramide on plastic CD1d. The 7-
azasphingosines 7 and 24 are able to compete with αGC for plate-bound CD1d. Weak reduction
of both (A) IL-4 and (B) GM-CSF release is observed.
on the biological activity.
Compounds 5–7 and 24 did neither activate iNKT cell clones when presented by human
CD1d-transfected APC nor by plate-bound human CD1d (data not shown). Compounds 5, 7,
and 24 were cytotoxic for APC and iNKT cells above 5 µg/ml as assessed by flow cytometry (data
not shown), and, therefore, cytotoxicity could mask their stimulatory capacity. Next, binding
to CD1d was evaluated in cell-free competition assays. When T cells were stimulated with
plate-bound recombinant CD1d and αGC, only the 7-azasphingosines 7 and 24 were partially
inhibitory at a 20-fold molar excess (see Figure 11.11, p.77). The large molar excess needed to
compete with αGC could be attributed to the fact that these lipids have only one tail, and thus
bind weakly to CD1d, whereas αGC binds with high affinity because it has two lipid tails. The
compounds were also tested for inhibition of the response to αGC using living APC. This is a
more sensitive assay than the one using plate-bound CD1d, but could be affected by other ways
of lipid-influence on APC. All compounds were carefully applied at nontoxic doses. As observed
with plate-bound assays, also with living APC, compounds 7 and 24 slightly inhibited T cell
response (see Figure 11.12, p.78). This was observed with all three tested cytokines (IL-4, IFN-γ
and TNF-α).
In conclusion, both 7-azasphingosines 7 and 24 do not stimulate iNKT cells but bind to human
CD1d, and might be used to influence iNKT cell responses.
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Figure 11.12
Competition of azasphingosines with alpha-galactosylceramide on APC. The 7-azasphingosines
7 and 24 are able to compete with αGC for CD1d on living APC. Reduction of iNKT cell
activation is seen by release of (A) IL-4, (B) IFN-γ and (C) TNF-α. Compounds 7 and 24 affect
potency and/or efficacy of αGC differently regarding the cytokine measured (open circles = no
competitor, open diamonds = 24, closed diamonds = 7).
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11.5. 4,5,6-tri-substituted piperidinones as conformationally
restricted ceramide analogues
Table 11.6 Structures of piperidinones with a single lipid tail
The 4,5,6-tri-substituted piperidinones without an additional alkyl chain at C(3)
The conformationally based piperidinone sphingosine analogues 7, 8, 15, and 16 i were syn-
thesized [Mathew et al. 2009 a] from allylic alcohol 34 via lactams 31 and 32. The l-arabino
diol 7 and the l-ribo diol 8 were transformed into the amino alcohols 17–24 (see Table 11.6,
p.79). The l-gluco ceramide analogues 43, 46a, and 47, and the l-altro ceramide analogues 51a
and 52 (see Table 11.7, p.80) were synthesized from either 31, or 32. The l-ribo diols 8 and 16,
and amino alcohols 19 and 20 inhibit sphingosine kinase 1, while the l-arabino analogues 7, 15,
17, and 18 are inactive. The l-arabino and the l-ribo dimethylamines 21–24, the l-gluco ce-
ramide analogues 43, 46a, and 47, and the l-altro ceramide analogues 51a and 52 did not block
sphingosine kinase 1. Neither the l-arabino diol 7 nor the l-ribo diol 8 inhibited sphingosine
kinase 2 or ceramide kinase. The l-arabino diols 7 and 15 stimulate iNKT cells when presented
by living APC and also by plate-bound human CD1d, whereas the l-ribo diols 8 and 16, the
l-arabino amino alcohols 17–18, and the dimethylamines 21–22 did not activate iNKT cells.
The l-gluco ceramide analogues 43, 46a, and 47 had a strongly stimulatory effect on iNKT cells
when presented by living APC and also by plate-bound CD1d, whereas the l-altro ceramide
analogue 52 activated only weakly. All activatory compounds preferentially induce the release
of proinflammatory cytokines, indicating the formation of a stable lipid-CD1d-TCR complex.
i Note that the compound numbers in this section refer to [Mathew et al. 2009 a]
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Table 11.7 Structures of piperidinones with two lipid tails
The 4,5,6-tri-substituted piperidinones with an additional alkyl chain at C(3)
(Glyco)sphingolipids and more specifically ceramides adopt a parallel orientation of the lipid
chains in the cell membrane, requiring a (Z)-configuration of the amide moiety, while the (E)-
configuration of amides is preferred in solution and in the solid state by a free energy difference
of ca. 1.2 kcal/mol [Langley et al. 2005; Pawar et al. 1998]. There is no a priori reason why the
amide moiety of a ceramide complexed to a receptor should either adopt the (E)- or the (Z)-
configuration. The crystal structure of αGC bound to the human and the mouse CD1d receptor
shows the (E)-configuration, i.e., the two alkyl chains diverge from each other [Koch et al. 2005],
suggesting that the configuration of the amide moiety and not only its hydrogen bond acceptor
and donor properties may be crucial for the interaction with receptors. Yet, only very few
compounds have been prepared that may be considered conformationally well-defined ceramide
analogues and are biologically active. The isoquinolines 1 were investigated as conformationally
restricted analogues of ceramide, and act as ligands of protein phosphatase 2A, a ceramide-
binding protein that has been implicated in signal transmission [Leoni et al. 1998]. The uracil
and thiouracil derivatives 2a and 2b, respectively, are further examples, exhibiting moderate
anti-tumor activity and toxicity in vitro and in vivo [Macchia et al. 2001]. Finally, the analogues
3 and 4 [Brodesser et al. 2003] inhibit GM-2 synthase. In 2006, AWA16-1 awajanomycin (5)
and its derivative 6, a piperidinone based cytotoxic agent, was isolated from the marine fungus
Acremonium sp. [Jang et al. 2006]. Both 5 and 6 inhibit the growth of A549 cells with half
maximal inhibitory concentration (IC50) values of 27.5 and 46.4 µg/ml, respectively.
We were interested in restricting the conformation of the headgroup of ceramide, and in par-
ticular of the amide moiety, as they are recognized and modified by sphingosine- and ceramide-
metabolizing enzymes. The conformationally restricted l-arabino and the l-ribo piperidinones
i 7 and 8, respectively, may be considered analogues of sphingosine, and the l-gluco, l-manno,
l-altro, and l-allo piperidinones 9–12, respectively, may be considered ceramide analogues mim-
icking the (Z)-configuration of the amide. The piperidinones 9–12, substituted at C(3) and C(6),
possess most of the structural features that are required for the biological functions of ceramides,
viz., C(1) and C(3) hydroxy groups [Koch et al. 2005], the C(2) N -acylamino substituent, a trans
i Piperidinones are also known as hexonolactams. The configuration is specified by the carbohydrate prefix in
the Theoretical Part, and by the (R/S)-designation in the Experimental Part [Mathew et al. 2009 a].
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double bond in the lipid chain of the sphingosine moiety [Koch et al. 2005; Malewicz et al. 2005],
and a substituent at C(3) corresponding to the lipid part of the N -acyl substituent. As com-
pared to sphingosines and ceramides, the piperidinones possess an additional center of chirality,
resulting in four diastereoisomeric pairs of enantiomers of the sphingosine analogues 7 and 8,
and in eight diastereoisomeric pairs of enantiomers of the ceramide analogues 9-12. Two and
four diastereoisomers possess the same configuration at the corresponding centers as d-erythro-
sphingosine (13) and ceramide (14), respectively. Starting from d-galactose will result in these
two and four diastereoisomers 7–12. Biological properties for which the piperidinone analogues
should be tested include the inhibition of sphingosine [Spiegel & Milstien 2007] and ceramide
kinases [Thevissen et al. 2006] and the effect on the production of lymphokines [Baumruker &
Prieschl 2002].
iNKT cells recognize a variety of lipid antigens presented by the CD1d molecule. Therefore, we
tested whether piperidinones are capable of stimulating this population of human T lymphocytes.
The piperidinones were first tested for cytotoxic effects in vitro. T cells were incubated overnight
with increasing doses of the sonicated piperidinones and the next day, cell death was assessed by
measuring the uptake of PI or 7AAD using a CYANTMADP flow cytometer (Beckman Coulter).
The LC50 were calculated for each compound (see Table 11.8, p.81).
Table 11.8 Median lethal concentrations (LC50) of piperidinones
Compound Configuration LC50 i Compound Configuration LC50
7 l-arabino 8 8 l-ribo nd ii
15 l-arabino 9 16 l-ribo nd
17 l-arabino 9 19 l-ribo 4.5
18 l-arabino 4.5 20 l-ribo 4
21 l-arabino 8 23 l-ribo 9.5
22 l-arabino 8 24 l-ribo nd
43 l-gluco >20 51a l-altro nd
46a l-gluco >20 iii 52 l-altro 7
47 l-gluco >20
i Given in µg/ml
ii Not determined
iii In activation it seemed toxic above 5 µg/ml (see Figure 11.15 (A-C), p.85)
The listed piperidinones (see Table 11.8, p.81), with the exception of l-altro 51a, were used to
stimulate iNKT cells (see Figure 11.13, p.83) presented by THP1 cells transfected with human
CD1d gene (THP1-hCD1d). In parallel experiments, plate-bound recombinant soluble human
CD1d was loaded with the relevant lipids and used to stimulate iNKT cells (see Figure 11.14,
p.84). Briefly, THP1-hCD1d cells or soluble plate-bound recombinant human CD1d (5 µg/ml)
were incubated with the sonicated compounds at the indicated concentrations in the presence
of T cells. For competition assays a fixed dose of the piperidinones was given 4.5 h in advance
of titrating αGC and addition of T cells. Culture supernatants were collected after 24 h, and
iNKT cell released cytokines were measured by ELISA [Shamshiev et al. 2002]. The l-arabino
diols 7 and 15 activated iNKT cells (see Figure 11.13, p.83), although they possess only one
lipid tail. This finding was unexpected, since all the iNKT cell stimulatory compounds described
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in the literature at the time possess two lipid chains. More recently, several studies reported
the binding of lipids with a single tail to CD1d [Cox et al. 2009; Yuan et al. 2009] and their
activatory capacity for iNKT cells [Fox et al. 2009], thus introducing a new class of stimulatory
lipids for iNKT cells.
In order to confirm that the T cell stimulatory activity is due to formation of complexes with
CD1d and not to cellular modifications induced by these piperidinones in APC, T cell activation
was tested using CD1d plate-bound assays. Both l-arabino diols 7 and 15 were active also in
this type of assay (see Figure 11.14, p.84), thus confirming that they form stimulatory complexes
with CD1d. The formation of complexes with CD1d is also supported by the finding that only
the l-arabino diols 7 and 15 possess stimulatory capacity whereas the l-ribo diols 8 and 16 do
not (see Figure 11.13, p.83).
Importantly, iNKT cells are activated by the l-arabino diol 7, but not by the l-arabino amino
alcohol 17 and the dimethylamino alcohol 21, with 7 differing from 17 and 21 only by the
C(6)-hydroxymethyl group. A similar activity was observed for the l-arabino diol 15 that is
active, whereas the l-arabino amines 18 and 22 are not. It is tempting to speculate that the
primary hydroxy group is important in interacting, presumably via hydrogen bonding, with the
CD1d molecule, thus determining its position within CD1d. This hydroxy group might also make
binding contacts with the TCR of iNKT cells, thus stabilizing the lipid-CD1d-TCR trimolecular
complex, as shown for the αGC antigen [Borg et al. 2007; Wun et al. 2008; Zajonc & Wilson
2007]. A second important finding is that only the l-arabino diols 7 and 15 were active, whereas
the l-ribo diols 8 and 16 were not, suggesting that binding of the lipid to CD1d, or its positioning
within CD1d, is dictated also by this structural element. Since the presence of a second lipid tail
in the lipid antigen might stabilize the lipid-CD1d stimulatory complexes and facilitate T cell
activation, we tested piperidinones with an additional substituent at C(3).
The l-gluco ceramide analogues 43, 46a, and 47 had a strongly stimulatory effect on iNKT
cells when presented by living APC and also by plate-bound human CD1d, whereas the l-altro
ceramide analogue 52 activated only weakly (see Figure 11.15, p.85), suggesting that also in
these compounds the configuration of C(3) and C(4) is important. A similar stimulatory activity
was observed in plate-bound assays (see Figure 11.16, p.86), confirming that each molecule forms
stimulatory complexes with CD1d. The compounds with two lipid tails showed a similar efficacy
and potency as 7 and 15, which have only one lipid tail, indicating that addition of a short
alkenyl chain at C(3) does not change this biological activity.
A final unexpected finding was that all tested compounds preferentially induce release of TH1-
like cytokines IFN-γ and TNF-α, whereas the TH2 cytokine IL-4 is released in low amounts,
as shown by the IFN-γ/IL-4 and TNF-α/IL-4 ratios with αGC, the l-arabino diols 7 and 15
(see Figure 11.14 (D), p.84), the l-gluco ceramide analogues 43, 46a, and 47, and the l-altro
ceramide analogue 52 (see Figure 11.16 (D), p.86), respectively. Thus, these piperidinones induce
preferentially a TH1 response. As the tested iNKT cells release both classes of cytokines when
the αGC agonist is used as antigen, the TH1-biased response has to be ascribed to the type of
lipid-CD1d complexes formed by these piperidinones. TH1-responses have been associated with
prolonged TCR engagement, whereas TH2-responses have been ascribed to weak interactions. It
is therefore tempting to speculate that piperidinones form complexes with CD1d that make high
affinity interactions with the TCR of iNKT cells and/or the complexes accumulate in detergent-
resistant membrane microdomains [Im et al. 2009]. Future studies will address this point.
In conclusion, fine-tuning the structure of piperidinones may lead to the rational design of
new iNKT cell activatory compounds with unique biological properties. The generation of lipid
compounds preferentially inducing TH1 responses might have applications in novel vaccination
and anti-tumor therapies.
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Figure 11.13
Single tail piperidinones presented by living APC activate iNKT cells. The l-arabino diols 7
and 15 stimulate iNKT cells when presented by THP1-hCD1d APC as measured by release of
(A) IL-4, (B) IFN-γ and (C) TNF-α (closed circles = 7, open circles = 8, closed triangles = 15,
open triangles = 16). (D) Diols 7 and 15 preferentially induced a TH1 response, as visualized by
the IFN-γ/IL-4 ratio of the stereotype TH1 versus TH2 cytokines IFN-γ and by the TNF-α/IL-4
ratio.
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Figure 11.14
Single tail piperidinones presented by plate-
bound CD1d activate iNKT cells. The l-
arabino configured diols 7 and 15 induce cy-
tokine production by iNKT cells when pre-
sented on recombinant soluble plate-bound hu-
man CD1d, as measured by released IL-4.
11.6. Final conclusions and outlook
Overall, the techniques introduced here will not only enable highly sensitive identification of
antigen-specific iNKT cells but testing of their response towards a large variety of antigens
designed as vaccines, as tumor antigens or for other applications. Broadening of these techniques
to type 2 NKT cells and to other CD1-restricted T cells remains a challenge for the future.
Our finding that certain types of antigen, namely piperidinones, preferentially induce a TH1-
like phenotype has to be confirmed in vivo as so far it has been thought that second signals
determine iNKT cell function [Taniguchi et al. 2010]. iNKT cells are well know for their self-
reactivity and ability to readily release large amounts of cytokines, bridging innate and acquired
immunity. Homeostatic self-ligand recognition appears to prime or rather prepare, as manifested
by acquisition of activation markers and accumulation of cytokine messenger RNA, iNKT cells
without eliciting any effector functions. This activated phenotype of iNKT cells under steady
state conditions in vivo ensures a rapid response to exogenous antigens. However, this might
indicate that iNKT cells require additional environmental signals to mediate their functions.
As iNKT cells can functionally resemble TH1 or TH2 cells, in vivo manipulation may change
the balance between pro- and anti-inflammatory cytokines to favor the desired outcome of the
immune response depending on the disease or treatment context. In conclusion, the screening of
a large number of synthetic molecules has shown that design of compounds like the piperidinones
may provide optimized therapeutic reagents to induce protective or regulatory immune responses.
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Figure 11.15
Double tail piperidinones presented by living APC activate iNKT cells. The l-gluco ceramide
analogues 43, 46a, 47, and the l-altro ceramide analogue 52 presented by THP1-hCD1d promote
release of (A) IL-4, (B) IFN-γ and (C) TNF-α (stars = αGC, open triangles = 43, gray triangles
= 46a, closed triangles = 47, open circles = 52). The dotted lines indicate background activation
cytokine levels. (D) All active compounds induced more of a TH1 response, as seen by the ratios
IFN-γ and TNF-α to IL-4.
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Figure 11.16
Double tail piperidinones presented by plate-bound CD1d activate iNKT cells. The l-gluco
ceramide analogues 43, 46a, and 47, and the l-altro configured ceramide analogue 52 are stim-
ulatory for iNKT cells when presented on dimerized plate-bound human CD1d, as IL-4 (A) and
GM-CSF (B) are released.
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12. Invariant natural killer T cells link inflammation
and neovascularization in human atherosclerosis
Atherosclerosis is a chronic inflammatory disease of large arteries. It is complicated
by cardiovascular events which are usually provoked by plaque rupture or erosion.
Inflammation participates in lesion progression and plaque rupture. Identification of
the cause of inflammation and hence the leukocyte populations involved in plaque
destabilization is important for effective prevention of cardiovascular events. As lipid
retention supports growth of atherosclerotic plaques, lipid-specific invariant natu-
ral killer T (iNKT) cells and their antigen-presenting molecule (APM) CD1d were
investigated.
In human atherosclerotic lesions, CD1d+ antigen-presenting cells (APC) and iNKT
cells were correlated with disease severity and activity. We aimed to elucidate poten-
tial mechanisms whereby these cells might be involved in plaque formation and/or
destabilization. CD1d+ APC colonized advanced plaques in symptomatic patients
and were most abundant in plaques with concomitant signs of ectopic neovascular-
ization. iNKT cells were detected in plaques and therein their frequency among the
T cell compartment exceeded the one in blood. iNKT cell lines isolated from plaques
promptly produced proinflammatory cytokines when stimulated by CD1d-expressing
APC and alpha-galactosylceramide proving the presence of CD1d-restricted T cells.
Antigen-stimulated iNKT cell-derived culture supernatants showed angiogenic activ-
ity in an endothelial cell-spheroid model of in vitro microvascular sprout formation
and strongly activated endothelial cell migration. This functional activity was as-
cribed to interleukin (IL)-8 released by iNKT cells upon lipid recognition.
These findings introduce iNKT cells as novel cellular candidates to promote plaque
neovascularization and destabilization in human atherosclerosis. Furthermore iNKT
cell-lipid antigens with beneficial effects might be designed to be used in medical
treatment or as vaccines.
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Cardiovascular events which are usually precipitated by plaque rupture or erosion [Naghavi
et al. 2003 a,b; Steg et al. 2007; Virmani et al. 2005] are complicating atherosclerosis (ATH),
a chronic inflammatory disease of large arteries. Vulnerable plaques that are prone to rupture
are characterized by spatially and temporally interconnected inflammation [Hansson 2005; Libby
2002; Redgrave et al. 2006; Ross 1999; van der Wal et al. 1994; Virmani et al. 2005], plaque
hemorrhage [Kolodgie et al. 2003; Virmani et al. 2005] and abnormal apoptosis [Clarke et al.
2006; Lim et al. 2008]. Both innate and acquired immune responses can modulate atheroscle-
rotic plaque development [Binder et al. 2002]. Macrophages and T lymphocytes infiltrating the
arterial wall during atherosclerosis [van der Wal et al. 1989] are supposed to produce proin-
flammatory cytokines, chemokines, metalloproteinases and mesenchymal growth factors which
are all potentially involved in plaque growth and rupture but might also contribute to plaque
stabilization. A histopathological quantitative analysis has suggested that macrophages in the
arterial wall seem to be protective in the early, but deleterious in the late stages of the disease
[Fleiner et al. 2004]. T cell populations with different functional capacities have been identified
within atherosclerotic lesions [van der Wal et al. 1989] and this contributes to the pathogenic
complexity of the inflammatory process [Robertson & Hansson 2006].
In addition to inflammation, other mechanisms such as lipid retention [Tabas et al. 2007],
neovascularization [Doyle & Caplice 2007; Moreno et al. 2006; Virmani et al. 2005] and tissue re-
modeling [Lijnen 2003; Newby 2006] support plaque growth. How different leukocyte populations
contribute to or are affected by these additional mechanisms remains elusive. T cells recognizing
protein or lipid antigens that accumulate within plaques are likely to be involved and invariant
natural killer T (iNKT) cells have recently attracted attention in this respect [Major et al. 2006].
αGC, the archetype pan-iNKT cell antigen, accelerates atherosclerotic lesion formation in the
mouse [Major et al. 2004; Nakai et al. 2004; Tupin et al. 2004] and CD1d-deficient as well as
TCR Vα14-deficient mice, both lacking iNKT cells, are protected in this model of atherosclerosis
[Aslanian et al. 2005; Rogers et al. 2008; Tupin et al. 2004]. Moreover, adoptive transfer of iNKT
cells markedly increases plaque burden [VanderLaan et al. 2007]. Taken together, these animal
studies provide strong evidence that iNKT cells are involved in lesion development. However,
no detailed investigations have focused on iNKT cells in human atherosclerosis. Although CD1d
is expressed at the protein level in human atherosclerotic lesions [Melian et al. 1999] it remains
unknown whether CD1d expression correlates with lesion severity or disease activity.
Identification of leukocyte populations involved in plaque formation and destabilization is
important for effective prevention and treatment of cardiovascular events. The aim of this
project was to investigate CD1d-positive antigen-presenting cells (APC) and iNKT cells in human
atherosclerotic lesions, correlate them with disease severity and activity, and elucidate potential
mechanisms by which these cells might be involved in plaque formation, progression and desta-
bilization. Lesional CD1d+ APC were present in large quantities in advanced plaques and were
most abundant in plaques with accompanying ectopic neovascularization. iNKT cells were de-
tected inside plaque tissue and were enriched in frequency among CD3+ T cells when compared
to blood. For the first time phenotypical iNKT cell lines were isolated from plaques. The isolated
iNKT cell lines were able to promptly and efficiently produce large amounts of proinflammatory
cytokines upon stimulation by CD1d-expressing APC presenting αGC, thus proving the presence
of CD1d-restricted T cells. Furthermore, their antigen-specific activation threshold is reduced
by at least one log compared to iNKT cells from blood of healthy donors, meaning the antigen
potency is increased tremendously. Cell culture supernatants derived from antigen-stimulated
iNKT cells showed angiogenic activity in an endothelial cell-spheroid model of in vitro microvas-
cular sprout formation and strongly induced endothelial cell migration. This functional influence
on endothelial cell activity was imputed to interleukin (IL)-8 released by iNKT cells upon lipid
recognition.
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12.1. CD1d-expressing cells in atherosclerotic lesions are a sign of
arterial vulnerability
Macrophages and CD1d+ cells were quantified in arterial tissue (see Figure 12.1, p.91) obtained
from asymptomatic patients (n = 27) and patients with symptomatic disease (n = 22) using
human arterial tissue microarrays [Fleiner et al. 2004]. With this technique we investigated a
total number of 196 arterial sectors. Each sector was histologically scored for plaque type ac-
cording to the American Heart Association (AHA) consensus report [Stary et al. 1992] and the
presence of CD1d+ cells and CD68+ macrophages as well as von Willebrand factor-positive mi-
crovessels was determined. Cell numbers were determined per intimal area to enable appropriate
comparison between sectors. This approach allowed us to correlate histomorphological findings
with disease activity and lesion severity. The clinical characteristics of the 49 patients are shown
in a table (see Table 9.2, p.53). Both CD68+ macrophages and CD1d+ cells were more com-
monly found in advanced lesions than in early plaque stages (see Figure 12.1 (A), p.91). We
found CD68+ macrophages (P=0.029) and CD1d+ cells (P<0.001) more frequently in plaques
from symptomatic patients with previous cardiovascular events (see Figure 12.1 (B), p.91). In
patients with symptomatic, clinically active disease, atherosclerotic plaques with ectopic neovas-
cularization (neovessels) [Fleiner et al. 2004] had on average the highest numbers (P<0.001 and
P=0.002 respectively) of macrophages and CD1d+ cells (see Figure 12.1 (B), p.91). Among the
patients with symptomatic ATH, 16 died of a incidental cardiovascular event. The number of
CD1d+ cells inside the intimae of these 16 patients (4.24 (0.72-11.55) cells/mm2) was comparable
to that of the 6 patients with stable cardiovascular disease (2.25 (0.74-31.91) cells/mm2). This
suggests that CD1d+ cell accumulation represents an irreversible, rather than a transient pro-
cess of plaque destabilization. It is remarkable that CD1d+ cells are virtually absent from early
lesions and are uncommon in asymptomatic patients. For the tissue microarray analysis, arterial
rings were harvested on average 24 h after death. We tested whether the number of detectable
CD1d+ cells would diminish with progressive time after death and found no correlation between
these two parameters (data not shown). Since the presence of CD1d+ APC in the arterial intima
positively correlates with lesion severity, disease activity and neovascularization, these cells may
participate critically in plaque growth and destabilization.
12.2. iNKT cells are found in atherosclerotic lesions
The presence of CD1d+ APC in advanced, unstable atherosclerotic lesions prompted a search
for iNKT cells. Due to the predicted scarcity of these cells, several different approaches were
applied to demonstrate their presence in atherosclerotic plaques. Lesional arterial intima from
5 patients with ATH was examined by confocal microscopy. We demonstrated the presence of
CD3+/Vα24+ and CD3+/Vβ11+ cells, which represented up to 3% of total infiltrating CD3+ T
cells in all lesions analyzed [Kyriakakis et al. 2009]. Since these findings only suggest but do not
prove the presence of iNKT cells we next prepared cell suspensions from thrombendarterectomy
specimens and performed co-staining with anti-Vα24 and anti-Vβ11 mAb [Kyriakakis et al.
2009]. The identification of Vα24/Vβ11 double-positive (DP) cells provided evidence that iNKT
cells are present in the diseased arterial wall.
We additionally performed fluorescence and confocal microscopy of lesional tissue from 20
patients with anti-CD1d and anti-TCR Vα24-Jα18 mAb, which recognizes the iNKT-specific
pairing of the TCR α-chain variable and joining region namely Vα24 to Jα18 [Exley et al. 2008;
Montoya et al. 2007]. Representative micrographs unequivocally demonstrate the presence of
iNKT cells in atherosclerotic lesions (see Figure 12.2, p.93). In tissues incubated with an iNKT
cell clone to allow their invasion, TCR Vα24-Jα18 staining was mostly seen within lesional
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Figure 12.1
APC in atherosclerotic lesions. APC in atherosclerotic lesions. The number of CD68+
macrophages and CD1d+ cells per intima area were determined with arterial tissue microar-
rays. For each arterial sector, the intima area was morphometrically measured and the CD1d+
and CD68+ cells in the intima counted (expressed as cells/mm2). Each data point represents
a single sector. In addition, median values are shown and error bars represent the interquartile
range. (A) Macrophage and CD1d+ cell counts in arterial sectors affected by atherosclerotic
lesions of increasing severity according to the AHA classification. (B) Quantitative analysis of
macrophage and CD1d+ cell counts in arterial sectors according to disease activity (i.e. whether
patients suffered cardiovascular events during their lifetime or not and said to have asymptomatic
(ASA) or symptomatic ATH (SA)). Neovessels were detected as von Willebrand factor-positive
microvessels in the arterial intima and plaques were scored positive (closed circles) or negative
(open circles) with respect to this anatomical sign. * P<0.5, ** P<0.01, *** P<0.001, ****
P<0.0001, ns = not significant. Experiments were performed in part by Jan Andert.
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vasa vasora/neovessels or adjacent tissue but not deep within the tissue as observed for tissue
sections of patients. Furthermore, there was evidence of iNKT TCR and CD1d polarization
towards each other and even colocalization of the iNKT TCR with CD1d (see Figure 12.3, p.94).
These findings indicate an ongoing activation of iNKT cells on CD1d+ APC deep inside the
atherosclerotic tissue.
To confirm and formally prove that iNKT cells reside within atherosclerotic lesions we next
isolated and expanded iNKT cells from thrombendarterectomy specimens containing plaques
obtained from symptomatic patients and performed phenotypic and functional studies. We
established 6 bulk T cell lines by stimulation with αGC and CD1d+ APC. Flow cytometry
analysis using 5 color staining showed that 60-90% of CD3+ cells were co-expressing TCR Vα24
and Vβ11 chains (see Figure 12.4 (A), p.95). In all lines, Vα24+/Vβ11+ cells were also stained
with αGC-loaded soluble human CD1d dimers and five out of the six iNKT cell isolates expressed
the CD4 molecule, as shown by one representative line (see Figure 12.4 (A), p.95), and one was
double-negative (DN) for CD4 and CD8. When plaque-derived iNKT cells were stimulated with
αGC and CD1d+ APC [Brossay et al. 1998], they produced large amounts of IL-4, TNF-α, IFN-
γ and GM-CSF (see Figure 12.4 (B), p.95), resembling iNKT cells from peripheral blood. To
compare responsiveness of plaque-derived iNKT cell lines to circulating iNKT cells, we calculated
the half maximal effective concentration (EC50) values of αGC of the established lines and a
set of iNKT cell clones from peripheral blood of different normal donors when releasing IL-4,
IFN-γ (see Figure 12.5 (C), p.96), TNF-α and GM-CSF (data not shown). For iNKT cell lines
from plaques the EC50 values of αGC were at least 10-fold lower as compared to peripheral
blood-derived iNKT cell clones, pointing to a high responsiveness of plaque-derived iNKT cells,
at least to this lipid antigen. Taken together, these results prove that the iNKT cells present
within atherosclerotic lesions have phenotypic and functional features of bona fide iNKT cells
[Godfrey & Kronenberg 2004 a] and react to αGC with unusual high efficiency maybe due to
an antigen selection mechanism inside plaques. The mechanism by which the antigen-specific
activation threshold of iNKT cells is lowered in or by plaques remains unknown and needs further
investigation.
12.3. Reduction of circulating iNKT cells in ATH patients
Next we investigated whether a similar expansion of iNKT cells was detectable in the circulating
blood of vulnerable patients with symptomatic ATH. Three groups of donors, namely patients
with symptomatic ATH, age-matched control patients free of cardiovascular events in the past
(i.e. asymptomatic) and young healthy control individuals free of any sign of atherosclerotic
disease were compared. Single living iNKT cells were detected in peripheral blood mononuclear
cells (PBMC) [Mutschelknauss et al. 2007] with four color immunofluorescence analysis using
anti-CD3, anti-TCR Vα24, anti-TCR Vβ11 mAb and αGC-loaded CD1d dimers. Unexpectedly,
we detected a profound reduction of circulating iNKT cells in symptomatic patients (P=0.001)
compared with the two control groups (see Figure 12.6, p.96). A reduction was also observed
in elderly patients free of cardiovascular events (P<0.01), possibly reflecting an age-related ef-
fect on this lymphocyte subset [Jing et al. 2007]. When taken together with the colonization
of atherosclerotic lesions by CD1d+ cells (see Figure 12.1 (B), p.91), our observations are in
accordance with the concept that iNKT cells undergo tissue redistribution and perhaps home
preferentially to atherosclerotic lesions in patients with clinically active disease.
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Figure 12.2
Specific identification of iNKT cells in ATH lesions. Columns (left to right) show the staining
of iNKT cells with anti-TCR Vα24-Jα18 (6B11), of CD1d+ cells (51.1), iNKT in red merged to
CD1d+ cells in green (merged), and of nuclei (Hoechst). The first three rows from the top show
staining of tissue from three different patients. The fourth row gives a representative isotype
staining of tissue from one of the three patients. The fifth row depicts a staining of a section
from arterial tissue invaded by an iNKT cell clone. Scale bars represent 10 µm.
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Figure 12.3
Polarization of the TCR on iNKT cells towards CD1d on APC in ATH lesions. Columns (left
to right) show the staining of iNKT cells with anti-TCR Vα24-Jα18 (6B11), of CD1d+ cells
(51.1), iNKT in red merged to CD1d+ cells in green (merged), and of nuclei (Hoechst). The
rows show staining of three representative tissue sections of two individual patients demonstrating
polarization and/or colocalization of the TCR on iNKT cells towards CD1d on APC and vice
versa. Scale bars represent 10 µm.
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Figure 12.4
iNKT cells from atherosclerotic plaque tissue. (A) A representative (of 6 total) bulk T cell
line isolated from plaques and expanded after stimulation with αGC. T cells were stained with
anti-CD3, -CD4, -CD8 (not shown), -TCR Vα24 and -TCR Vβ11 mAb and with αGC-loaded
CD1d dimers (DIMER). Density plots gated on CD3+ (left) and on CD3/TCR Vα24/TCR Vβ11
triple-positive cells (right) are shown. (B) Lymphokine release from one representative plaque-
derived iNKT cell line upon in vitro stimulation with αGC in the presence (closed circles) or
absence (open circles) of CD1d+ APC. Results are expressed as mean ng/ml of triplicates ± SD.
Similar results were obtained with the other 5 cell lines in at least two independent experiments.
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Half maximal effective concentration of
alpha-galactosylceramide with iNKT cells from
atherosclerotic plaque tissue. Potency of αGC
on iNKT cell clones established from PBMC
(open symbols) or with iNKT cell lines iso-
lated from plaque tissue (closed symbols).
iNKT cells were added after αGC titration on
APC, cytokine release assessed by ELISA and
EC50 values calculated. Each symbol repre-
sents the EC50 value of one titration exper-
iment. Median and interquartile range are
given per group. For all cytokines measured
the potency of αGC with plaque-derived iNKT
cells is at least 1 log lower than with iNKT
cells from PBMC (P-values are given beside
the brackets).
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Figure 12.6
Circulating iNKT cells are reduced in ATH patients. Distribution of iNKT cells in PBMC
from healthy young donors (N) and from age-matched patients with asymptomatic ATH (ASA)
or patients with symptomatic ATH (SA). iNKT cells were detected by FACS with αGC-loaded
CD1d dimers (DIMER+) or with anti-TCR Vα24 and anti-TCR Vβ11 mAb (iNKT). Data are
shown as percentage after gating on T cells by means of CD3 or as percentage of total PBMC.
P-values are given above brackets.
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12.4. Characterization of proatherosclerotic activity of iNKT cells
The presence of CD1d+ cells and iNKT cells within advanced atherosclerotic lesions, particularly
in patients with symptomatic disease, prompted us to investigate whether this T lymphocyte
population has a role in key processes of plaque formation and destabilization. Given the fact
that plaque-derived iNKT cell lines were prone to cytokine release (see Figure 12.6 (C), p.96), we
investigated the spectrum of cytokines and chemokines produced by antigen-stimulated iNKT
cells in a BioPlex assay and found the presence of a number of proinflammatory and poten-
tial angiogenic modulators [Kyriakakis et al. 2009]. Since neovascularized arterial sectors had
the highest numbers of CD1d+ cells, subsequent investigations focused on effects of iNKT cell
activation on angiogenic behavior of endothelial cells (EC).
We examined angiogenic potential of conditioned medium (CM) derived from iNKT cell cul-
tures stimulated with (CM+) or without (CM−) αGC using the EC-spheroid model of in vitro
microvascular sprout formation as a global functional test for angiogenesis. Visualization of
spheroids composed of human microvascular EC indicated that CM+ induced greater sprout
outgrowth than CM− (see Figure 12.7 (A), p.98). Morphometric analysis showed a significant
increase in both the number (see Figure 12.7 (B), p.98) and length (see Figure 12.7 (C), p.98) of
sprouts. CM collected from cultures containing αGC but lacking either CD1d+ APC or iNKT
cells, or both failed to enhance sprout outgrowth [Kyriakakis et al. 2009]. Taken together, these
data confirm that antigen-stimulated iNKT cells can promote angiogenesis in vitro.
12.5. Soluble factors released by iNKT cells promote EC
migration
Angiogenesis is a complex process and both proliferation and migration of EC contribute to this
phenomenon [Adams & Alitalo 2007; Doyle & Caplice 2007]. To identify which of these activities
is modulated in response to iNKT cell activation, we compared effects of CM on proliferation
and migration of EC in monolayer cultures. CM+ derived from different iNKT cells did not
activate EC proliferation [Kyriakakis et al. 2009] but did induce cell migration. Two different
methods were used to evaluate migration. Confluent EC monolayers were scrape-wounded and
EC migration into the wound was recorded over a 12 h period by time lapse videomicroscopy.
This wound healing assay showed more rapid migration into the wound area for EC cultured
in the presence of CM+ (see Figure 12.8, p.99). Representative videos showing EC motility
in the presence of CM− (FigS4video1-CM−.avi) and CM+ (FigS4video2-CM+.avi) are given
in the Supplemental Material Appendix [Kyriakakis et al. 2009]. The second assay quantified
transmigration of EC in a Boyden chamber and also demonstrated enhanced migration of EC
toward CM+ (see Figure 12.8 (C), p.99). These data suggest a chemokine-dependent effect on
EC angiogenic behavior.
12.6. IL-8 is produced by iNKT cells and induces EC migration
IL-8, a pleiotropic chemokine with known angiogenic activity in vitro and in vivo [Li et al.
2003; Simonini et al. 2000], was amongst numerous factors released by activated iNKT cells
[Kyriakakis et al. 2009]. iNKT bulk lines isolated from plaques (see Figure 12.9 (A), p.101)
and iNKT cell clones [Kyriakakis et al. 2009] showed strong intracellular staining for IL-8 when
stimulated with αGC proving that they readily produce this chemokine. To determine the
contribution of iNKT cell-released IL-8 to the angiogenic potential of CM+, wound-healing assays
were conducted in the presence of anti-IL-8 blocking antibodies or using CM which had been
subjected to immunodepletion of IL-8 prior to assay. Both treatments completely abrogated the
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Figure 12.7
Antigen activation of iNKT cells increases sprout outgrowth from EC spheroids. Conditioned
medium derived from iNKT cell cultures stimulated with (CM+) or without (CM−) αGC was
examined using the EC-spheroid model of in vitro angiogenesis. (A) Representative images of
whole spheroids 24 h after exposure to CM. Morphometric analysis of spheroids for total sprout
number (B) and total sprout length (C) shows significantly greater angiogenic potential for CM+
(filled bars) compared with CM− (open bars). Bars undermarked ‘no APC’ indicate the response
to CM from iNKT cells cultured alone. Data are mean ± SD from six independent experiments
(* P<0.05, ** P<0.01). CM+ from a second iNKT cell clone elicited similar proangiogenic effects
(data not shown). Experiments were performed in part by Emmanouil Kyriakakis
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Figure 12.8
Antigen activation of iNKT cells promotes EC migration. Confluent monolayers of EC were
scrape-wounded and the subsequent rate of wound closure monitored over a time period of
12 h by time lapse videomicroscopy. Acquired images were processed and analyzed using cellR
software. (A) Representative images of EC migration acquired at 0, 3, 6, 9 and 12 h after culture
of wounded EC monolayers in the presence of CM+ or CM−. White lines indicate the location of
the wound front and arrows indicate migration path length. (B) Quantitative analysis of the rate
of EC migration from the initial wound front into the wound area (path length versus time). The
data are representative of at least 30 independent experiments, each one performed in duplicate
and values are given as averaged path length measurements ± SD from triple fixed observation
fields/well. Motility was similarly enhanced by CM+ from different iNKT clones (data not
shown). (C) EC transmigration toward CM+ and CM− in Boyden chamber chemotaxis assay.
CM was present in the lower wells of the chamber. EC in serum-free culture medium were seeded
into the upper wells and transmigration quantified after a 6 h incubation. Data are reported as
mean ± SD (in arbitrary units) from three separate experiments each performed in duplicate.
*** P<0.001. Experiments were performed in part by Emmanouil Kyriakakis
99
12. iNKT cells link inflammation and neovascularization in human ATH
enhanced EC migration (see Figure 12.9 (B), p.101). Neither the inclusion of anti-IL-8 antibodies
nor IL-8-depletion affected the basal EC migration, thus excluding non-specific inhibitory effects
of the antibodies. Therefore, the enhanced migration response of EC to CM+ is dependent upon
IL-8 released by activated iNKT cells.
12.7. Discussion and Outlook
Our study investigated iNKT cells in human ATH.We found that cells expressing CD1d, the lipid-
antigen-presenting molecule (APM) for iNKT cells, are more abundant in advanced atheroscle-
rotic plaques and in lesions from patients with active, symptomatic disease. Amongst the patient
group with symptomatic disease, vascularized plaques had the highest number of CD1d+ cells.
We identified the presence of iNKT cells in atherosclerotic lesions and characterized their function
after isolation from plaques. iNKT cells from plaques show a high reactivity to the αGC antigen
and may promote neovascularization via an IL-8-dependent mechanism. Our study indicates
that iNKT cells may contribute to the predisposition of atherosclerotic plaques to rupture.
In order to perform a detailed and quantitative immunohistochemical analysis of inflammatory
cells in atherosclerotic plaques, we took advantage of tissue microarrays which allowed evaluation
of 196 samples from 49 patients. This technical approach facilitated the correlation of CD68+
macrophages and CD1d+ cells with lesion severity (i.e. plaque stage) and with plaque neo-
vascularization. Whereas CD68+ macrophages are commonly found in the human arterial wall
regardless of the plaque stage [Fleiner et al. 2004], CD1d+ cells were virtually absent from the
normal arterial intima or in early plaque stages. Expression of CD1d in human atherosclerotic
plaques has been reported in two studies [Bobryshev & Lord 2005; Melian et al. 1999]. However,
only a small number of samples was analyzed and a correlation was not made with the clini-
cal stage and neither with disease activity nor with histological hallmarks. Thus the question of
whether CD1d expression correlates with lesion grade was left open. In our study a large number
of CD1d+ cells was observed in advanced lesions (AHA type >IV) and particularly in lesions with
signs of neovascularization, thus demonstrating a close correlation with advanced disease. We
found that in asymptomatic patients, CD1d expression was present in only a minority (<20%)
of arterial sectors. In contrast, in patients with symptomatic ATH CD1d+ cells were found
more frequently and in up to 65% of the sectors with concomitant signs of neovascularization.
The preferential localization of CD1d+ cells in areas with neovascularization could be explained
by their efficient recruitment into vascularized plaques [Moulton et al. 2003] or, alternatively,
by their capacity to promote plaque neovascularization. Our data are in accordance with the
concept that CD1d may present lipid antigens locally to specific T cells, including iNKT cells,
which in turn may release angiogenic factors and contribute to neovascularization.
In the diseased arterial wall we found T cells expressing Vα24 or Vβ11 TCR chains, which are
used by iNKT cells. The identity of iNKT cells was confirmed by detection of TCR Vα24-Jα18,
the iNKT cell-specific TCR α-chain variable and joining region pairing, in tissue sections, by
detection of Vα24 and Vβ11 co-expressing T cells freshly isolated from lesions, and by expansion
of iNKT cell lines from plaques. The intraplaque infiltration of iNKT cells is accompanied by
their significant reduction in circulating blood in symptomatic patients. Although we could
not directly compare the iNKT cell numbers in plaques and circulating blood from the same
individuals, our results suggest that in plaques there is a 10-100 fold enrichment of iNKT cells
relative to T cells. This unusual accumulation might be caused by preferential homing to plaques
and retention following local activation and/or local proliferation upon antigen recognition.
The presence of iNKT cells in lesions has been inferred in mouse ATH models by molecular
investigations and not cellular isolation. In a pioneering study on ApoE-deficient mice under
high cholesterol diet, the presence of iNKT cells was suggested by RT-PCR studies [Paulsson
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Figure 12.9
Antigen activated iNKT cells produce IL-8 which promotes EC migration. (A) Intracellular
IL-8 analyzed by FACS in plaque-derived lines either resting (APC alone) or activated with
APC + αGC or with PMA + ionophore. Cells were stained intracellularly with anti-IL-8 and
anti-CD3 mAb. Percentages of CD3+ cells producing IL-8 are indicated. (B) Effects of inclusion
of anti-IL-8 blocking mAb (upper panels) and of IL-8 immunodepletion (lower panels) of CM on
EC migration examined by wound assay. Upper graphs: assays were performed in the absence
(open circles) and presence of neutralizing anti-IL-8 mAb or isotype control IgG (closed or
open triangles, respectively). Lower graphs: assays were performed with untreated CM (open
circles), or CM subjected to immunodepletion protocols using neutralizing anti-IL-8 mAb or
isotype control IgG (closed or open squares, respectively). Data shown are the average path
length measurements ± SD from triple fixed observation fields/well of duplicate samples. Similar
results were obtained in three independent experiments using CM from different iNKT cell clones.
Experiments were performed in part by Emmanouil Kyriakakis
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et al. 2000]. This observation was more recently confirmed using the same technique [Major et al.
2004; Nakai et al. 2004]. Nevertheless, to date iNKT cells have neither been isolated from plaques
nor functionally characterized. In one study, CD3+/CD161+ cells were histologically detected
in carotid specimens and appeared with a frequency of 0.3-2% among plaque infiltrating T cells
[Bobryshev & Lord 2005]. Yet, CD161 is expressed by a variety of T lymphocytes including iNKT
cells and therefore is not a specific marker for this latter population. In a second study, CD3+ cells
were expanded from aortic aneurysms with polyclonal activation [Chan et al. 2005]. However, all
expanded cells expressed the CD161 marker, suggesting an abnormal proliferation of this cell type
in vitro. Since the expression of semi-invariant TCR Vα24/Vβ11 was not further investigated
the presence of iNKT cells was not confirmed. We isolated plaque-infiltrating iNKT cells which
all were Vα24+ and Vβ11+. The fact that they also bound αGC-loaded CD1d dimers is clear
evidence that they are classical (type I) iNKT cells. These cells were also efficiently activated
by αGC presented by CD1d-expressing APC and released large amounts of cytokines, including
IL-4, IFN-γ, GM-CSF and TNF-α. Thus, in atherosclerotic plaques there is accumulation of
cells expressing phenotypic and functional features of bona fide iNKT cells.
Importantly, the iNKT cell lines isolated from plaques all showed an extremely low threshold
of activation when stimulated with αGC. The same low threshold was instead found only in a
minor fraction of iNKT cell clones isolated from peripheral blood. These findings might suggest
that in plaques there is a preferential accumulation of iNKT cell populations expressing high
affinity TCR. Another possibility is that plaque-derived iNKT cells lack expression of natural
killer (NK) inhibitory receptors and therefore they are activated by very low doses of antigen.
Recently, it has been reported that in a model of atherosclerosis in ApoE-deficient mice iNKT
cells with low expression of the inhibitory Ly49 receptors show proatherogenic activity, which
is more pronounced than that of Ly49-positive iNKT cells [To et al. 2009]. Future studies will
compare the expression of inhibitory receptors on iNKT cells isolated from plaques and peripheral
blood of the same donors.
How iNKT cell activation has a proatherogenic effect remains an open issue. One potential
mechanism relates to inflammation. Human atherosclerosis is also characterized by progressive
inflammation; since human iNKT cells isolated from plaques do release proinflammatory cy-
tokines, potentially in response to very low amounts of antigen, their chronic in situ activation
by lipid antigens might lead to lesion progression. This hypothesis is in line with many studies
conducted in mice. Injection of the potent iNKT cell agonist αGC increases the size and number
of plaques in a mouse ATH model [Tupin et al. 2004]. This experimental manipulation of iNKT
cell activation elicits a massive release of type 1 helper T cell (TH1) and type 2 helper T cell
(TH2) cytokines and an elevation in plasma levels of IL-6 and monocyte chemoattractant protein
1, which have been proposed to enhance local inflammation [Major et al. 2006; Tupin et al. 2004].
A second pathogenic mechanism may relate to neovascularization. The significant association
of CD1d+ cells with neovascularization in plaques suggested that iNKT cells may be directly
involved in angiogenic processes. Our findings revealed that iNKT cell activation by antigen has
proangiogenic effects as shown by enhanced microvascular sprout formation in an in vitro assay
of angiogenesis. This effect was not associated with EC proliferation but with EC migration
as demonstrated by enhanced EC motility in both wound healing and transmigration Boyden
chamber assays. Amongst the multiple cytokines that were produced by activated iNKT cells,
IL-8 was the most promising candidate to further investigate in this context. iNKT cells isolated
from plaques produce IL-8 as shown by intracellular staining. IL-8 was also detected previously
in the supernatant from lipid-stimulated blood-derived iNKT cells [Chang et al. 2007]. We found
that enhanced EC migration was dependent on IL-8 produced by iNKT cells. The experiments
with IL-8-blockade or IL-8 immunodepletion showing abrogation of the response support this
conclusion but do not rule out that co-stimulating agonists of IL-8 signaling are present in the
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culture media. Furthermore, these ex vivo studies do not prove that iNKT cell-derived IL-8 is
directly involved in plaque neovascularization and this hypothesis should be tested in appropri-
ate animal models. The participation of IL-8 in atherosclerotic lesion progression is suggested
by several studies [Reape & Groot 1999]. IL-8 has been detected in atheromatous tissue [Apos-
tolopoulos et al. 1996; Simonini et al. 2000; Wang et al. 1996] and can be induced in monocytes
by oxidized LDL and cholesterol [Terkeltaub et al. 1994; Wang et al. 1996]. Functionally, IL-8
contributes to intimal macrophage accumulation [Boisvert et al. 1998], to endothelial adhesive-
ness for monocytes [Gerszten et al. 1999], has mitogenic and chemoattractant effects on smooth
muscle cells [Yue et al. 1994] and may also facilitate plaque recruitment of CD8+ effector T cells
with high cytotoxic potential [Hess et al. 2004]. IL-8 has been proposed as an important mediator
of angiogenesis in cardiovascular lesions contributing to plaque growth [Simonini et al. 2000]. It
is tempting to speculate that iNKT cells, when locally activated by lipid antigens, exert both
promigratory and proinflammatory functions which may become important for plaque neovas-
cularization and destabilization. These functions might be shared with resident monocytes and
other T cells recognizing specific antigens in plaques. At present, the endogenous lipid antigens
stimulating iNKT cells are unidentified. If the lipid antigens would be known, their detection
within atherosclerosis lesions would support a cause-effect relationship in man.
In conclusion, our studies have revealed CD1d+ cells in advanced, vascularized atherosclerotic
lesions from patients with active disease. We have identified the presence of iNKT cells within
plaques. We have isolated plaque iNKT cells and demonstrated their high sensitivity to antigen
stimulation and proinflammatory and proangiogenic potential in vitro. By these mechanisms,
iNKT cells could participate in plaque growth and destabilization. The hypothesis recently
emerged that atherosclerosis is an autoimmune disease and immunotherapeutic approaches were
discussed [Hansson & Libby 2006]. In the context of a potential T memory stem cell population
induced by the chronic progression of ATH, our observations might introduce iNKT cells, and
CD1d+ APC, as potential candidate targets for immuno-preventative and -therapeutic inter-
ventions in the future. Furthermore, identification of the lipid antigens involved in iNKT cell
activation would enable novel types of immunomodulatory treatments and thereafter a direct
demonstration of a cause-effect relationship in man by vaccination.
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13. Rafting and docking with CD1a
In professional antigen-presenting cells (APC) like dendritic cells (DC), CD1a is
mainly expressed at the cell surface and its organization within membranes is poorly
understood. Our studies report that major histocompatibility complex (MHC) class
II, invariant chain (Ii) and CD9 are coimmunoprecipitated with CD1a in immature
DC and that CD1a/invariant chain colocalization is dependent on raft integrity. Ex-
pression of CD1a in priorly CD1a-negative cells leads to increased invariant chain
trafficking to the cell surface. Silencing of invariant chain in DC induces CD1a accu-
mulation at the plasma membrane while the overall CD1a expression remains similar.
Localization of CD1a in lipid rafts is functionally relevant as raft disruption inhibits
CD1a-restricted antigen presentation. These findings identify invariant chain and
lipid rafts as key regulators of CD1a organization on the surface of immature DC
and of its immunological function as antigen-presenting molecule (APM).
Having elucidated the surface appearance, organization and internalization of
CD1a, its intracellular routes and molecular trafficking mechanisms are still elusive.
A major step in understanding differences in the nature of antigen presentation was
the realization that MHC class I molecules sample peptides transported to the en-
doplasmic reticulum (ER) from the cytosol while class II molecules sample peptides
generated within lysosomes. Among the CD1 isoforms, CD1a is unique because it
lacks any sorting motifs (e.g. a tyrosine-based cytoplasmic sorting motif, responsible
for internalization by the clathrin-mediated pathway) and solely localizes to the early
endocytic and recycling compartments.
Our investigations of CD1a trafficking and the role of its short cytoplasmic tail
revealed that CD1a can be internalized by a clathrin- and dynamin-independent
pathway and that it follows a Rab22a- and adenosine diphosphate ribosylation factor
6-dependent recycling pathway, similar to other clathrin-independent cargo. Post-
translational S-acylation of the CD1a cytoplasmic tail was found to occur but neither
determines the rate of internalization nor recycling nor its localization to detergent-
resistant membrane microdomains. These findings place CD1a closer to MHC class I
in its trafficking and potential antigen-loading compartments among CD1 isoforms.
As each of the five members of the CD1 family (CD1a-e) localizes to a distinct
subcompartment of endosomes, it has been widely assumed that the distinct traf-
ficking of CD1 isoforms must have evolved to enable them to survey lipid antigens
that follow different routes. Predictably, CD1a might have evolved to cope with lipids
that are contained in the early endocytic and recycling compartments. Strikingly, the
glycolipid antigen sulfatide also localizes almost exclusively to these compartments.
Swapping the cytoplasmic tail of CD1a for the one of CD1b and hence targeting it
to the late endosomal and lysosomal compartments decreased its capacity to present
antigen and shortened the half-life of stimulatory complexes. Thus, the intracellular
trafficking route of CD1a is essential for efficient presentation of lipid antigens that
traffic through the early endocytic and recycling pathways.
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13.1. CD1a associates with Ii, HLA-DR and CD9
Amongst the CD1 family the CD1a, CD1b, and CD1c isoforms are included in the CD1 group
1 based on their sequence homology [Porcelli & Modlin 1999], are detected on activated human
monocytes [Gregory et al. 2000; Sloma et al. 2004], and are highly expressed on monocyte-
derived immature DC [Martin et al. 1986] and on dermal DC in vivo. During their maturation,
DC undergo cellular changes which increase peptide loading and cell surface transport of major
histocompatibility complex (MHC) class II-peptide complexes while reducing MHC class II en-
docytosis [Pierre et al. 1997; Turley et al. 2000]. An important difference between presentation
of peptide and lipid antigens is that optimal peptide presentation to MHC class II-restricted T
cells is dependent on this maturation, whereas both immature and mature DC optimally present
lipid antigens to CD1-restricted T cells [Cao et al. 2002]. The T cell response to peptide antigens
is initiated by recognition of MHC class II expressed at the surface of professional APC. This
recognition is improved when MHC class II-peptides complexes are concentrated on the APC
plasma membrane in small lipid-rich microdomains [Huby et al. 1999; Poloso & Roche 2004].
Although MHC class II organization in lipid rafts of various cell types is now well documented,
this is not the case for CD1 molecules. Two studies have demonstrated the constitutive and
restricted presence of the CD1d isoform in the lipid rafts of mouse cells [Lang et al. 2004; Park et
al. 2005], whereas the localization of human CD1 molecules in specialized surface microdomains
of professional APC has not been explored.
We have focused our attention on CD1a localization and organization in immature DC. This
study [Sloma et al. 2008] investigates which proteins associate with CD1a, the possible interven-
tion of tetraspanins, proteins acting as molecular adaptors, the CD1a distribution in specialized
microdomains at the cell surface of immature DC, and the functional consequences of this or-
ganization on lipid antigen presentation. The results described in this study demonstrate that
CD1a molecules are associated with invariant chain (Ii) in immature DC, that CD1a and Ii
are recruited to cell surface lipid rafts, and that colocalization of CD1a and Ii is dependent on
cholesterol-dependent lipid rafts. Moreover, we show that CD1a-induced expression in a HeLa-
class II transactivator (CIITA) cell line led to an increased trafficking of Ii to the cell surface, and
that silencing of Ii in immature DC induced significant CD1a accumulation at the cell surface.
Finally, we show the role of immature DC membrane lipid rafts in T cell response to glycolipidic
antigen presented by CD1a. The overall results of the present study suggest that Ii and lipid
rafts have an impact on CD1a surface expression and CD1a-restricted T cell response.
The expression of CD1a, Ii, and human leukocyte antigen (HLA)-DR molecules on the plasma
membrane of immature DC was analyzed on day 5 and 7 of their differentiation from monocytes.
Analysis of cell surface and intracellular expression showed that CD1a was highly expressed at
the cell surface and poorly detected in intracellular compartments of immature DC [Sloma et al.
2008]. There was a low level of Ii chain expression and it was predominantly intracellular. The
HLA-DR molecules were clearly detected both at the cell surface and in intracellular compart-
ments. To find the partner molecules associated to CD1a at the surface of immature DC, we
performed immunoprecipitation experiments.
13.1. CD1a associates with Ii, HLA-DR and CD9
With CHAPS lysates, three major proteins around 33–35 and 24 kDa were coprecipitated specif-
ically with CD1a. With regard to previous studies we speculated that the p33–35 proteins de-
tected in the CD1a precipitates may be the 33 and 35 kDa isoforms of the Ii and/or the 35 kDa
HLA-DRα-chain. The CD1a precipitates were analyzed by Western blot with Ii- or HLA-DR-
specific mAb and relatively high levels of Ii were detected in CD1a precipitates as compared
with the relatively low levels of HLA-DR molecules (see Figure 13.1 (A), p.109). These results
demonstrate the association of CD1a and Ii in immature DC. To confirm this association at the
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cell surface, we performed sequential immunoprecipitation experiments. Ii was immunoprecip-
itated from surface biotinylated immature DC and eluted material was reimmunoprecipitated
with CD1a- or Ii-specific mAb. Ii isoform at ≈ 33 kDa and specific Ii dimers at ≈ 66-80 kDa
[Neumann et al. 2001] were visualized in Ii precipitates. Reciprocally, surface CD1a was precip-
itated from Ii-immunoprecipitates (see Figure 13.1 (B), p.109), thus demonstrating that CD1a
and Ii are indeed associated at the cell surface of immature DC. This observation does not
preclude that a third molecular partner could be involved in this association. The tetraspanin
CD9 has been shown to be mostly expressed at the plasma membrane of human immature DC
[Unternaehrer et al. 2007], and it can also interact with MHC class II at the surface of human
monocytes [Zilber et al. 2005]. We thus explored the possibility that the p24 protein detected in
CD1a precipitates could be CD9. After solubilization in CHAPS, many surface-biotin-labeled
proteins were coprecipitated specifically with CD9 including a 49 and 33 kDa protein [Engering
& Pieters 2001]. Western blotting of CD1a precipitates with the CD9 mAb Syb.1, identified the
p24 protein as CD9 (see Figure 13.1 (A), p.109). Identical experiments performed on immature
DC lyzed in Brij-98 led to the same observations (data not shown). These results show that
CD1a associates with the Ii, the tetraspanin CD9 and MHC class II molecules, and demonstrate
the CD1a/Ii association at the cell surface in human immature DC.
13.2. Ii silencing increases CD1a at the cell surface
While in steady-state, the four molecules are uniformly distributed at the cell surface, cross-
linking of CD1a led to its redistribution either in caps or in patches at the cell surface [Sloma
et al. 2008]. Dynamic recruitment of CD1a at the surface of immature DC was demonstrated
to induce a highly significant redistribution of Ii and CD9 together with CD1a and partial
redistribution of HLA-DR.
After sorting from the Golgi apparatus, Ii is mainly directed to endo-/lysosomal compartments.
Nevertheless, a pool of Ii can also escape from this trafficking and directly reach the cell surface
without entering endosomal compartments. As we have observed a tight link between CD1a and
Ii at the surface, we asked whether CD1a could participate in cell surface transport of Ii. We have
established HeLa-CIITA cell lines stably expressing CD1a or CD1b fused to green fluorescent
protein (GFP), and controlled that GFP does not modify the cell surface or the cellular trafficking
of the proteins as compared with wild type (WT) ones, as previously demonstrated [Manolova et
al. 2006]. We have analyzed the surface and total expression of Ii and HLA-DR on these CD1a+
cells and compared the results with those observed on CD1b+ cells and mock-treated HeLa-CIITA
cells. A significant increase in the surface expression level of Ii was observed in CD1a+ HeLa-
CIITA cells, while the total (surface and intracellular) Ii expression was unchanged in comparison
with the non-CD1a expressing HeLa-CIITA cell lines [Sloma et al. 2008]. This indicates that, on
CD1a+ HeLa-CIITA cells, the proportion of Ii molecules transported to the surface is increased.
Concerning HLA-DR expression, these cells harbored a slight and equivalent increase in both
surface and total expression. This suggests a global increase of HLA-DR expression in those cells
without any change in surface versus intracellular HLA-DR distribution.
The expression of Ii and MHC class II molecules in CD1b-expressing HeLa-CIITA cells was
equivalent to that observed on mock cells: a slight decrease of Ii was observed at the cell surface
as well as in permeabilized cells, and HLA-DR was decreased at the cell surface. Thus, the
increase in Ii surface transport was a specific effect of the CD1a expression in HeLa-CIITA cells.
To further investigate the functional relevance of CD1a/Ii association on immature DC, we
performed ribonucleic acid (RNA) interference experiments to knockdown the Ii expression on
immature DC. Immature DC obtained at day 5 of monocyte differentiation were transiently
transfected with small interfering RNA (siRNA) specific for Ii and analyzed by cytofluorimetry.
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Figure 13.1
CD1a associates with CD9, HLA-DR and Ii. (A) Unlabeled immature DC were lyzed in
CHAPS and CD1a precipitates were analyzed by Western blot with anti-CD9 (Syb.1), anti-
HLA-DRα (DA6.147), or anti-Ii (LN2) mAb. (B) Ii molecules were immunoprecipitated from
biotin-labeled immature DC. Material eluted from Ii precipitates was then subjected to a second
immunoprecipitation with CD1a- and Ii-specific mAb. CD1a and isotype control mAb were used
in first round of immunoprecipitation as controls: no material was detected in IgG1 negative
control precipitates and CD1a was clearly detected in CD1a positive control precipitates. β2
microglobulin (β2m) had run off the bottom of the gel to concentrate attention on proteins
with a molecular weight between 20 and 80 kDa. The data shown are representative of four
independent experiments.
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Figure 13.2
Ii interference induces CD1a accumula-
tion at the cell surface of immature DC.
Cell surface and total expression of CD1a
(mAb HI149) and HLA-DR (mAb D1.12) on
siRNAIi-treated immature DC expressed as
percentage mean fluorescence intensity vari-
ation with respect to siRNA control-treated
immature DC. Around 40 cells were exam-
ined in each preparation and the images shown
are representative cells observed in the same
preparation. The data shown are representa-
tive of four independent experiments.
Expression of CD83 was not detected on immature DC transfected with Ii- or control-siRNA
indicating that transfection did not induce DC maturation [Sloma et al. 2008]. Under these
conditions, the total expression of Ii was reduced by 95% (data not shown). As expected, the
surface and total HLA-DR expression was decreased (see Figure 13.2, p.110). Silencing of Ii
resulted in an increase of surface CD1a expression by ≈ 20% (see Figure 13.2, p.110). Therefore,
these results indicate that in the absence of Ii, CD1a molecules accumulate at the cell surface
and suggest that the Ii participates in CD1a endocytosis.
13.3. CD1a partition to detergent-resistant membrane
microdomains is necessary for efficient exogenous antigen
presentation
Clustering of proteins at the cell surface involves different actors and among them the tetraspanins
have been implicated due to their capacity to link numerous proteins and raft microdomains.
For this reason, we next asked whether there was a particular localization of these molecules
in specialized membrane microdomains [Simons & Ikonen 1997; Xavier & Seed 1999]. Protein
examination and quantification in Triton X-100 lysates of immature DC after fractionation by
sucrose-gradient density ultracentrifugation revealed that a significant proportion (12.8%) of CD1
molecules is found in lipid rafts. To determine the localization of CD1, HLA-DR, Ii, and CD9
molecules in cell surface lipid rafts, co-patching experiments at the surface of living cells were
performed using cholera toxin β, which binds to GM1, a constituent of cell surface lipid rafts.
Z-stack analysis on single cells confirmed total and partial colocalization (data not shown) of Ii
and CD1a with cholera toxin β, respectively. In agreement with previous studies [Poloso et al.
2006; Zilber et al. 2005], only a minor fraction of CD9 molecules colocalized with GM1. We then
examined whether the dynamic recruitment of Ii and CD9 with CD1a at the surface of immature
DC is dependent on lipid raft integrity. Cells were treated with methyl-β-cyclodextrin (MβCD)
to deplete cholesterol and disrupt lipid rafts, and colocalization experiments were performed
as described above. Induced CD1a relocalization after MβCD treatment no longer led to the
enrichment of Ii into CD1a patches. The few areas of HLA-DR/CD1a colocalization observed
before treatment with MβCD were almost completely lost by cholesterol depletion. In contrast,
the CD1a/CD9 colocalization was still observed after raft disruption. These results indicate
that the recruitment of Ii with CD1a is highly dependent on lipid raft integrity. To further
investigate the CD1a/Ii association in immature DC surface lipid rafts, CD1a was pulled-down
from sucrose gradient fractions of surface biotinylated immature DC and revealed surface protein
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Figure 13.3
CD1a partitions to detergent-resistant mem-
brane microdomains, which are necessary for
efficient CD1a-restricted exogenous antigen
presentation. CD14+ monocytes from hu-
man donors were differentiated into immature
monocyte-derived DC and cholesterol depleted
by treatment with methyl-β-cyclodextrin. DC
were then fixed and incubated with indicated
concentrations of sonicated antigen and CD8-
2 T cells, which recognize dideoxymycobactin
presented by CD1a. After 21 h, the release
of IFN-γ was measured by ELISA. Error bars
represent SD of triplicate measurements, and
the results are representative of three indepen-
dent experiments.
with streptavidin Western blotting. We observed that CD1a was equally distributed throughout
the gradient, including the lipid raft enriched fractions, confirming that CD1a is present in cell
surface lipid rafts of immature DC in steady state conditions. Moreover, a p33 protein corre-
sponding to the molecular weight (MW) of Ii p33, was exclusively detected in CD1a precipitates
from raft fractions (fraction 3–4) [Sloma et al. 2008]. Altogether these results demonstrate that
the CD1a/Ii association is constitutive in immature DC and can take place during the dynamic
recruitment of CD1a in lipid rafts.
To confirm that detergent-resistant membrane microdomains are important for CD1a-dependent
antigen presentation, we tested the efficiency of presentation of a CD1a-dependent antigen in
cholesterol-depleted immature monocyte-derived DC. We treated DC with MβCD, fixed the
cells and incubated with dideoxymycobactin and CD8-2 T cells [Moody et al. 2004]. We found
a striking decrease in the efficiency of presentation of this antigen, which in these experimental
conditions has to be surface loaded (see Figure 13.3, p.111). The same was seen when MβCD-
treated fixed immature DC were loaded with sulfatide and used to stimulate the CD1a-restricted
sulfatide-specific human T cell clone K34B9.1 (data not shown). Non-fixed cells, in which MβCD
is washed away after treatment, do not present any defect in dideoxymycobactin presentation
(data not shown). Thus circumstances allowing for raft reconstitution restore the T cell response
and this indicates that the cells are neither dead nor functionally impaired after cholesterol de-
pletion. These results [Barral et al. 2008; Sloma et al. 2008] suggest that plasma membrane
detergent-resistant membrane microdomains are important for CD1a-restricted antigen presen-
tation in DC.
13.4. CD1a chimeras – tail to traffic twists
Albeit CD1 molecules are structurally similar to MHC class I, they functionally resemble MHC
class II in regard to the ability of both molecules to survey endocytic compartments and, specif-
ically, late endosomes (LE)/lysosomes for antigen acquisition.
The cytoplasmic tail of CD1b and CD1d [Barral & Brenner 2007] proteins has been shown to
be critical for CD1 intracellular localization and its antigen-presenting function. The cytoplasmic
tails of human CD1b, CD1c and CD1d, and also murine CD1d, all possess a tyrosine-based motif
of the YXXφ type in which Y is a tyrosine, X is any amino acid and φ is a bulky hydrophobic
residue. In contrast, CD1a does not contain any recognizable sorting motifs (see Table 13.1,
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Figure 13.4
CD1a cartoon I - CD1a raft association, partners and dependency. Schematic view of a cell
representing our findings that CD1a partitions (10-15%) into lipid rafts and associates with
Ii, HLA-DR (DR), and CD9. CD1a/Ii interaction is dependent on lipid raft integrity whereas
CD1a/CD9 interaction does not depend on lipid raft integrity. Ii is involved in CD1a internal-
ization and recycling. Efficient activation of CD1a-restricted T cells is dependent on detergent-
resistant membrane microdomains.
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p.113). The deletion of the cytoplasmic tails of CD1b and murine CD1d reduces or abolishes
the internalization and trafficking of the respective proteins to late endocytic compartments
[Briken et al. 2002; Chiu et al. 2002; Jackman et al. 1998; Lawton et al. 2005; Sugita et al. 1996].
Moreover, tail-deleted (TD) CD1b and CD1d mutants display an impaired antigen-presenting
capacity [Chiu et al. 1999; Chiu et al. 2002; Jackman et al. 1998]. In addition, some CD1 proteins
possess putative dileucine-based sorting motifs [Moody 2006], although it has not been shown if
these play any role in trafficking or function.
Table 13.1 CD1a chimeras – tail to traffic twists
molecule tail i trafficking
human CD1a .RKRCFC surface and sorting endosomes
human CD1a TD ii .RKR ?
human CD1aab .aTM iii & R(K)RRSYQNIP ?
human CD1abb .bTM & RRRSYQNIP ?
human CD1b .RRRSYQNIP surface, LE iv, lysosomes
human CD1c .KKHCSYQDIL surface and EE v (LE)
human CD1d .KRQTSYQGVL surface, LE, lysosomes
mouse CD1d .RRRSAYQDIR surface, LE, lysosomes
i Tyrosine-based motifs are in bold and red
ii Tail-deleted
iii Transmembrane
iv Late endosomes
v Early endosomes
Tyrosine- and dileucine-based motifs are known to bind adaptor protein (AP) complexes, such
as AP-2, which is involved in endocytosis [Bonifacino & Traub 2003]. In fact, human CD1b and
CD1c and murine CD1d cytoplasmic tails have been shown to bind AP-2 or one of its subunits
[Briken et al. 2002; Lawton et al. 2005]. This last finding implies that CD1b, CD1c and CD1d are
internalized in an AP-2-dependent manner, a pathway that is also mediated by clathrin, which
coats the endocytic vesicles, and dynamin, which is thought to be involved in membrane fission.
Indeed, CD1b internalization has been shown to be dynamin-dependent [Briken et al. 2002].
Despite lacking any known sorting motifs in its cytoplasmic tail, CD1a is internalized from
the plasma membrane into endosomal compartments and recycles back to the plasma membrane
through the endocytic recycling compartment [Salamero et al. 2001; Sugita et al. 1999]. It is not
clear, however, if the CD1a cytoplasmic tail determines the intracellular trafficking pathways
followed by this molecule. We investigated the internalization and recycling pathways followed
by CD1a and the role of the CD1a cytoplasmic tail. Our results suggest that CD1a and MHC
class I follow similar trafficking pathways within the endocytic system.
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13.5. Tail-deletion does not change the subcellular distribution of
CD1a
In a search of a possible role for the CD1a cytoplasmic tail in internalization and trafficking
of the molecule, we analyzed the presence of posttranslational modifications that can occur in
the cytoplasmic tail. Palmitoylation consists of the covalent attachment of a fatty acid (which
can be palmitate or another fatty acid, hence the more appropriate designation S-acylation)
to a cysteine. Contrary to myristoylation, another type of posttranslational lipid modification,
there is no consensus sequence for S-acylation and it does not always occur at the N-terminus.
Interestingly, CD1a possesses two cysteines in its cytoplasmic tail (see Table 13.1, p.113), which
is striking considering that it only has six residues in total. We therefore investigated if CD1a
could be S-acylated by incubating HeLa:CD1a stable transfectants with radiolabeled palmitic
acid, followed by lysis and immunoprecipitation of CD1a [Barral et al. 2008]. As a control,
we were able to detect labeled transferrin receptor (TfR), which is a known S-acylated protein.
Strikingly, we also detected labeled CD1a, indicating that, indeed, CD1a is S-palmitoylated (data
not shown). We predicted that, if CD1a is S-acylated in its cytoplasmic tail, a truncation of the
tail would abolish the lipid modification. Therefore, we generated HeLa cells that stably express
a CD1a tail-truncated mutant, with no cytoplasmic cysteines (HeLa:CD1a TD; (see Table 13.1,
p.113)). Notably, we failed to detect labeled CD1a in HeLa:CD1a TD cells, indicating that CD1a
is S-acylated on one or both cysteines of the cytoplasmic tail.
Many palmitoylated proteins, such as kinases and some Gα proteins [Resh 1999], are known to
localize to detergent-resistant membrane microdomains or lipid rafts, which are domains enriched
in cholesterol and sphingolipids [Magee & Parmryd 2003]. Also, glycosylphosphatidylinositol-
anchored proteins, which follow a nonclathrin, dynamin-independent pathway of internalization
[Sabharanjak et al. 2002], partition into detergent-resistant membrane microdomains establishing
a dynamin-independent internalization pathway in these microdomains. As we had found that
MHC class II Ii can associate with a fraction of CD1a molecules in immature DC and that this
association is dependent on detergent-resistant membrane microdomains integrity where CD1a
is partially located, we investigated if CD1a partitions into detergent-resistant membrane mi-
crodomains also in HeLa cells, which do not express Ii. We extracted the detergent-resistant
membrane microdomains by lyzing HeLa:CD1a stable transfectants in cold Triton-X-100 and
fractionating the lysate using a sucrose step gradient. Under these conditions, the detergent-
resistant membrane microdomains float and can be isolated from other membranes. CD1a par-
titions together with a detergent-resistant membrane microdomains marker, caveolin, concen-
trating specifically in fraction number 10 (see Figure 13.5 (A,B), p.115). Nevertheless, most of
the CD1a protein is detected in fractions that do not float (fractions numbers 1–4), although a
significant amount of caveolin also partitions to these fractions. As a control, TfR, which is a
non-detergent-resistant membrane microdomains protein, is virtually undetectable in detergent-
resistant membrane microdomains-containing fractions [Barral et al. 2008]. These results suggest
that, indeed, a fraction of the CD1a present in the cell is associated with detergent-resistant
membrane microdomains, independently of Ii.
Because CD1a was shown to partition to detergent-resistant membrane microdomains and is
S-acylated, we investigated if the CD1a TD mutant, which is not S-acylated, also partitions into
detergent-resistant membrane microdomains. Interestingly, we were able to detect this mutant
in detergent-resistant membrane microdomains fractions, suggesting that the S-acylation does
not determine the partition of this protein into detergent-resistant membrane microdomains (see
Figure 13.5 (C), p.115).
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Figure 13.5
Tail-deletion does not change the subcellu-
lar distribution of CD1a. HeLa:CD1a WT
(A) or HeLa:CD1a TD (C) stable transfectant
cells were surface biotinylated, lyzed and frac-
tionated in a sucrose step gradient. Fractions
were collected from the bottom and CD1a im-
munoprecipitated (A and C). Samples were re-
solved on 12.5% SDS–PAGE and immunoblot-
ted with HRP-conjugated streptavidin (A and
C) or with rabbit polyclonal anti-caveolin (B),
followed by HRP-conjugated anti-rabbit anti-
bodies. In (A), associated β2m is also shown.
Results are representative of at least two inde-
pendent experiments.
13.6. CD1a TD shows normal surface expression, internalization
and recycling
S-acylation of the cytoplasmic tail of transmembrane proteins is known to influence their traf-
ficking. For instance, S-acylation of one cysteine in the cytoplasmic tail of the cation-dependent
mannose 6-phosphate receptor is critical for the correct trafficking and function of this receptor
[Schweizer et al. 1996].
We therefore investigated whether the trafficking of CD1a TD is altered compared with CD1a
WT. We first studied the expression of CD1a TD on the cell surface. We analyzed by flow
cytometry the levels of CD1a on the surface of transiently transfected HeLa cells and saw no
apparent difference in the surface expression of CD1a TD mutant when compared with CD1a
WT (see Figure 13.6 (A), p.116). We also analyzed the internalization and recycling rates of
CD1a TD. Surprisingly, the CD1a internalization rate was relatively fast and reached equilibrium
after 20 min (see Figure 13.6 (B), p.116). This result was unexpected because CD1a does not
have any sorting motif in its cytoplasmic tail, like other CD1 isoforms that possess tyrosine-
based motifs (see Table 13.1, p.113), and it is not internalized in a clathrin-dependent manner
(see Figure 13.8, p.119). Notably, when we compared the internalization rates of CD1a WT and
CD1a TD, we saw no difference (see Figure 13.6 (B), p.116).
To study the recycling rates, we analyzed by flow cytometry the reappearance of CD1a on
the cell surface after internalizing the protein bound to an antibody and stripping the antibody
bound to non-internalized proteins. Similar to the internalization and surface expression studies,
no differences between the recycling of CD1a WT and CD1a TD were detected (see Figure 13.6
(C), p.116). Therefore, these results identified no differences in trafficking between CD1a WT and
CD1a TD. To confirm this, we compared the intracellular localization of CD1a WT and CD1a
TD by transfecting these constructs into HeLa cells and performing confocal microscopy analysis.
CD1a is known to recycle through the endocytic recycling compartment without trafficking to
late endocytic compartments [Sugita et al. 1999]. Therefore, we used transferrin (Tf) ligand,
which also recycles through the endocytic recycling compartment [Killisch et al. 1992], as a
marker for this compartment. CD1a TD, similarly to CD1a WT, displays punctate staining
after internalization and accumulation in the perinuclear region where the endocytic recycling
compartment is localized. As expected, there is colocalization with Tf, suggesting that there are
no differences in trafficking after internalization between the two molecules [Barral et al. 2008]
at this level of resolution.
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Figure 13.6
CD1a TD shows normal surface expression,
internalization and recycling. (A) HeLa cells
were transiently cotransfected with CD1a WT
and enhanced GFP (EGFP) or CD1a TD and
EGFP, stained for CD1a and analyzed by
flow cytometry, gating on EGFP+ cells. (B)
HeLa:CD1a WT and HeLa:CD1a TD stable
transfectants were surface biotinylated with a
cleavable biotin at 4 ◦C, shifted to 37 ◦C for
the indicated periods of time (to allow for in-
ternalization), after which cells were placed on
ice to stop internalization. Surface biotin was
cleaved with a reducing agent (on ice), and
cells were then lyzed and lysates probed for
different proteins by ELISA with each condi-
tion performed in duplicate. The results (in
arbitrary units) are normalized for the total
CD1a protein present in each lysate and the
internalization at time zero. (C) HeLa cells
were transiently cotransfected with CD1a WT
and EGFP or CD1a TD and EGFP, stained
for CD1a and incubated at 37 ◦C to allow for
internalization. After stripping the surface-
bound antibody with a brief acidic wash, cells
were incubated at 37 ◦C for different periods
of time to allow for recycling. Cells were
then stained with phycoerythrin-labeled anti-
mouse secondary antibody and analyzed by
flow cytometry, gating on EGFP+ cells. The
results (in arbitrary units) are normalized for
the recycling at time zero. Error bars in
(A–C) represent the SD of three independent
experiments.
Together, these results indicate that the S-acylation of the CD1a cytoplasmic tail does not
play a significant role in the internalization or recycling of the protein or its localization to
detergent-resistant membrane microdomains.
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Figure 13.7
CD1a TD efficiently presents sulfatide to T cells. Nervonoyl sulfatide, at the indicated con-
centrations, was incubated with HeLa:CD1a WT or HeLa:CD1a TD and the CD1a-restricted
sulfatide-specific human T cell clone K34B9.1 during the whole assay (A and B) or pulsed for
1 h at 37 ◦C (C and D). Supernatants were collected after 48 h, and release of IFN-γ (A and
C) and TNF-α (B and D) was measured by ELISA. Error bars represent the SD of triplicate
measurements.
13.7. Tail-deletion does not affect presentation of sulfatide to T
cells
All the assays described thus far failed to show any differences in localization and trafficking
between CD1a WT and CD1a TD. However, differences below the detection level of our assay
systems could still lead to functional defects. We therefore compared the ability of the CD1a TD
to present the antigen sulfatide with specific CD1a-restricted T cells [Shamshiev et al. 2002] and
compared this with CD1a WT. When transfected HeLa cells were pulsed with sulfatide antigen,
recognition by CD1a-restricted, sulfatide-specific T cells revealed no significant difference between
CD1a WT and CD1a TD (see Figure 13.7, p.117). This suggests that the CD1a cytoplasmic tail
does not appear to influence the antigen-presenting function of CD1a.
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13.8. CD1a surface expression is not changed by inhibition of the
clathrin pathway
CD1a was previously found in clathrin-coated pits and clathrin-coated vesicles [Salamero et al.
2001; Sugita et al. 1999]. However, unlike other CD1 isoforms, CD1a does not possess a tyrosine-
based motif or other known sorting motifs that can bind AP-2 and mediate clathrin-dependent
internalization (see Table 13.1, p.113). Therefore, we investigated the pathway of internaliza-
tion followed by CD1a. We first utilized a knockdown approach directed at the clathrin heavy
chain and the µ2 subunit of AP-2 using siRNA. For this, HeLa cells stably expressing CD1a or
CD1b were transfected with siRNA oligos [Barral et al. 2008] and analyzed for the presence of
CD1 molecules on the surface by flow cytometry (see Figure 13.8, p.119). As a control, TfR,
a molecule known to follow a clathrin-mediated pathway of internalization, was used. The TfR
showed a marked increase in surface expression when either the clathrin heavy chain or the µ2
subunit of AP-2 were knocked down. Strikingly, CD1a surface expression did not show any
changes (see Figure 13.8 (A), p.119), contrary to CD1b [Barral et al. 2008] that is known to bind
AP-2 and follow a clathrin-mediated internalization pathway [Briken et al. 2002]. We also dis-
rupted the clathrin-mediated pathway by using a dominant-negative mutant of dynamin 2. HeLa
cells stably transfected with CD1a or CD1b and transiently transfected with dynamin 2 K44A
dominant-negative mutant (defective in GTP binding) expectedly showed an increase in TfR
surface expression [Barral et al. 2008]. In accordance with the results obtained with siRNA, the
surface expression of CD1a did not show significant changes, while CD1b surface levels were up-
regulated. These results suggest that CD1a follows a clathrin-, AP-2- and dynamin-independent
internalization pathway. The experiments directly measuring CD1a internalization in dynamin 2
K44A transfectants were not fully conclusive as they showed a small but nonsignificant reduction
(data not shown). Importantly, we also analyzed human immature monocyte-derived DC, which
normally express all CD1 isoforms. We detected increased surface levels of TfR when AP-2 µ2
was knocked down by short hairpin RNA (shRNA) transduction, whereas no increase in CD1a
surface levels could be detected (see Figure 13.8 (A), p.119). Moreover, we detected a decrease
in CD1a surface expression, further suggesting that CD1a and TfR follow different pathways of
internalization.
13.9. CD1a follows a Rab22a-dependent recycling pathway
As shown in (see Figure 13.8, p.119), the CD1a internalization pathway differs from the one
followed by cargo internalized in a clathrin-dependent manner, such as TfR. Recently, the small
guanosine triphosphatase Rab22a was shown to be involved in the recycling of proteins that are
not dependent on clathrin for internalization [Weigert et al. 2004]. This recycling pathway, which
can be distinguished from the classical slow recycling pathway followed by TfR, is inhibited
by the expression of Rab22a constitutively active or dominant-negative mutants [Weigert et
al. 2004]. However, a different study found significant inhibition in the recycling of TfR by a
Rab22a constitutively active mutant [Magadan et al. 2006]. This disparity could be because
of the difference in the species origin (human versus canine) of Rab22a used [Magadan et al.
2006]. We used the same human constructs, as used in the study mentioned first [Weigert et al.
2004], in HeLa cells and saw striking colocalization between CD1a and Rab22a (see Figure 13.9
(D), p.120) and CD1a and Rab22a-Q64L (defective in GTP hydrolysis) constitutively active
mutant (see Figure 13.9 (H), p.120) in the tubular structures that represent tubular recycling
endosomes [Weigert et al. 2004], suggesting that CD1a follows a Rab22a-dependent recycling
pathway. Importantly, TfR could not be detected in these tubular recycling endosomes (see
Figure 13.9 (C,F), p.120), consistent with the results obtained in the other study using the same
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6-dependent pathway
Figure 13.8
CD1a surface expression is not affected by
inhibition of the clathrin-mediated pathway.
(A) HeLa:CD1a stable transfectants were
transiently transfected with clathrin heavy
chain or µ2 subunit of AP-2 (µ2) siRNA oli-
gos, twice at intervals of 72 h, then stained
with anti-CD1a or anti-TfR antibodies and an-
alyzed by flow cytometry. Error bars repre-
sent the SD of three independent experiments.
For results with HeLa:CD1b see [Barral et al.
2008]. (B) CD14+ monocytes were differenti-
ated into immature monocyte-derived DC and
transduced (or not) with GFP or µ2 subunit
of AP-2 (µ2) shRNA encoding lentivirus for 6
days and analyzed in the same way. The MFI
is represented in all cases, and the error bars
represent the SD of four different shRNA for
µ2.
constructs [Weigert et al. 2004]. When we used a Rab22a dominant-negative mutant (Rab22a
S22N, defective in GTP binding as is S19N), we detected a marked reduction in the CD1a
recycling rate, strongly suggesting that CD1a follows a Rab22a-dependent recycling pathway
(5.07-fold change in CD1a surface expression after 30 min in the control versus 2.43-fold change
in cells transfected with the dominant-negative mutant Rab22a S22N). The residual recycling
observed in the dominant-negative mutant could be because of an incomplete block of Rab22a-
dependent recycling or the existence of an alternative recycling pathway.
Proteins of the CD1 family show similarity to MHC class I at the sequence and structural
level. Interestingly, MHC class I also follows a clathrin- and dynamin-independent internalization
pathway and a Rab22a-dependent recycling pathway [Naslavsky et al. 2003; Weigert et al. 2004],
similar to what we observed with CD1a. Therefore, we determined if MHC class I and CD1a
colocalize under steady-state conditions. We observed striking colocalization [Barral et al. 2008]
between these two proteins, including in the perinuclear area. These data further suggest that
CD1a and MHC class I follow similar intracellular trafficking pathways.
13.10. CD1a is internalized and recycled by an adenosine
diphosphate ribosylation factor 6-dependent pathway
CD1a endosomal recycling has been shown to be adenosine diphosphate ribosylation factor (ARF)
6-dependent [Sugita et al. 1999]. Interestingly, MHC class I is also a marker for this pathway
[Radhakrishna & Donaldson 1997]. We therefore made use of an ARF6 constitutively active
mutant (ARF6-Q67L, defective in GTP hydrolysis), which blocks membrane trafficking shortly
after internalization and sequesters cargo that normally traffics through the ARF6-dependent
endocytic recycling pathway [Brown et al. 2001], such as MHC class I. HeLa cells transfected
with the ARF6-Q67L mutant showed typical enlarged vacuolar structures where MHC class I
accumulated (see Figure 13.10, p.121). Strikingly, CD1a, but not TfR (which is internalized in
a clathrin-dependent manner), accumulated in the same structures.
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Figure 13.9
CD1a follows a Rab22a-dependent recycling pathway. HeLa:CD1a stable transfectants were
transiently transfected with enhanced green fluorescent protein (EGFP)–Rab22a (WT or Q64L
constitutively active mutant). After 24 h, cells were serum starved for 30 min and incubated with
Alexa 647-conjugated Tf (C) or Alexa 546-conjugated Tf (F) and anti-CD1a mAb (B and G) for
30 min on ice. Cells were then washed and incubated with Alexa 647-conjugated Tf for 45 min
at 37 ◦C (upper panels) or switched only to 37 ◦C for 30 min (lower panels). After stripping the
surface-bound antibody with a brief acidic wash, cells were fixed, permeabilized and labeled with
Alexa 546-conjugated anti-mouse (B) or Cy5-conjugated anti-mouse (G) antibodies. Arrowheads
depict tubular structures that contain both EGFP–Rab22a and CD1a. In the merge panel (D),
colocalization is indicated by the yellow color, while in panel (H), it is indicated by the color
cyan. Scale bars, 10 µm.
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Figure 13.10
CD1a is internalized and recycled by an ARF6-dependent pathway. HeLa:CD1a stable trans-
fectants were transiently transfected with ARF6-Q67L constitutively active mutant. After 24 h,
cells were serum starved for 30 min and incubated with Alexa 647-conjugated Tf (C) for 30 min
on ice. Cells were washed, incubated with Alexa 647-conjugated Tf for 30 min at 37 ◦C and
then fixed, permeabilized and incubated with Alexa 488-conjugated anti-MHC class I (A) and
Alexa 546-conjugated anti-CD1a (B) antibodies. Arrowheads depict typical enlarged vacuolar
structures induced by ARF6-Q67L expression. Scale bar, 10 µm.
13.11. CD1b does not accumulate in ARF6-Q67L-positive
enlarged vesicles
As expected, CD1b, which is internalized in an AP-2- and dynamin-dependent manner [Briken et
al. 2002], could not be detected in these enlarged vacuolar structures (see Figure 13.11, p.122).
These results are in agreement with the finding that CD1a follows an AP-2- and dynamin-
independent internalization pathway (see Figure 13.8, p.119) and strongly suggest that CD1a
follows a similar recycling pathway to MHC class I. Furthermore, they indicate that these two
proteins not only share structural similarities but also are similar in their intracellular trafficking.
13.12. Relocation of CD1a to lysosomes by providing residues of
CD1b cytoplasmic tail
It has been previously shown that CD1a localizes to the endocytic recycling compartment,
whereas, CD1b localizes to LE or lysosomes. To investigate the importance of tyrosine-based
motifs in CD1 molecule trafficking, HeLa CD1a:CD1b tail chimeric constructs (see [Cernadas
et al. 2009] and references therein) containing the tyrosine-based motif of CD1b were gener-
ated (see Table 13.1, p.113) and intracellular localization of CD1 molecules analyzed by confocal
microscopy. The CD1aab tail chimera showed a different localization from CD1a WT and an
identical staining pattern compared with WT CD1b (see Figure 13.13 (A), p.124). This was
further demonstrated by colocalization of the CD1aab chimera to LE/lysosomes with lysosome-
associated membrane glycoprotein 1 (LAMP-1) as it was also demonstrated for WT CD1b. This
is in agreement with the known important role for the tyrosine-based sorting motif of CD1b in
binding AP-3 and directing trafficking to the lysosomes. In contrast and as expected, there was
no colocalization between WT CD1a and LAMP-1 (see Figure 13.13 (B), p.124). Both WT and
chimeric proteins were well expressed on the cell surface as demonstrated by flow cytometry.
The CD1aab chimera transfectants consistently showed lower surface mean fluorescence inten-
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Figure 13.11
CD1b does not accumulate in ARF6-Q67L-
positive enlarged vesicles. HeLa:CD1b stable
transfectants were transiently transfected with
ARF6-Q67L constitutively active mutant. Af-
ter 24 h, cells were fixed, permeabilized and
incubated with anti-hemagglutinin polyclonal
antibody (A) and anti-CD1b mAb BCD1b3.2
(B), followed by Alexa 488-conjugated anti-
rabbit and Alexa 546-conjugated anti-mouse
secondary antibodies. Arrowhead depicts an
enlarged vacuole induced by ARF6-Q67L ex-
pression. Scale bar, 10 µm.
sity compared to WT CD1a as determined by flow cytometry (data not shown). It should be
noted that there was significant anti-CD1a mAb intracellular staining with anti-CD1a mAb of
the CD1aab chimera indicating conformational stability of the CD1a extracellular domain in the
late endocytic system (see Figure 13.13 (A), p.124).
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Figure 13.12
CD1a cartoon II - CD1a mimics MHC class I trafficking. Scheme of a cell depicting our re-
sults that the CD1a pathway does not require any motifs in the cytoplasmic tail but follows
a similar intracellular trafficking route as MHC class I (MHC I). Recycling is dependent on
ARF6 and Rab22a and internalization is neither dependent on clathrin, nor AP-2, nor dynamin.
Nevertheless, CD1a shows fast internalization kinetics by reaching the steady state equilibrium
after 20 min. Mutants studied were dynamin 2 K44A (dominant negative mutant defective in
GTP binding), Rab22a S19/22N (dominant negative mutant defective in GTP binding), Rab22a
Q64L (constitutively active mutant defective in GTP hydrolysis), ARF6 T27N (dominant nega-
tive mutant defective in GTP binding) and ARF6 Q67L (constitutively active mutant defective
in GTP hydrolysis). Routes are abbreviated as follows: CRE = clathrin recycling endosomes,
EE = early endosomes, LE = late endosomes, MIIC = MHC class II compartment, NRE =
nonclathrin recycling endosomes, RE = recycling endosomes and SE = sorting endosomes. Red
arrows indicate the routes taken by MHC class I and CD1a.
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Figure 13.13
CD1a is redirected to lysosomes by providing residues of CD1b cytoplasmic tail. HeLa CD1a
WT, CD1b WT and CD1aab tail chimera transfectants were analyzed by confocal microscopy.
(A) The CD1 transfectants were stained with antibodies directed at their extracellular domains.
CD1a WT transfectants show cell surface and perinuclear staining. The CD1b WT and CD1aab
chimera have similar intracellular staining patterns. (B) Colocalization studies with anti-LAMP-
1 mAb demonstrated the localization of the CD1aab chimera to LAMP-1+ compartments similar
to WT CD1b. There is no colocalization between CD1a and LAMP-1. The fluorescent label used
for each protein is indicated by color.
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13.13. Colocalization of CD1a and sulfatide
Several T cell antigens presented by CD1a have been described including dideoxymycobactin,
a lipopeptidic antigen isolated from Mycobacterium tuberculosis, and sulfatide [Moody et al.
2004; Shamshiev et al. 2002]. Sulfatide (3’-sulfated β1-d-galactosylceramide) is an endogenous
glycolipid highly expressed in neuronal cells, kidney and pancreas [Fredman et al. 2000; Sandhoff
et al. 2002; Vos et al. 1994] and its synthesis is upregulated in DC upon bacterial infection
[De Libero et al. 2005 a]. Sulfatide can be presented by all group 1 CD1 molecules including
mouse and human CD1d [Shamshiev et al. 2002; Zajonc et al. 2005 a] (M. Cavallari and G. De
Libero, unpublished results). It can be efficiently loaded on the cell surface of DC and can be
presented without internalization or endosomal acidification [Shamshiev et al. 2002]. Differences
were observed in the antigen presentation capabilities of sulfatide-pulsed DC for each of the
CD1 isoforms over time. DC pulsed with sulfatide maintained the ability of DC to stimulate
CD1a-restricted T cells over a three day period. In contrast, the ability of the DC to stimulate
CD1b- and CD1c-restricted T cells was reduced by ≈ 75% over the same time period. These
findings suggest an especially prolonged interaction between CD1a and sulfatide in myeloid DC.
However, these studies cannot distinguish between higher affinity of CD1a binding for sulfatide
versus more extensive colocalization of the antigen presenting molecule with the antigen.
Despite extensive prior analyses of CD1a and CD1b trafficking, only rarely has lipid antigen
trafficking been directly visualized, since tagging of lipid antigens often alters their trafficking
and few mAb against lipids exist. No prior studies have examined the trafficking of CD1a-
presented lipid antigens. We developed a protocol to determine the intracellular distribution of
sulfatide using confocal microscopy and the anti-sulfatide specific mAb (O4) in sulfatide-pulsed
HeLa CD1 transfectant cells. Strikingly, HeLa CD1a transfectants incubated with sulfatide
demonstrated an almost exclusive localization of sulfatide to the early endocytic and recycling
pathways [Cernadas et al. 2009], identified using anti-Rab5- and early endosome antigen 1-specific
mAb and fluorescently-labeled Tf. There was marked colocalization between sulfatide and the
early endocytic markers Rab5 and early endosome antigen 1. Sulfatide was also present in the
endocytic recycling compartment as demonstrated by its partial colocalization with Tf. CD1a
and Tf also demonstrated partial overlap consistent with the previously published [Barral et al.
2008; Sugita et al. 1999] localization of CD1a in the endocytic recycling compartment. However,
there was no colocalization with LAMP-1, a marker of the late endocytic system.
Next, the colocalization pattern of CD1a and CD1b and the CD1a:CD1b chimera with sulfatide
was examined. HeLa CD1a WT, CD1b WT and CD1a:CD1b chimera transfectants were pulsed
with sulfatide and stained with anti-CD1a, anti-CD1b and anti-sulfatide mAb. Consistent with
the above findings there was a marked colocalization of CD1a with sulfatide in the HeLa CD1a
WT transfectant cells (see Figure 13.14 (A), p.126). On the other hand, little to no colocalization
of CD1b with sulfatide was found in the HeLa CD1b WT transfectants (see Figure 13.14 (A),
p.126). Compared to CD1a WT, there was a marked reduction in the colocalization of sulfatide
with the CD1aab tail chimeric protein (see Figure 13.14 (A), p.126). This suggests that the
intracellular localization provided by the CD1b tyrosine-based motif determines the degree of
interaction of the CD1aab tail chimera with sulfatide. The distribution of sulfatide was very
similar in cells expressing CD1a WT and CD1aab tail chimera as demonstrated by the almost
complete colocalization of sulfatide and Rab5 and there was no redirection of sulfatide to the
late endocytic system with the CD1aab tail chimera (see Figure 13.14 (B), p.126).
Time course studies of sulfatide distribution to investigate whether sulfatide traffics to LE
at late time points showed that there is no detectable colocalization of LAMP-1 with sulfatide
[Cernadas et al. 2009] up to 20 h after sulfatide pulse. This lack of colocalization was observed for
both the CD1a WT and CD1aab tail chimera transfectants. Minor colocalization was observed
for sulfatide and CD1b at late time points (data not shown). At all time points the vast majority
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Figure 13.14
Marked intracellular colocalization between CD1a and sulfatide. HeLa CD1a WT, CD1b WT
and CD1aab chimera transfectants were pulsed with sulfatide and analyzed by confocal mi-
croscopy. (A) Colocalization between each CD1 molecule and sulfatide was determined for each
transfectant. The fluorescent labels used for each protein are indicated by color. (B) Colocaliza-
tion between sulfatide and early (Rab5) and late endocytic (LAMP-1) markers was determined
in sulfatide-pulsed CD1a WT and CD1aab tail chimera transfectants.
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of sulfatide staining remained in the early endocytic and recycling compartments. The absence
of sulfatide detection in LAMP-1+ compartments even at later time points is likely due to its
preferential sorting to the early endocytic and recycling compartments and to the degradation
of sulfatide by endogenous lysosomal arylsulfatases that are well described to be present in
this compartment [Diez-Roux & Ballabio 2005]. Lastly, to rule out the possible contribution of
sulfatide to changes in CD1a expression, intracellular distribution or cell morphology, confocal
microscopy was performed with increasing concentrations of sulfatide or ceramide (C24) as an
additional control. No changes were observed by confocal microscopy in the distribution or
localization of CD1a nor in the transfectant morphology [Cernadas et al. 2009] after culture with
either lipid.
These findings [Cernadas et al. 2009] were confirmed in primary cells, namely human monocyte-
derived DC that express all CD1 isoforms, and are in agreement with the known localization of
CD1a and CD1b molecules in monocyte-derived DC to the endocytic recycling compartment
or to late endosomal/lysosomal compartments, respectively [Cao et al. 2002; van der Wel et
al. 2003]. Briefly, human monocyte-derived DC were pulsed with sulfatide as described above.
Confocal microscopy of DC demonstrated areas of strong colocalization between sulfatide and
CD1a molecules but not between sulfatide and CD1b.
In contrast to the specific colocalization of CD1a with sulfatide, lipoarabinomannan, an anti-
gen presented by CD1b, strictly colocalized with CD1b but not with CD1a [Cernadas et al.
2009] in monocyte-derived DC. The localization of lipoarabinomannan with CD1b is consistent
with the known interaction of lipoarabinomannan with mannose receptors that likely mediate
the internalization and direct targeting of lipoarabinomannan and similar antigens to the late
endocytic system [Schlesinger et al. 1996]. These findings suggest that CD1 molecules select the
lipid antigen to be presented according to their capacity to bind and form stable complexes and
also according to the endosomal localization of each lipid antigen and its intersection with the
relevant CD1 molecule.
13.14. WT CD1a transfectants present sulfatide more efficiently
than CD1aab chimera
In order to determine the functional relevance of the intracellular trafficking of CD1a in antigen
presentation, we next examined the ability of CD1a WT and different CD1a:CD1b tail chimeras
to activate CD1a-restricted sulfatide-specific T cells. First, to assess the appearance of sul-
fatide:CD1a stimulatory complexes we performed pulse experiments using HeLa CD1a WT and
CD1aab chimera transfectants with matched cell surface expression of CD1a as determined by
flow cytometry. The transfectants were pulsed with sulfatide for different time periods before
addition of T cells. The ability of sulfatide-pulsed transfectants to stimulate the sulfatide-specific
T cell clone K34B9.1 increased with increasing pulse period independently of the measured cy-
tokine (IFN-γ, TNF-α or IL-4). CD1a WT transfectants outperformed the CD1aab chimera at
pulse periods longer than 30 min (see Figure 13.15, p.128). CD1aab chimera transfectants even
showed a slight decrease in stimulatory capacity at pulse periods longer than 30 min.
13.15. CD1a:CD1b chimeras have shorter-lived ability to
stimulate T cells
Secondly, to assess the disappearance of sulfatide:CD1a stimulatory complexes we performed
chase experiments using T2 CD1a WT and CD1a:CD1b chimeras instead of HeLa transfectants
to avoid effects on stimulation due to trypsinization. The T2 transfectants were pulsed with
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Figure 13.15
WT CD1a transfectants present sulfatide more efficiently than CD1aab chimeric transfectants.
WT CD1a (white diamonds) HeLa transfectants showed increased capacity to stimulate the
CD1a-restricted sulfatide-specific T cell clone K34B9.1 as compared to CD1aab chimeric trans-
fectants (gray diamonds) for pulse periods longer than 30 min. Both transfectants were pulsed
with nervonoyl sulfatide for indicated times, then washed and co-incubated with T cells. Super-
natants were harvested after 24 h and the release of IL-4 (A), IFN-γ (B) and TNF-α (C) was
measured by ELISA. Error bars represent SD of triplicate measurements.
sulfatide and chased for indicated time periods before addition of T cells and cytokine release
measurement. At each time point control groups were represented by transfectants incubated
with sulfatide and T cells together to determine the maximal antigen presenting capacity. The
ability of sulfatide-pulsed transfectants to stimulate the sulfatide-specific clone K34B9.1 decayed
with increasing chase period independently of the measured cytokine. WT CD1a transfectants
showed half maximal stimulation at 40 h of chase, whereas CD1abb transfectants showed half
maximal stimulation at 20 h. CD1aab transfectants showed intermediate behavior, with half
maximal stimulation at 30 h (see Figure 13.16, p.129). After 72 h CD1a WT transfectants were
still capable of stimulating sulfatide-specific T cells, whereas both chimera transfectants were no
longer stimulatory.
13.16. Conclusions and outlook
Our first study [Sloma et al. 2008] demonstrates that in human immature DC CD1a associates
with the Ii, HLA-DR, and the tetraspanin CD9 and partitions into lipid rafts. The CD1a/Ii
association takes place during recruitment of CD1a into surface lipid rafts and this type of mem-
brane localization promotes efficient antigen presentation and T cell activation. We also provide
evidence that on the one hand CD1a participates in controlling the pool of surface Ii and that on
the other hand Ii participates in CD1a endocytosis. Our biochemical analysis revealed that sev-
eral molecules, such as HLA-DR, Ii p35, Ii p33, and CD9 coprecipitate with CD1a. The amounts
of Ii and CD9 proteins detected in CD1a precipitates are strikingly more abundant than those
of coprecipitated HLA-DR. Cocapping experiments are in agreement with this finding, because
confocal microscopy showed a faint presence of HLA-DR within CD1a clusters, and a promi-
nent colocalization of CD1a with Ii and CD9. The scarce number of CD1a-HLA-DR clusters
argues against their physiological relevance. The association of the CD9 tetraspanin with CD1a,
which resembles the CD9/HLA-DR clusters present on human monocytes [Zilber et al. 2005],
appears to be more important. Another CD1 isoform, CD1d, has been found associated with the
CD82 tetraspanin and MHC class II molecules. CD1d may associate with MHC class II indepen-
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Figure 13.16
CD1a:CD1b chimeras have shorter-lived ability to stimulate sulfatide-specific T cells than WT
CD1a molecules. WT CD1a (white diamonds) T2 transfectants showed prolonged capacity to
stimulate the CD1a-restricted sulfatide-specific human T cell clone K34B9.1 as compared to
CD1aab (gray diamonds) or CD1abb (black diamonds). All transfectants were pulsed with ner-
vonoyl sulfatide and chased for indicated times before addition of T cells. In control wells fresh
antigen was added to chased T2 cells together with T cells. Supernatants were harvested af-
ter 24 h and the release of IL-4 (A), IFN-γ (B) and TNF-α (C) was measured by ELISA and
expressed as percent of control at time zero ± SD (of triplicates or quadruplicates) normal-
ized at each time point for the maximal antigen presenting capacity of the APC calculated as
chase / chase with fresh antigen
no chase / no chase fresh antigen × 100.
dently of CD82 [Kang & Cresswell 2002 b]. The reason why CD1d does not coprecipitate with
tetraspanins remains unclear. Tetraspanins associate with numerous surface molecules and form
networks which organize the local distribution of interacting molecules. These networks are also
formed in membrane domains outside lipid rafts, thus demonstrating the important general role
of tetraspanins in membrane organization [Poloso et al. 2006; Tarrant et al. 2003]. The presence
of large amounts of CD9 molecules that laterally associate with CD1a, may have the double
effect of organizing CD1a in the membrane and enhancing CD1a-mediated antigen presentation,
as has been reported for HLA-DR in DC [Jayawardena-Wolf et al. 2001; Unternaehrer et al.
2007]. A second mechanism used by proteins to concentrate at the cell surface is to enter lipid
rafts microdomains [Xavier & Seed 1999].
Our results reveal that CD1a molecules are constitutively present in raft compartments of
immature DC total lysates and in cell surface lipid rafts. A significant portion of Ii and MHC
class II molecules that are associated with CD1a distribute in lipid rafts. Previous studies have
described the association of MHC class II with lipid rafts in monocyte-derived human immature
DC and have shown that only 10–20% of the total MHC class II pool localizes in rafts, the
remaining MHC class II molecules being constitutively distributed in non-raft compartments of
immature DC [Eren et al. 2006; Setterblad et al. 2003]. Similarly to MHC class II, we find that
only 10–15% of CD1a molecules are detected in immature DC lipid rafts. To evaluate the impact
of raft integrity on the CD1a proximity to Ii and CD9, we performed cholesterol depletion exper-
iments. We found that CD1a/Ii colocalization is, to a great extent, dependent on the integrity of
lipid rafts, whereas CD1a/CD9 colocalization is not. This observation can result from physical
differences between lipid rafts and tetraspanin-enriched microdomains. Despite the potential
of tetraspanins to associate with gangliosides and cholesterol, which typically are resident in
lipid rafts, the tetraspanin-enriched microdomains are resistant to cholesterol depletion [Hemler
2003; Zilber et al. 2005]. The association of CD1a with Ii and the dynamic recruitment of these
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Figure 13.17
CD1a cartoon III - the view of CD1a trafficking and antigen-presentation to date. Presenting
(see Figure 13.4, p.112) and cargo-associated molecules (see Figure 13.12, p.123) are shown as
before. Routes are given as follows: CRE = clathrin recycling endosomes, EE = early endo-
somes, LE = late endosomes, MIIC = MHC class II compartment, NRE = nonclathrin recycling
endosomes, RE = recycling endosomes and SE = sorting endosomes. The routes taken by MHC
class I and CD1a are colored red.
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complexes in lipid rafts has important functional consequences on CD1a antigen presentation. In-
deed, CD1a association with lipid rafts facilitates activation of CD1a-restricted T cells, especially
at low antigen doses. This result is in agreement with the finding that lipid raft recruitment of
MHC class II molecules promotes the response of peptide-specific T cells [Anderson et al. 2000].
That study and our findings make the important point that the membrane localization of the
presenting molecule is crucial independently of the type of presented antigen and responding T
cell. It is tempting to speculate that clustering of antigen-loaded CD1a molecules has a major im-
pact in the presence of low antigen amounts because it can facilitate TCR focusing and signaling
cascade in T cells despite the low numbers of CD1a-antigen complexes. Another important ques-
tion raised in this study is the role of Ii in CD1a trafficking to the plasma membrane and through
the endocytic pathway. αβIi complexes may use two distinct trafficking pathways [Dugast et al.
2005]. The first pathway is dependent on AP-1, which promotes direct traffic to endosomes. The
second, which is the major pathway, is dependent on AP-2, which allows rapid passage of these
complexes to the cell surface. Therefore, Ii may impart different traffic behavior to associated
proteins, according to the adaptor protein it is associated with. Ii has been implicated in direct
membrane trafficking of MHC class II. For example, in CD1a-negative APC, such as B cells and
monocytes [Delia et al. 1988; Gogolak et al. 2007] a minor fraction of newly synthesized MHC
class II molecules can directly reach the cell surface as αβ/Ii-p33 complexes [Warmerdam et al.
1996]. Our coprecipitation data together with the increased Ii surface expression in the presence
of CD1a suggest that a fraction of Ii molecules directly traffic to the plasma membrane when
associated with CD1a. This mechanism could operate in immature DC, a cell population express-
ing large amounts of CD1a, in which the majority of newly formed αβIi complexes appear firstly
on the cell surface before they start recycling [Saudrais et al. 1998]. However, the association
with Ii is not an absolute requirement for surface appearance, because CD1a directly reaches the
cell surface after egress from the endoplasmic reticulum (ER) and trans Golgi network in both
Ii-positive or Ii-negative cells [Sugita et al. 1999]. Our experiments also show that extinction of Ii
in primary human DC induces an increased surface expression of CD1a, which we interpret as a
result of diminished internalization. Thus, Ii is not required for surface display of newly synthe-
sized CD1a molecules, but might be involved in CD1a internalization and recycling. Endocytosis
of other CD1 molecules is largely dependent on intracytoplasmic tail motifs allowing interaction
with AP-2 [Briken et al. 2000]. The inability of the CD1a cytoplasmic tail to interact with AP-2
raises the question of the mechanism involved in CD1a internalization. We propose that CD1a
molecules that associate with Ii benefit from the efficient internalization signal in the Ii cytoplas-
mic tail and then follow a fast internalization pathway. As a large pool of CD1a molecules binds
exogenous ligands present in the extracellular environment on the cell surface [Manolova et al.
2006], it is possible that only the minor fraction of CD1a molecules associated with Ii recycle
in clathrin-coated vesicles and early endosomes (EE) and sample intracellular antigens. Further
investigations are needed to examine the physiological significance of Ii in CD1a endocytosis and
presentation of intracellular antigens.
Our second study [Barral et al. 2008] focuses on trafficking of CD1a and its dependency on the
cytoplasmic tail. Most cytoplasmic tails from different CD1 isoforms across species have well-
characterized tyrosine-based sorting motifs or, alternatively, putative dileucine-based sorting
motifs [Moody 2006]. Primate (including human) CD1a cytoplasmic tails are the shortest known
with only three residues downstream of the three basic residues present in all CD1 proteins
[Moody 2006] (C. C. Dascher, Mt. Sinai School of Medicine, New York, unpublished data).
We investigated possible lipid modifications of the cysteines of the CD1a cytoplasmic tail and
showed that the CD1a cytoplasmic tail is S-acylated on one or both cysteines. Interestingly,
we were also able to detect S-acylation of CD1c, which has a cysteine next to the third residue
of the cytoplasmic tail like CD1a, but not of CD1b, which does not have any cysteines in its
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cytoplasmic tail (D. C. Barral unpublished data) (see Table 13.1, p.113).
Protein S-acylation is known to be important for membrane targeting, localization to mem-
brane microdomains, signaling and protein trafficking [Bijlmakers & Marsh 2003]. It is therefore
surprising that the truncation of the last three residues of the CD1a cytoplasmic tail did not
affect trafficking, including the rate of internalization and recycling. This suggests that the
pathway followed by CD1a does not require any specific motifs in the cytoplasmic tail. In the
absence of specific motifs to direct intracellular trafficking, the pathway followed by CD1a could
represent what might be described as a default recycling pathway for cell surface proteins. Al-
ternatively, CD1a could interact with an unknown protein other than Ii [Sloma et al. 2008] that
regulates its trafficking along the endocytic pathway. Furthermore, we did not detect any defects
in the antigen-presenting capacity of CD1a TD compared with CD1a WT, suggesting that the
S-acylation of the CD1a cytoplasmic tail does not play a significant role in the function of the
protein. However, CD1a has been shown to be capable of loading antigens on the cell surface
[Manolova et al. 2006], which could mask changes in intracellular loading of antigens onto CD1a.
Earlier we have shown that MHC class II/Ii associates with CD1a [Sloma et al. 2008] and may
influence CD1a trafficking. Our new findings complement the first study by examining directly
the CD1a internalization and recycling pathway and the role of CD1a cytoplasmic tail in a cell
type that does not express Ii. Furthermore, we confirmed that CD1a localizes to detergent-
resistant membrane microdomains in HeLa cells, but this was not dependent on the S-acylation
of its cytoplasmic tail. We also confirmed that cholesterol-depleted immature monocyte-derived
DC are less efficient in presenting CD1a-dependent exogenous antigens loaded on the cell sur-
face by using dideoxymycobactin in addition to sulfatide. This suggests that plasma membrane
detergent-resistant membrane microdomains are essential for CD1a-restricted antigen presenta-
tion in DC.
We found that CD1a and MHC class I follow similar intracellular trafficking pathways. Both
molecules can be detected in the Rab22a-dependent recycling pathway and recycle in an ARF6-
dependent manner, contrary to TfR and other cargo internalized in a clathrin-dependent fashion.
Indeed, we show in HeLa cells and DC that the internalization of CD1a is essentially clathrin,
AP-2 and dynamin-independent. The reduction in CD1a surface levels, seen only in DC when
the AP-2 m2 subunit was knocked down, was unexpected. One possibility is that DC might
upregulate clathrin-independent pathways of internalization, such as the one followed by CD1a,
when the clathrin-mediated pathway is blocked. Our study looked for the first time at the
internalization of CD1a, and we were surprised to find that the kinetics were very fast reaching
equilibrium after 20 min, a rate matching receptor-mediated internalization. This implies that
the clathrin-independent pathway followed by CD1a mediates fast internalization, similar to the
clathrin-dependent pathway.
It is generally accepted that CD1 evolved from a classical MHC class I ancestor early in
vertebrate evolution [Dascher 2007]. In this context, CD1a could represent a more primordial
CD1 isoform, when compared for example with CD1b, because it has a smaller antigen-binding
groove and binds lipids with short alkyl chains (e.g. sulfatide) [Shamshiev et al. 2002; Zajonc
et al. 2003]. It also can bind lipids on the surface of the cell, contrasting with CD1b, which
can accommodate lipids with C80 alkyl chains in its antigen-binding groove and can only load
these long lipids in acidic compartments such as LE and lysosomes [Manolova et al. 2006; Moody
et al. 2002]. A model has been proposed where, after gene duplication, different CD1 isoforms
acquired different trafficking patterns, which then led to changes in the antigen-binding groove, to
accommodate lipids that were present in the newly surveyed intracellular compartments [Dascher
& Brenner 2003]. Our results fit this model in the sense that CD1a shows a similar trafficking
pattern to MHC class I. Recently, the presence of two CD1 genes in chicken was reported,
which makes these the most ancient known so far [Miller et al. 2005; Salomonsen et al. 2005].
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Interestingly, one of these proteins shows an intracellular distribution similar to human CD1a (D.
C. Barral, M. B. Brenner and C. C. Dascher, unpublished data). Therefore, our study describes
another level of similarity between MHC class I and CD1a, namely their intracellular trafficking,
and these molecules essentially identify an internalization and recycling pathway that is only
partially characterized. Yet, this pathway may be followed by a number of cell surface molecules
with important immunological functions.
Our third study [Cernadas et al. 2009] investigates the pathways followed by CD1a and their
intersection with lipid pathways of potential antigens. Successful antigen presentation involves an
orchestrated series of steps that are critically dependent on the intersection of antigens with the
relevant antigen presenting molecules. Lessons from the MHC class I and MHC class II pathways
have made it clear that access to the proper antigen loading compartment is a key feature for
those presentation systems to succeed. The proteolytic environment present in lysosomes plays a
critical role in the ability of a cell to process protein antigens for prolonged antigen presentation.
APC such as macrophages with high levels of lysosomal proteases rapidly degrade internalized
proteins reducing their capacity for sustained antigen presentation compared with DC [Delamarre
et al. 2005]. Although the ability of MHC class I and II molecules to survey different intracellular
compartments and antigens is a hallmark of these systems, the role of CD1 trafficking in the
presentation of exogenous and endogenous antigens has been examined in only a few cases.
The unique intracellular distribution of each CD1 isoform has been appreciated for some time.
It has been demonstrated for the CD1b and CD1c isoforms that their intracellular trafficking is
directed by their respective tyrosine-based motifs using tail-deleted constructs [Briken et al. 2000;
Sugita et al. 2002]. Tail-deleted CD1b molecules have been demonstrated to have significant im-
pairment in their antigen presenting abilities in vitro [Sugita et al. 2002]. Glucose monomycolate
possessing a long lipid tail has been shown to require the acidic environment found in the late
endocytic system to be loaded efficiently [Cheng et al. 2006; Moody et al. 2002].
CD1a is the only CD1 isoform that does not have a tyrosine-based motif and almost exclu-
sively localizes to the early endocytic and recycling pathways. Here, we demonstrate that the
localization of CD1a to the early endosomal and recycling compartments is critical for the effi-
cient and sustained presentation of specific antigens that also predominantly localize to the same
endosomal sites. CD1a and sulfatide are almost exclusively colocalized to early endocytic and
recycling compartments. The redirection of CD1a to LE by the addition of the transmembrane
and/or cytoplasmic CD1b tyrosine-based motif to the extracellular domain of CD1a resulted in
loss of colocalization with sulfatide and a correspondingly significant reduction in the ability of
these transfectants to stimulate CD1a-restricted sulfatide-specific T cells. Since the extracellular
domains of the chimeric molecules are identical, the most likely explanation for these findings is
the difference in trafficking imparted by the chimeric cytoplasmic tails.
The activity and localization of endogenous sulfatases suggests that even if some sulfatide
is delivered to lysosomes it would be rapidly degraded. There are two classes of sulfatases,
catabolic and synthetic. The catabolic sulfatases are localized in lysosomes and exert their
activity at acidic pH on a wide range of molecules including sulfolipids and glycosoaminoglycans.
Accumulation of these molecules occurs in the setting of lysosomal sulfatase deficiency and leads
to human disease including several mucopolysaccharidoses and metachromatic leukodystrophy
[Diez-Roux & Ballabio 2005]. The prolonged ability of CD1a molecules to present sulfolipids such
as sulfatide may be critically dependent on their localization to early endocytic compartments
where the sulfatide antigen is not degraded by sulfatases. The absence of a tyrosine-based
motif allows CD1a to traffic and recycle through the early endocytic system where it can most
efficiently present lipid antigens that preferentially localize there or that would be destroyed
either enzymatically or as a result of acidic pH in the late endocytic system. This is supported
by the enhanced ability of WT CD1a to present sulfatide compared to the CD1aab tail chimeras
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and the sustained ability of sulfatide-pulsed DC to activate CD1a- compared to CD1b- and
CD1c-restricted sulfatide-specific T cells. Additional interactions or pathways may contribute
to CD1a antigen presentation as well. For example, the colocalization of CD1a with the unique
Langerhans cell-specific C-type lectin required for Birbeck granule formation, langerin, in the
eponymous endosomal subcompartment has been shown to augment CD1a-mediated antigen
presentation [Hunger et al. 2004]. We cannot rule out the possibility that the CD1aab-sulfatide
complexes dissociate in the lysosome. We should also mention the possibility that the anti-
sulfatide mAb may not be able to detect sulfatide in the lysosome secondary to changes to
the antigenic epitope recognized. However, similar sulfatide colocalization patterns have been
observed with other anti-sulfatide mAb making this less likely.
The differential localization of CD1a to the early endocytic compartment may be important in
vivo. The efficient and sustained presentation of antigens such as sulfatide by CD1a+ DC during
their migration to regional lymph nodes is likely critical for maximizing T cell activation and
proliferation. This may be even of greater importance in vivo where antigen concentrations are
likely lower than in our studies where higher concentrations of sulfatides were added to allow for
antibody detection and localization by microscopy.
The specific intracellular distribution of CD1 molecules and their antigens may also explain
the evolutionary diversity of the CD1 isoforms [Dascher 2007]. It is interesting to speculate
that the distribution of the different CD1 isoforms throughout the endocytic system may have
developed to allow for the presentation of differentially distributed antigens or antigens that are
destroyed either enzymatically or by the acidic microenvironment of the late endocytic system.
The CD1a, b, c, and d isoforms may have developed to maximize the efficient and sustained
antigen presentation of endogenous and exogenous lipids with differences in both intracellular
distribution and half-life.
These studies also highlight the importance of the differential intracellular trafficking of lipid
antigens in immunity. This was demonstrated by the specific intracellular localization of sulfatide
to early endocytic and recycling pathways and the receptor-mediated internalization of LAM
to LE. The biophysical properties of lipid antigens, both the headgroup and acyl chains have
been demonstrated to be important in antigen presentation. Interaction between the glycan
headgroups of CD1a- and CD1b-restricted antigens such as M. leprae lipid antigens and LAM
and the C-type lectins langerin and mannose receptor, respectively, have been demonstrated to
play important roles in antigen uptake and presentation [Hunger et al. 2004; Prigozy et al. 1997].
The length and saturation of the acyl chain of the glycosphingolipid glucose monomycolate and
GM1 length have been demonstrated to be important in CD1b-mediated antigen presentation
[Cheng et al. 2006; Shamshiev et al. 2000]. Lipid length, saturation and headgroups have also
been demonstrated to contribute to the endocytic sorting of lipids and the preferential retention
of certain lipids in organelles [Holthuis & Levine 2005; Mukherjee & Maxfield 2000].
CD1-mediated sulfatide antigen presentation may be of increased importance in APC that
express CD1a and in the setting of increased sulfatide availability. Upregulation of the production
of sulfatide and other glycosphingolipids in activated DC has already been shown to play a role
in CD1-mediated immunity [De Libero et al. 2005 a]. The high levels of expression of CD1a, long
a marker of Langerhans cells, on myeloid DC point to its importance in self and foreign lipid
antigen presentation. Further, since so many pathways of internalization of exogenous antigens
traverse the early endocytic system, the role of CD1a as the principal lipid antigen presenting
molecule in this location highlights its distinctive role as the main sentry at this entry point.
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TCR γδ non-peptidic ligands
T lymphocytes expressing the T cell receptor (TCR) γδ provide immediate pro-
tection and proinflammatory response during the first hours of infections. The vast
majority of human γδ T cells is activated by isopentenyl pyrophosphate (IPP) and
other phosphorylated metabolites, generated in the cytosol of a cell. How these anti-
gens interact with the TCR γδ and a potentially involved antigen-presenting molecule
(APM) remains unknown.
We found that the multidrug resistance-associated protein 5 (MRP5) transporter
encoded by the ABCC5 gene is involved in presentation of phosphoantigens, as in-
dicated by the inhibitory activity on antigen presentation of drugs blocking MRP5
as well as by ABCC5 gene inactivation and overexpression. MRP5 transports IPP
within the endoplasmic reticulum (ER) lumen and early endosomes (EE) as suggested
by its accumulation in the membranes of these compartments, thus optimizing IPP
secretion. This mechanism of action resembles that of transporter associated with
antigen processing (TAP) peptide transporter and depicts a similar strategy used for
antigen presentation to TCR αβ and γδ cells.
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T cell receptor (TCR) γδ cells are involved in the first line of defense during infections, in anti-
tumor immunity, in control of allergic reactions and in autoimmune diseases. These immunolog-
ical functions are dependent on the release of a large variety of soluble factors, which facilitate
or inhibit the immune response, and on their capacity to kill target cells. The vast majority of
circulating human TCR γδ cells express Vγ9 (also called Vγ2) and Vδ2 chains, characterized by
junctional sequences in which N-nucleotides and recurrent J gene segments are frequently used.
T cells expressing the Vγ9/Vδ2 TCR heterodimer are rare in thymus and placental blood [De
Libero et al. 1991; Groh et al. 1989]. They increase over time after birth and may represent up
to 10% of total circulating T cells in adults [Parker et al. 1990]. The expansion in the periphery
has been ascribed to continuous stimulation by exogenous microbial and endogenous self ligands
during an individual’s lifetime [De Libero 1997]. Indeed, this population of TCR γδ cells, which
is present in primates but not in rodents, is activated by a family of self and microbial non-
peptidic ligands, that are prenylated and pyrophosphorylated intermediate metabolites of the
mevalonate and 2-C-methylerythritol 4-phosphate (MEP) pathways in eukaryotic and microbial
cells, respectively. The most active self-ligand known is isopentenyl pyrophosphate (IPP) [Buerk
et al. 1995; Gober et al. 2003], which is an important intermediate generated during cholesterol
synthesis, whereas the most stimulatory microbial ligand is (E)-4-hydroxy-3-methyl-but-2-enyl
pyrophosphate (HMBPP) [Hintz et al. 2001], which is an intermediate of the MEP pathway.
Because of these antigenic specificities, TCR Vγ9/Vδ2 cells are activated by tumor cells accu-
mulating high levels of IPP [Gober et al. 2003], by cells infected with microbes, that accumulate
IPP as consequence of mevalonate pathway dysregulation [Kistowska et al. 2008], as well as by
exogenous HMBPP [Hintz et al. 2001], released by dying microbial cells. With the exception of
the latter case, when the stimulatory ligands are freed into the extracellular space, in tumor cells
or in infected cells, self antigens are generated within the cytoplasm. The site of ligand generation
is the cytosolic leaflet of the endoplasmic reticulum (ER), where the enzymes of the mevalonate
pathway are localized [van Meer et al. 2008]. The mechanism how phosphorylated metabolites
are recognized by the TCR γδ has not been evidenced so far. Stimulation with both IPP and
HMBPP occurs only upon contact with other cells [De Libero et al. 1991; Lang et al. 1995],
that bind these compounds [Sarikonda et al. 2008] and behave as APC. The nature of the puta-
tive antigen-presenting molecule (APM), albeit not identified to date, is indirectly indicated by
its exerted function as a ubiquitous, non-polymorphic, non-β2m-associated and species-specific
molecule [De Libero et al. 1991; Gober et al. 2003; Sarikonda et al. 2008; Wei et al. 2008].
Antigenicity of phosphoantigens depends on two important features. First, the two phosphates
present in IPP and HMBPP structures are essential for TCR γδ cell stimulation and synthetic
analogues with three, one, or no phosphates behave as weak agonists or are not stimulatory at all
[Tanaka et al. 1995]. Secondly, IPP is synthesized within the cytoplasm and its negative charges
pose severe limitations to free membrane diffusion. Both of these arguments raise the important
question of how IPP reaches the cell surface of an APC, where it associates with the putative
APM. Because of its negative charges it is very difficult to imagine passive transport of IPP
through the cell membrane despite its low molecular mass. Instead, it is more probable that IPP
molecules are translocated by an active inside-out transport mechanism. It is rather unlikely that
the transport of endogenous IPP occurs via exocytosis from late endosomes (LE)/lysosomes due
to the fact that the low pH of these endosomal compartments is detrimental for the pyrophosphate
group [Van Wazer 1964] and thereby IPP immunogenicity is lost [Morita et al. 2001; Tanaka et
al. 1995]. Hence, we considered the hypothesis that the membrane transport of phosphorylated
antigenic metabolites is mediated by a transporter protein located within cell membranes.
137
14. MRP5 transporter is required for TCR gamma-delta-ligand transport
14.1. The transporter of TCR γδ ligands belongs to the ABC
family
The type of the putative transport protein was investigated using a series of drugs inhibit-
ing known transporters. Main objective of our investigation were three families of organic an-
ion transporters, namely ATP-binding cassette (ABC), monocarboxylate, and inorganic trans-
porters. In addition, we also studied the potential energy-dependence of the putative transport
protein by assessing the involvement of different classes of ATPases.
All drugs, inhibiting candidate transporters, were tested for their capacity to block TCR γδ
cell activation. Daudi cells, used as APC, were first treated with zoledronate (ZOL) to induce
accumulation of endogenous IPP [Gober et al. 2003], then extensively washed and incubated with
each drug individually. Preliminary experiments were performed to carefully identify the maximal
non-toxic drug doses allowed under these experimental conditions. To ascertain whether each
drug was specifically acting on the TCR γδ recognition of endogenous phosphorylated antigenic
metabolites, several control experiments were conducted. First, drug influence on the response of
the same TCR γδ cells to exogenously added IPP was evaluated by using APC identically treated
with the drug but not with ZOL in the presence of exogenous IPP. Secondly, drug inhibition of
mitogen-induced activation of TCR γδ cells was tested by using the same drug-treated APC and
phytohemagglutinin mitogen, which induces T cell activation independently of TCR specificity.
Thirdly, a TCR αβ clone was stimulated with its specific peptide antigen in the presence of each
drug. The effects of the inhibitory drugs were considered specific when TCR γδ cell activation
with PHA and activation of TCR αβ cells were inhibited less than 20%. In case of drugs that
were toxic when kept in culture for prolonged time, pulsing experiments were performed and
toxic drugs were washed out before addition of T cells. The percentage of inhibition of T cell
activation was calculated for each tested drug (see Table 14.1, p.139). Several drugs with a
specific rather than a general effect on antigen presentation were identified, pointing to certain
characteristics of a candidate transporter.
The activation of TCR γδ cells was not influenced by isopentenol, geraniol, or farnesol (the
alcohol analogs of stimulatory IPP) or by geranyl diphosphate or farnesyl diphosphate (data not
shown); suggesting that the putative transporter selectively interacts with the negatively charged
pyrophosphate group of none but IPP [Constant et al. 1994; Pfeffer et al. 1990; Schoel et al.
1994; Tanaka et al. 1994]. Furthermore, neither inhibitors of inorganic phosphate transporters
(foscarnet) [Timmer & Gunn 1998; Yusufi et al. 1986] nor of monocarboxylate transporters
(lactate, phloridzin and phenylpyruvate) [Halestrap & Price 1999] were able to diminish TCR
γδ cell activation.
On the contrary, 4,4’-diisothiocyanatostilbene-2,2’-disulfonic acid (DIDS), a potent inhibitor
of anion translocators, specifically reduced ZOL-induced activation, but neither stimulation by
IPP nor by PHA. These findings additionally support the hypothesis that an anion transporter
is involved in the stimulation of TCR γδ cells.
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Table 14.1 Drugs blocking transport proteins inhibit γδ T cells
Drug i Dose ii % γδ T % αβ T
inhibition inhibition
ZOL IPP PHA iii antigen
Isopentenol 200 µM 0 0 0 nd iv
Geraniol 40 µM 0 0 0 nd
Farnesol 20 µM 0 0 0 nd
Foscarnet 300 mM 0 0 0 0
Lactate, Phloridzin, Phenylpyruvate 100 µM 0 0 0 nd
DIDS v 300 µM 40 20 15 0
ARL-67156, β,γ-MAT 300 µM 0 0 0 0
Omeprazol 30 µg/ml 0 0 0 0
Bafilomycin A1 100 nM 0 0 0 nd
Ouabain 30 µM 0 0 0 0
Oligomycin 100 µg/ml 30 20 10 0
PSC-833 100 µM 100 70 40 35
PKF-274 100 µM 100 75 45 40
Niflumic acid 100 µM 0 0 0 0
Quercetin 100 µM 30 10 0 0
Sulfinpyrazone 10 mM 95 10 0 nd
Benzbromarone 100 µM 65 40 0 nd
Probenecid 3 mM 0 0 0 0
Methotrexate 100 µM 0 0 0 0
MK-571 300 µM 50 30 10 10
i For the specificity of the listed drugs see http://edoc.unibas.ch/701/ Table 4
ii Experiments were performed by Hans-Jürgen Gober
iii Phytohemagglutinin
iv Not determined
v 4,4’-diisothiocyanatostilbene-2,2’-disulfonic acid
The energy dependence of such an anion transport process was evaluated by ATPase inhibitors.
ARL-67156, β,γ-MAT, Omeprazol, Bafilomycin A1, and Ouabain were not blocking TCR γδ
responses, thus making an involvement of ecto-ATPase, H+-ATPase, V-type ATPase and Na/K
transport ATPase unlikely. Whereas a depleting agent of intracellular ATP (oligomycin) showed
specific inhibition, demonstrating the requirement of energy supplied in the form of ATP for this
transport mechanism.
Two inhibitors of ABC transporters, PSC-833 and PKF-274, also decreased TCR γδ cell-
activation, thus suggesting the possible involvement of this ATP-dependent family of trans-
porters. Both drugs are capable of blocking various transporters of different ABC families [Boesch
et al. 1991; Lum et al. 1993; Paul et al. 1996], thus forcing additional experiments to identify the
responsible protein for IPP transport.
The drugs sulfinpyrazone (SPZ) and benzbromarone (BZB) were strong and notably specific
inhibitors in this type of T cell activation assay. The fact that these compounds stop the action
of various ABC anion transporters [Bakos et al. 2000; Evers et al. 2000] reinforced the argument
that transporters involved in TCR γδ activation recognize the anionic part of the stimulatory
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ligands. Moreover, specific blocking was observed in the presence of quercetin, an inhibitor of
ABCC transporters [Walgren et al. 2000]. Based on these findings, we narrowed our studies to the
subfamily C of ABC transporters (for chromosomal localization see [Dean & Allikmets 2001 a]
and for tissue distribution see [Dean et al. 2001 b] of ABC transporters), which have previously
been described as important anion transporters [Miyazaki et al. 2004].
14.2. Involvement of ATP-binding cassette transporter of the C
subfamily in transport of TCR γδ ligands
Men contain 49 documented ABC transporter genes whereof the ABCC family is composed of
12 functional members plus 1 pseudo-gene: 10 multidrug resistant proteins (MRP) (MRP1-10,
MRP10 being a pseudo-gene (ABCC13 )-expressed truncated protein), two sulfonylurea receptors
and a cystic fibrosis transmembrane conductance regulator [Zhou et al. 2008]. The cystic fibrosis
transmembrane conductance regulator is a chloride channel and the sulfonylurea receptors are
the ATP-sensing regulatory subunits of a complex potassium channel. The human MRP/ABCC
transporters except MRP9/ABCC12 are all able to transport organic anions, such as drugs
conjugated to glutathione, sulphate or glucuronate. MRP1-8 are organic anion pumps differing
in substrate specificity and tissue distribution. Reports on MRP9 have been controversial and it
seems to be an unusual MRP in many respects [Ono et al. 2007]: it does neither recognize any
known MRP substrate nor show any N-glycosylation and most importantly, despite its messenger
RNA (mRNA) being readily detected in human tissue and cells, the expressed protein is not.
As phosphoantigen presentation to TCR γδ cells is exerted by APC of different tissue origin
[De Libero et al. 1991; Gober et al. 2003], it is conceivable that the transporters involved in
antigen trafficking have broad tissue distribution. Therefore, we limited candidate transporters to
those that are ubiquitously expressed. Cystic fibrosis transmembrane conductance regulator was
excluded because niflumic acid, a potent inhibitor of cystic fibrosis transmembrane conductance
regulator [Scott-Ward et al. 2004], did not alter TCR γδ cell stimulation.
We excluded MRP7 and MRP8 as well as MRP2, MRP3, and MRP6 [Borst et al. 1999] due
to their low abundance and/or limited tissue distribution and focused on MRP1, MRP4, and
MRP5 transporters, that are widely expressed in the body. The leukotriene analog MK-571, that
specifically inhibits active transport of MRP1, MRP4, and MRP5 [Reid et al. 2003], blocked the
activation of TCR γδ and not of TCR αβ cells. Probenecid and methotrexate, which are two
potent MRP1 inhibitors [Bakos et al. 2000], were not inhibitory, thus indicating that MRP1 is
not involved in IPP transport and presentation. These results restricted our studies to MRP4
and MRP5.
MRP proteins are functionally characterized by structural features. MRP1, 2, 3, 6, and 7
possess an amino-terminal transmembrane domain and a P-glycoprotein-like core consisting of
two transmembrane domains and two nucleotide-binding domains. On the other hand MRP4,
5, 8, and 9 lack the amino-terminal transmembrane domain (denoted TMD0) found in the other
MRP [Tusnady et al. 2006]. MRP1 mutants deleted for the TMD0 show comparable substrate
transport levels to the full length protein but display impaired trafficking to the plasma mem-
brane, whereas MRP1 with deletions in cytoplasmic loop 3 do not show altered trafficking but
differ in substrate recognition and transport activity [Frelet & Klein 2006]. The same is seen for
MRP2, where the TMD0 domain is required for correct targeting to the apical membrane but is
not required for transport function. Being close structural relatives, only MRP5 but not MRP4
has a ubiquitous tissue distribution [Kool et al. 1997] and even more crucially, MRP4 is absent
from thymus [Borst et al. 2007]. A quantitative RT-PCR (reverse transcription polymerase chain
reaction) analysis was conducted to discriminate MRP4 and MRP5 mRNA levels in cell lines of
different tissue origin which stimulate TCR γδ cells (see Table 14.2, p.141).
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Table 14.2 MRP4 and MRP5 expression in γδ T cell-stimulatory cell lines
Cell line i MRP4 MRP5
A-375 positive positive
A-431 negative positive
CEM 1.3 positive positive
Colo-201 positive positive
Daudi negative positive
HepG2 positive positive
HL-60 positive positive
HuH6 positive positive
K562 positive positive
i Experiments were performed by Hans-Jürgen Gober
Importantly, MRP4 mRNA was absent in A-431 and Daudi cells which very efficiently activate
TCR γδ cells. In contrast, MRP5 mRNA was detected in all cell lines (primer sequences are
given in http://edoc.unibas.ch/701/). In another set of experiments Daudi cells appeared
negative for the expression of MRP7, 8 and 9 genes (data not shown), thus formally excluding
these transporters as involved in TCR γδ stimulation.
14.3. MRP5 overexpression increases stimulation of TCR γδ cells
To confirm that MRP5 is the transporter of the stimulatory ligands, a MRP5-overexpressing
Daudi cell line was generated. The stimulatory capacity of MRP5-transfected Daudi cells is
significantly increased over non-transfected cells (see Figure 14.1 (A), p.142).
A-375 cells are strong stimulators of TCR γδ cells when pulsed with ZOL. Therefore, we trans-
fected A-375 cells with the MRP5 gene and tested their stimulatory capacity (see Figure 14.1
(B,C), p.142). MRP5 overexpression facilitates TCR γδ cells activation at all ZOL doses, suggest-
ing that a more effective transport contributes to increased presentation of endogenous antigens
(see Figure 14.1 (B), p.142). The stimulatory effect of MRP5-transfected cells is limited to TCR
γδ cells because the presentation of MART peptide to a MART-specific and major histocom-
patibility complex (MHC) class I-restricted TCR αβ clone is not affected (see Figure 14.1 (C),
p.142). To further investigate the involvement of MRP5 in T cell activation, APC were treated
with a fixed dose of ZOL to induce accumulation of endogenous ligands and incubated with
increasing doses of the MRP5-inhibitor sulfinpyrazone. MRP5 transfectants require three times
more sulfinpyrazone than WT cells to observe the same level of T cell inhibition, thus confirming
the specificity of this drug and further supporting the involvement of MRP5 in transport of
endogenous ligands (see Figure 14.2, p.143). Neither exogenous addition of antigen (IPP) nor a
control mitogen (PHA, data not shown) stimulation is affected by SPZ.
14.4. MRP5 gene silencing affects stimulation of TCR γδ cells
In order to further validate the involvement of MRP5 in the transport of TCR γδ stimulatory
ligands, we knocked down the MRP5 protein by specific gene silencing. Four different short
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Figure 14.1
Gamma-delta T cell-activation is increased by MRP5 overexpression. (A) MRP5-transfected
(closed bars) or WT Daudi cells (open bars) were used as APC in TCR γδ cell-activation assays
and MRP5 transfectants show a higher stimulatory capacity. Experiments were performed by
Hans-Jürgen Gober. (B) MRP5 overexpression in A-375 cells facilitates activation of TCR γδ
cells by ZOL treated APC. MRP5-overexpressing A-375 cells (closed diamonds) stimulate γδ T
cells more efficiently than A-375 WT cells (open diamonds). (C) Stimulation of a MHC class
I-restricted, MART peptide-specific TCR αβ clone is not influenced by MRP5 overexpression.
MRP5-transfected A-375 cells (closed diamonds) and A-375 WT cells (open diamonds) were used
as APC. Experiments were performed by Magdalena Kistowska (B,C).
hairpin RNA (shRNA) interference constructs targeting MRP5 mRNA were generated. A-375
transfected separately with each of these constructs were used as APC in TCR γδ activation
experiments. All A-375 cells transfected with MRP5 shRNA interference constructs (sequences
are given in http://edoc.unibas.ch/701/), stimulate TCR γδ cells less efficiently than control
non-transfected APC or APC transfected with a firefly luciferase shRNA construct (Ff1 [Paddison
et al. 2002]). The decrease in T cell activation was observed when MRP5-silenced APC were
treated with ZOL or pulsed with IPP (see Figure 14.4, p.145). There was a direct correlation
of MRP5 levels after RNA interference and the stimulatory capacity, since cells transfected
with the shRNA 3344 construct had the lowest of MRP5 mRNA levels and also showed the
lowest stimulatory capacity (data not shown). A significant reduction of MRP5 expression in
shRNA 3344 transfected cells was confirmed by confocal laser scanning microscopy (CLSM) (see
Figure 14.3, p.144). The low antigen presentation capacity of MRP5 shRNA-transfected APC is
TCR γδ-specific because presentation of MART peptide to a TCR αβ MART-specific clone by
the same APC is unchanged (see Figure 14.4 (C), p.145). Finally, the response of two other TCR
Vγ9/Vδ2 clones was also reduced when shRNA 3344-expressing APC were used, thus confirming
that the MRP5 transporter is important for the stimulation of this T cell population (data not
shown).
14.5. MRP5 transports isopentenyl diphosphate across
membranes
Inverted red blood cell membranes allow direct measurement of transport activity of individual
substrates. They have been instrumental to confirm that cGMP is transported by different
transporters, including MRP5 [Boadu & Sager 2000, 2004; Klokouzas et al. 2003; Sager 2004].
Inverted red blood cell membranes were able to transport radioactive IPP similar to cGMP (see
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Figure 14.2
MRP5 overexpression increases resistance to ABC transporter blockers. MRP5 transfectants
or WT A-375 cells were treated with ZOL (A) or pulsed with IPP (B) and used to activate TCR
γδ T cells in the presence of sulfinpyrazone. Exogenous addition of the TCR γδ-ligand IPP
unalteredly stimulated γδ T cells over a broad range of applied sulfinpyrazone concentrations.
Conversely, ZOL treatment was less efficient on WT cells than on MRP5-overexpressing cells in
the presence of sulfinpyrazone. MRP5 transfection confers resistance to sulfinpyrazone as the
dose needed to reach IC50 levels is increased three times (x-axis difference of the two dashed
vertical lines) from WT to MRP5-overexpressing cells. The dashed horizontal line represent the
half-maximal stimulation. Experiments were performed by Magdalena Kistowska.
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Figure 14.3
Specific silencing of MRP5 visualized by CLSM. HeLa wild type (WT, upper left), HeLa MRP5
shRNA 3344 (shRNA, upper right), and HeLa MRP5 (MRP5, lower left) were stained with
polyclonal anti-human MRP5 (green) antibodies and Hoechst (red). HeLa wild type (iso, lower
right) were stained with control antibodies and Hoechst. Downregulation of MRP5 expression
by 3344 shRNA is obvious whereas upregulation by MRP5 transfection is hardly visible. Similar
results were obtained for A-375 cells (data not shown). Scale bar, 10 µm.
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Figure 14.4
Specific silencing of MRP5 alters TCR gamma-delta cell-responses. (A and B) A-375 WT cells
(white diamonds), A-375 cells transfected with the MRP5-specific shRNA interference silencing
construct pCMV_3344 (light gray diamonds) or with irrelevant shRNA silencing construct Ff1
(dark gray diamonds) were used as APC in endogenous (A) antigen presentation assays. (B)
The constructs did not have any impact on the activation of a MHC class I-restricted, MART
peptide-specific TCR αβ clone. Experiments were performed by Magdalena Kistowska.
Figure 14.5, p.146). IPP transport was inhibited by the MRP5-blocking drugs sulfinpyrazone
and benzbromarone, but not by the MRP1-blocking drug methotrexate (see Figure 14.5, p.146).
IPP transport is ATP-dependent (see Figure 14.6 (left top panel), p.147). Furthermore, active
transport over OSV membranes could be reduced to background levels by cold IPP (see Fig-
ure 14.6 (left bottom panel), p.147). This is likely to occur by competition for the binding site
by the cold versus the hot, radioactive compound. Another possibility that we can not formally
exclude is that the high amounts of IPP compete with ATP for the hydrolysis site and thus
decline the energy supply for the MRP5 transporter. This would only be the case if IPP can
not be hydrolyzed itself inside the ATP-binding site of MRP5. The high energy phosphate bond
in pyrophosphates is a known biological short term energy depot and readily hydrolyzed under
appropriate environmental conditions. Against the thought of IPP blocking the ATP-binding
site is argued by the fact that the transport of cGMP, being energy- and thus ATP-dependent,
is not disturbed (see Figure 14.6 (right bottom panel), p.147).
These findings confirm that MRP5 is involved in transport of IPP across membranes and raised
the question of where this transport occurs within a cell other than an erythrocyte with solely a
plasma membrane.
14.6. MRP5 resides in membranes of the endoplasmic reticulum
and of early endosomes
Initial studies suggested that MRP5 might be localized on the plasma membrane and partly
intracellularly [McAleer et al. 1999; Wijnholds et al. 1997]. Later investigations indicated that
this protein is almost completely localized within the cell, although an exact localization was not
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Figure 14.5
Blocking of MRP5 by specific drugs decreases IPP transport over membranes. Transport of
3H cGMP control (left panel) and of 14C IPP (right panel) over membranes of one-step inside-
out membrane vesicles (see section 8.4 (OSV), p.49) in the presence of the ATP regenerating
system (creatine phosphate, creatine phosphokinase) with ATP alone or ATP plus blocking by
benzbromarone, methotrexate (both 100 µm), or sulfinpyrazone (800 µm). Benzbromarone and
sulfinpyrazone inhibit transport of 14C IPP and 3H cGMP into inverted vesicles. Methotrexate
significantly blocks transport of 3H cGMP but fails to block 14C IPP altogether. Uptake rates
of radioactive substrates were in the range of 10 pmol/mg of protein for both compounds. SD
values for 14C IPP are below 400 cpm.
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Figure 14.6
IPP transport by MRP5 is ATP-dependent
and can be competed by cold IPP. Transport
of 3H IPP (left panels) and 3H cGMP con-
trol (right panels) over OSV membranes in
the presence of the ATP regenerating system
(creatine phosphate, creatine phosphokinase)
with ATP alone, with ATP-γ-S, with ATP
and the inhibitory drug benzbromarone (BZB,
100 µm), or with ATP and competition by 10-
fold molar excess of cold IPP. Specific, ATP-
dependent transport is given by the differ-
ence of transported substrate in the presence
of ATP versus ATP-γ-S (a non-hydrolyzable
ATP analogue). Benzbromarone completely
inhibits specific transport of 3H IPP and
3H cGMP into inverted vesicles. Only ra-
dioactive IPP but not cGMP is competed by
cold IPP, excluding secondary effects of cold
IPP to the transport system. Uptake rates
of tritiated substrates were in the range of
10 pmol/mg of protein for both compounds.
SD values for both substrates are less than
300 cpm. P values were lower than 0.05 for
all six plots except the lower right one; cold
IPP did not block 3H cGMP transport.
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established [Torky et al. 2005]. This would be more in line with the fact that the amino-terminal
transmembrane domain (TMD0) of the ABCC transporters, conferring the ability to traffic to
the plasma membrane (at least for MRP1 and MRP2), is missing in MRP5.
We studied the intracellular localization of MRP5 in HeLa, A-375 and Daudi cells by confocal
microscopy. In all cases, the transporter colocalized with the ER marker p63 and the transferrin
receptor (TfR) in recycling early endosomes (EE) (see Figure 14.7 (row 1/2), p.149), but not with
markers of the plasma membrane (data not shown), Golgi, and LE/lysosomes (see Figure 14.7
(row 3/4), p.149). To analyze the significance of the confocal studies, the Pearson’s and the
Mander’s colocalization coefficients as well as the intensity correlation quotients of at least four
complete images (with more than eight cells) per staining were calculated. Mander’s M2 showed
that MRP5 (green) was significantly colocalized with the TfR (EE) and p63 (ER) compartment
(red) markers (see Figure 14.8, p.150). Moreover, the colocalized voxel intensities of green and
red are positively (linearly) related (Person’s Rtotal) and the MRP5 and compartment stainings
are dependent (intensity correlation quotient).
A tubular distribution was detected, resembling that observed for other ER-localized proteins
[Klopfenstein et al. 1998; Lorenz et al. 2006; Shnyrova et al. 2008; Snapp et al. 2003]. This
localization shows that MRP5 is involved in antigen presentation to TCR γδ cells by transporting
relevant antigens within the ER and suggests that MRP5 is not directly contacting the TCR. A
possible scenario is that IPP is transported to the ER lumen, where it forms complexes with a
dedicated APM and, after trafficking to the cell surface, is presented to the TCR γδ.
14.7. Conclusions and outlook
Our data show that the immune system has hijacked a biological relevant system to transport
negatively charged metabolites out of the cytoplasm. This strategy resembles that of ATP-
dependent TAP involved in peptide traffic from the cytosol into ER [Momburg et al. 1994; Neefjes
et al. 1993]. TAP molecules are part of complex protein multimers composed of several proteins
that facilitate the assembly of MHC class I proteins and also provide transport and loading
of peptides onto these presenting molecules [Cresswell et al. 1999]. At present, it is not clear
whether MRP5 constitutes multi-subunit complexes with several functions including assembly
of the presenting molecule, transport of phosphoantigens and formation of stimulatory antigenic
complexes. The formation of such protein multimers might represent an efficient strategy to
directly deliver phosphoantigens to dedicated presenting molecules.
The functional consequences arising out of MRP5 localization to EE are unclear and remain
to be investigated. Lately, TAP was shown to be localized to EE and ‘cross-presentation’ of
exogenous antigens on MHC class I molecules was demonstrated to occur in EE distinct from
the ER in a TAP-dependent manner [Burgdorf et al. 2008; Gazi & Martinez-Pomares 2009].
Another non-immunological function of MRP5 might be control of the mevalonate pathway.
Previous studies have identified MRP5 as a transporter for cyclic nucleotides, especially cGMP
and it was suggested that MRP5 removes cGMP from the cytosol during signal transduction
[Jedlitschky et al. 2000]. IPP and perhaps other phosphorylated metabolites generated in the
mevalonate pathway are additional physiological substrates of MRP5. The mevalonate pathway
is tightly controlled by feedback regulation of gene transcription, enzyme activity, and stability,
thus accurately regulating cholesterol synthesis and protein prenylation [Brown & Goldstein 1997;
Goldstein & Brown 1990; Goldstein et al. 2006]. By removing IPP accumulated in the cytosol,
MRP5 might represent a novel mechanism controlling the abundance of mevalonate metabolites.
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14.7. Conclusions and outlook
Figure 14.7
MRP5 colocalizes partially with EE and ER. Each row is showing the staining in HeLa cells of
MRP5, a compartment marker, MRP5 merged to compartment all pixels, and MRP5 merged to
compartment colocalized pixels only. Partial colocalization with ER (p63, first row) and with EE
(TfR, second row). Neither colocalization with Golgi (giantin, third row) nor with LE/lysosomes
(LAMP-1, forth row). Similar compartmentalization was seen for A-375 and Daudi cells (data
not shown). Colocalized pixels were calculated in ImageJ using the Colocalization Highlighter
(CH) plugin with the median channel thresholds of channel 1 and channel 2 of all images of a
specific marker established by the Colocalisation Thresholds plugin and the results are shown as
binary image. Scale bar, 10 µm.
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Figure 14.8
CLSM image analysis and quantification of MRP5 colocalization. Images were loaded into
ImageJ, visualized using HiLo LUT for background correction (thresholding), and quantified by
the Intensity Correlation Analysis and Colocalisation Thresholds plugins. At least four complete
images containing more than 8 single HeLa cells without ROI selection were used to calculate
Mander’s Colocalization Coefficients for channel 1 (M1: e.g. red overlapping with green) and
channel 2 (M2: e.g. green overlapping with red) and the Intensity Correlation Quotient (ICQ:
random staining ICQ ≈ 0, segregated staining 0 > ICQ ≥ −0.5, dependent staining 0 < ICQ
≤ +0.5). Rtotal gives the Pearson’s correlation coefficient for all the non zero-zero pixels in the
image and closer it is to ± 1, the more linearly related are all the voxels’ intensities in the two
channels. p63 (ER), TfR (EE), giantin (Golgi), LAMP-1 (LE/lysosomes). Values are given as
median ± SD.
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It is well established that the CD1 family of proteins present lipid antigens to T cells. However,
in vivo studies of CD1 function have been carried out almost exclusively using mouse models,
despite the fact that mice lack most of the CD1 genes that are found in humans and other
mammals [Dascher & Brenner 2003]. Therefore vaccination studies [Cerundolo et al. 2009; Reddy
et al. 2009; Silk et al. 2004] have been hampered. Moreover lipid uptake by diet can affect the
immune response to lipids [Niazi et al. 2002] but can be hardly controlled in human beings.
Considering the lymphocytes involved in non-peptidic antigen response, it would be of great
worth to obtain immunological tools to monitor these cells as it has been successfully done for
invariant natural killer T (iNKT) cells with lipid antigen-loaded antigen-presenting molecule
(APM)-multimers. A newly established system to generate mouse iNKT cells from embryonic
stem cells [Watarai et al. 2009], if applicable to human cells, will allow molecular studies about
development and potentially lead to therapies with functionally selected iNKT cells.
On the antigen side, the design of new lipidic ligands was enabled by the crystal structures of
the APM, thus reports on the CD1c structure as well as the identification of the TCR γδ-APM
are eagerly awaited. Meanwhile, new non-peptidic antigens as the piperidinones or the αGC
analogues with a terminal phenyl ring on the acyl chain [Schiefner et al. 2009] for the known
APM will elucidate APM-TCR interactions. Optimized ligands may help to prevent immune
evasion as f.i. CD1 downregulation seen by infection with Mycobacterium tuberculosis [Stenger
et al. 1998] and to direct the immune system towards a TH1- or TH2-response.
Transporters for non-peptidic compounds will be more selectively studied using specific sub-
strates as methotrexate diglutamate for MRP5 [Kruh et al. 2007] and effective translocation
can be monitored by lately introduced tandem mass spectrometry methods to rapidly and sensi-
tively detect and simultaneously quantify the eight main nonsterol intermediates of the isoprenoid
biosynthesis pathway [Henneman et al. 2008]. As crystals of such multi-transmembrane trans-
porters are unlikely to be obtained, artificial proteins [Licen et al. 2008] and molecular modeling
data [Ravna et al. 2008, 2009] will be crucial to answer selectivity [Sager & Ravna 2009] and
translocation of such transporters to understand their functions [Pratt et al. 2005; Warren et al.
2009]. Future MRP mouse models could be helpful and realized as mouse orthologs have been
identified and studied for all human MRP genes except MRP8 [Maher et al. 2005]. The amino acid
sequence of human MRP5 revealed 94.1% identity to that of mouse mrp5 and the hydrophobicity
plots were almost congruent [Suzuki et al. 2000]. The mrp5 knockout mouse has no spontaneous
phenotype [Borst et al. 2007] but the γδT cell compartment remains to be studied. Therefore
the transgenic mouse model of the human TCR Vγ9/Vδ2 heterodimer created in our laboratory
(see http://edoc.unibas.ch/701/ Part 4) might give further insights into the major human
TCR γδ population in PBMC normally absent in non-primates like mice.
A recent report finds MRP5 preferentially expressed in B cells and to a lower extent in T
cells among the lymphocytes [Hoellein et al. 2009]. This is in line with our findings that γδT
cells are capable of self-stimulation when treated with ZOL or pulsed with IPP. In total PBMC
the same group found MRP5 highly abundant in granulocytes (CD15- or CD16-positive cells)
by quantitative real-time RT-PCR. Interestingly, eosinophils, a granulocyte subpopulation, have
been proven to express functional TCR γδ molecules [Legrand et al. 2009]. In allergic pleurisy
a correlation of γδT cells migration and activation with accumulation of eosinophils has been
reported in mice [Costa et al. 2009].
Studies about lipids, their well preserved metabolic pathways, and transport systems are of
great importance as they are not sole structural components of a cell but are involved in many
dynamic processes as intra- and extracellular signaling [van Meer et al. 2008] as well as in immune
responses by several means. They are able to strengthen an immune response by concentrating
the molecules of an immune synapse locally in a membrane (raft) [Anderson et al. 2000; Eren
et al. 2006; Im et al. 2009; Park et al. 2005]. Moreover, non-peptidic compounds can directly be
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immunogenic and presented as antigens by an antigen-presenting cell [De Libero & Mori 2009 a;
Kabelitz 2008]. Furthermore, being evolutionary highly conserved, lipid metabolic pathways are
ideal drug targets in pathogens as f.i. the isoprenoid biosynthetic pathways [Rohdich et al. 2005].
Overall, a longtime neglected scientific field is worth more intense efforts to clarify underlying
mechanisms that will lead to new medical applications in future.
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Abbreviations
All abbreviations are designated to represent both the singular and plural forms.
Symbols
αGC alpha-galactosylceramide
β2m β2 microglobulin
7AAD 7-aminoactinomycin D
A
ABC ATP-binding cassette
AHA American Heart Association
AP adaptor protein
APC antigen-presenting cell
APM antigen-presenting molecule
ARF adenosine diphosphate ribosylation factor
ATH atherosclerosis
ATP adenosine triphosphate
B
BZB benzbromarone
C
CDR complementarity determining region
CFSE carboxyfluorescein succinimidyl ester
cGMP guanosine 3’,5’-cyclic monophosphate
CIITA class II transactivator
CLSM confocal laser scanning microscopy
cpm counts per minute
D
DAPI 4’,6-diamidino-2-phenylindole dihydrochloride
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DC dendritic cell
DMAPP dimethylallyl pyrophosphate
DMSO dimethyl sulfoxide
DN double-negative
DP double-positive
E
EC endothelial cell
EC50 half maximal effective concentration
EDTA ethylenediaminetetraacetate
EE early endosome
ER endoplasmic reticulum
F
FACS fluorescence-activated cell sorting
FCSM fetal calf serum medium
FPP farnesyl pyrophosphate
G
GFP green fluorescent protein
GM1 monosialotetrahexosylganglioside
H
HLA human leukocyte antigen
HMBPP (E)-4-hydroxy-3-methyl-but-2-enyl pyrophosphate
HSM human serum medium
I
IC50 half maximal inhibitory concentration
IEF isoelectric focusing
Ig immunoglobulin
iGb3 isoglobotrihexosylceramide
Ii invariant chain
IL interleukin
158
iNKT invariant natural killer T
IPP isopentenyl pyrophosphate
IVUS intravascular ultrasound
K
KIR killer cell immunoglobulin-like receptor
KLR killer cell lectin-like receptor
L
LAMP-1 lysosome-associated membrane glycoprotein 1
LC50 median lethal concentration
LE late endosome
M
MβCD methyl-β-cyclodextrin
mAb monoclonal antibody
MACS magnetic-activated cell sorting
MEP 2-C-methylerythritol 4-phosphate
MHC major histocompatibility complex
mRNA messenger RNA
MRP multidrug resistant protein
MW molecular weight
N
NCR natural cytotoxicity receptor
NK natural killer
P
PBMC peripheral blood mononuclear cell
PBS phosphate buffered saline
PFA paraformaldehyde
PI propidium iodide
R
RNA ribonucleic acid
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rpm revolutions per minute
RT room temperature
S
SD standard deviation
shRNA short hairpin RNA
siRNA small interfering RNA
SOP standard operating protocol
SPZ sulfinpyrazone
T
TH1 type 1 helper T cell
TH2 type 2 helper T cell
TAP transporter associated with antigen processing
TCR T cell receptor
TD tail-deleted
Tf transferrin
TfR transferrin receptor
W
WT wild type
Z
ZOL zoledronate
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Index
(E)-4-hydroxy-3-methyl-but-2-enyl pyrophosphate a natural intermediate of the 2-C-methylerythritol
4-phosphate (MEP) pathway of isopentenyl pyrophosphate biosynthesis. 26, 35, 137
αGC 20, see alpha-galactosylceramide
2-C-methylerythritol 4-phosphate the eponymous compound of a foreign alternative pathway
of isopentenyl pyrophosphate biosynthesis. 13, 26, 137
ABC 9, see ATP-binding cassette
alpha-galactosylceramide the pan-iNKT cell activating glycosphingolipid isolated from Agelas
mauritianus, an Okinawan sea sponge, in the 1990s by researchers at the Kirin Brewery in
Japan and denominated KRN7000. 20, 23, 42, 45, 59, 61
ATH 14, see atherosclerosis
atherosclerosis hardening of an artery, typically asymptomatic for decades, specifically due to an
atheromatous plaque with its three distinct components: the atheroma, cholesterol crystals
and calcification; note that atherosclerosis is a form of arteriosclerosis. 14, 89
ATP-binding cassette a protein domain consisting of a catalytic (ATP hydrolyzing) core domain
and a α-helical subdomain unique to ABC transporters. 9, 12, 138
benzbromarone a uricosuric therapeutic agent and potent inhibitor of CYP2C9 and MRP1-5 of
the ABCC transporter family. 139
BZB 139, see benzbromarone
CIITA 107, see class II transactivator
class II transactivator a protein controlling to a large extent expression of MHC class II genes.
107
clone clones are derived from a single common ancestor cell and hence share an identical geno-
type. 41
CLSM 142, see confocal laser scanning microscopy
confocal laser scanning microscopy high resolution optical imaging with controlled depth of
focus and laser scanning allowing 3D detection and reconstruction. 142
DC 18, see dendritic cell
dendritic cell the archetype professional antigen-presenting cell. 18, 42, 43, 105
DIMER β2m-associated human CD1d loaded with αGC and dimerized via an anti-tag mAb. 62,
63
161
DN 24, see double-negative
double-negative neither expressing CD4 nor CD8. 24, 26, 64, 92
double-positive expressing CD4 and CD8 in unison. 18, 24, 26, 90
DP 18, see double-positive
EC50 92, see half maximal effective concentration
FACS 46, see fluorescence-activated cell sorting
fluorescence-activated cell sorting a technique for counting, examining, and sorting micro-
scopic particles suspended in a stream of fluid. 46
GM1 25, see monosialotetrahexosylganglioside
half maximal effective concentration the dose of a substance required to provoke a response
halfway between baseline and plateau. 92
half maximal inhibitory concentration the dose of a particular substance needed to inhibit a
given biological process (or component of a process) by half. 80, 143
HLA 107, see human leukocyte antigen
HMBPP 26, see (E)-4-hydroxy-3-methyl-but-2-enyl pyrophosphate
human leukocyte antigen human leukocyte antigens were originally defined as cell surface anti-
gens that mediate graft-versus-host disease in HLA-mismatched donors. 107
IC50 80, see half maximal inhibitory concentration
Ii 19, see invariant chain
IL 37, see interleukin
interleukin a group of cytokines first seen to be expressed by leukocytes. 37, 87, 89, 92, 97,
100–103
intravascular ultrasound a medical imaging methodology using ultrasound to visualize the en-
dothelium of blood vessels in living individuals. 52
invariant chain a protein involved in formation, loading and deliverance of MHC class II. 19,
105, 107, 112
IPP 13, see isopentenyl pyrophosphate
isopentenyl pyrophosphate the eponymous compound of the self mevalonate pathway of isopen-
tenyl pyrophosphate biosynthesis. 13, 26, 35, 135, 137–139, 142
IVUS 52, see intravascular ultrasound
LAMP-1 16, see lysosome-associated membrane glycoprotein 1
LC50 46, see median lethal concentration
162
lysosome-associated membrane glycoprotein 1 a marker for late endosomes (LE) and lyso-
somes. 16, 121, 124–126, 149, 150
MACS 39, see magnetic-activated cell sorting
magnetic-activated cell sorting a method for separation of various cell populations depending
on their surface antigens. 39
median lethal concentration the dose of a toxic substance or radiation required to kill half the
members of a tested population. 46
MEP 13, see 2-C-methylerythritol 4-phosphate
monosialotetrahexosylganglioside the prototype ganglioside, a member of the ganglio series of
gangliosides which contain one sialic acid residue. 25, 35, 72, 110, 134
MRP 140, see multidrug resistant protein
multidrug resistant protein a ABBC transporter family member conferring multidrug resistance
to organic anion compounds. 140
rad 1 rad is 1 cGy is 10-2 Gy. 44
SPZ 139, see sulfinpyrazone
sulfinpyrazone a uricosuric medication and potent inhibitor of MRP1-5 of the ABCC transporter
family. 139, 141
TH1 70, see type 1 helper T cell
TH2 70, see type 2 helper T cell
type 1 helper T cell a T cell producing IFN-γ and mainly partnering with macrophages. 70,
82–85, 102, 153
type 2 helper T cell a T cell producing IL-4 and mainly partnering with B cells. 70, 74, 82–84,
102, 153
vaccination administration of antigenic material (the vaccine) to produce immunity to a disease
to prevent or ameliorate the effects of infection by a pathogen. 3
variolation inoculate a person with smallpox (Variola) in a controlled manner as to minimize
the severity of the infection and also to induce immunity against further infection. 3
ZOL 138, see zoledronate
zoledronate the synthetic aminobisphosphonate 1-hydroxy-2-imidazol-1-yl-1-phosphono-ethyl phos-
phonic acid blocking the active site of farnesyl pyrophosphate synthase. 138, 139, 141, 142
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Patient PBMC & plasma collecting procedure 
 
 
 
A) General notes 
 
• The whole procedure needs to be conducted under sterile conditions. 
• For all the centrifugation steps use only centrifuges with swinging rotors and with acceleration / 
brake adjustment possibility to avoid sample loss. 
• Carry out the complete procedure at room temperature (RT). 
• Use only PBS and FICOLL at RT. 
• Samples are to be labeled with a permanent marker as follows (example for the first patient): 
 
Plasma (P) Cells (Z) 
 
   
 
Use progressive patient numbering and keep patient data record. 
 
 
 
B) Material preparation 
 
1. Prepare and label (see above) per patient: 6 cryo tubes (4 for cells & 2 for plasma), 2 * 50ml 
Falcons, and 4 * 5ml Falcons. 
2. Take FICOLL stock out of the fridge and pipette 15ml of FICOLL to one 50ml Falcon tube and 
allow FICOLL to reach RT before proceeding. 
3. Make sure to have enough RT PBS (~80ml per patient). 
 
 
 
C) Plasma sampling 
 
4. Centrifuge the 4 tubes of patient blood 5min @ 770g, RT with brake and normal acceleration. 
5. Mark each tube at the surface level of the sample to register the total volume. 
6. Carefully aspirate plasma (yellow layer) of 4 patient blood tubes and transfer to 4 * 5ml Falcon 
tubes – do not aspirate completely to avoid taking white blood cells at the blood-plasma-interface. 
 
7. Take 0.5ml of each of the 4 * 5ml Falcon tubes and transfer to 2 properly labeled (“P”) cryo tubes 
(final 1ml each). 
 
 
 
D) Cell sampling 
 
8. Give back taken off plasma volume in RT PBS to the total volume mark and mix gently by 
pipetting. 
9. CAREFULLY layer all 4 RT PBS reconstituted patient blood samples (one by one) on top of the 
FICOLL (in one 50ml Falcon tube). 
10. Centrifuge the 50ml FICOLL tube of patient blood 20min @ 770g, RT WITH SLOW 
ACCELERATION and WITHOUT BRAKE. 
11. Collect ring of white blood cells (WBZ) to 1 new 50ml Falcon WITHOUT touching the red blood 
cells (RBZ). 
LU#0001 
Date 
Z
LU#0001 
Date 
P
aspirate 
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12. Fill 50ml Falcon tube ad 50ml with RT PBS. 
13. Centrifuge the 50ml Falcon tube 5min @ 770g, RT with normal acceleration and brake. 
14. A cell pellet MUST be visible. 
15. Discard supernatant (SN) by pouring (carefully). 
16. Resuspend pellet in 4ml 4°C freezing medium (just taken out of the fridge before usage). 
17. Aliquot 4 * 1ml of resuspension to 4 properly labeled (“Z”) cryo tubes. 
 
 
 
E) Plasma & Cell freezing 
 
18. Place all 6 cryo tubes into styropor box, close box well, and freeze @ -70°C in the back of the 
freezer together with the plasma samples (5ml Falcons). 
19. The samples should remain in the freezer for at least 2 days before shipping and can be stored 
up to 4 weeks @ -70°C. 
20. Organize shipment on dry ice after collection of several patient samples together with the 
Experimental Immunology lab (DF USB, Tel. 061 265 23 27, Fax 061 265 23 50, 
marco.cavallari@unibas.ch, lucia.mori@unibas.ch) and the Signal Transduction lab (DF USB, 
Tel. 061 265 24 22, Fax 061 265 23 50, Therese-J.Resink@unibas.ch). 
 
 
 
F) Material references 
 
• Falcon tubes (BDbiosciences.com, 352070 (50ml) & 352063 (5ml))  
 
• Cryo tubes (Nuncbrand.com, 375418 (1.8ml)) 
 
• FICOLL (Axon Lab, Lymphoprep) to be stored @ 4°C in the dark (alufoil wrapped) 
• PBS (Invitrogen.com (Gibco), 14190) 
• Freezing medium: 90% fetal bovine serum (FBS) & 10% DMSO to be stored @ 4°C 
 
 
 
G) General references 
 
  
 
 
55% plasma 
 
5% white blood cells Blood components 
 
40% red blood cells & platelets 
collect 
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H) Protocol at a glance 
 
Workflow:  
 
 
 
Plasma collecting 
& freezing 
(step 1) 
 
 
 
Get patient blood 
 
 
 
5 min 
770 g 
RT 
 
 
 
Plasma collecting 
 
    
 
Take 2ml of plasma 
(0.5ml from each 
Falcon) and 
transfer to 2 cryo 
tubes (1ml each) 
 
  
 
Volume 
adjustment 
(step 2) 
 
 
 
 
 
 
 
 
 
 
Adjust volume with 
RT PBS to initial 
volume 
 
 
 
FICOLL 
 
(step 3) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Layer blood on top 
of RT FICOLL 
 
 
 
20 min 
770 g 
RT 
slow acceleration & 
w/o brake 
 
 
 
WBZ colleting & 
washing 
(step 4) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Collect WBZ ring 
 
 
Fill ad 50ml with RT 
PBS 
 
 
 
5 min 
770 g 
RT 
 
 
 
WBZ freezing 
 
(step 5) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Discard 
supernatant by 
pouring 
 
 
 
Resuspend WBZ in 
4ml 4°C freezing 
medium and 
transfer to 4 cryo 
tubes (1ml each) 
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Mycoplasma detection procedure DF, USB 
 
 
 
 
 
I) Purpose 
 
The purpose of this Standard Operating Procedure (SOP) is to establish uniform procedures 
for ensuring that 
• Newly arriving cells or cell lines are screened upon arrival (not compulsory for commercially 
purchased cells or cell lines that are routinely tested and certified mycoplasma-free by the 
supplier, e.g. ATCC, ECACC, DSMZ, …). 
• All cell culture facilities of the DF are routinely checked for mycoplasma contaminations. 
• All cell culture facilities of the DF (become and) remain mycoplasma-free. 
• All liquid nitrogen tanks of the DF (become and) remain mycoplasma-free. 
• … 
 
 
 
II) Applicability & Compliance 
 
The procedure contained in, or referenced by, this SOP is applicable to all personnel in the DF cell culture 
facilities. 
Compliance evaluation inspections at the DF will be conducted in a manner which will maintain the 
existing level of bio-safety at the facility being inspected. 
 
 
 
III) Summary of Procedure 
 
The mycoplasma screening and possible decontamination will be accomplished in three stages 
• Pre-screening cell (and potential mycoplasma) expansion and DNA isolation 
• Screening by genomic PCR 
• Post-screening (if mycoplasma-positive) attempt to eliminate the contamination(s) 
 
 
 
IV) Definitions 
 
The following definitions are applicable to this SOP. 
• Mycoplasma: Concerning a first reference to mycoplasma it is suggested to read Appendix A 
(taken from http://en.wikipedia.org/wiki/Mycoplasma 27th of February 2007). 
• Bio-safety & GLP: The practices and procedures (in accordance with the “Organization and 
Guidelines of the DF”) which if implemented are likely to prevent or greatly reduce the likelihood 
of the spread of a mycoplasma contamination. 
• Health and Safety Warnings: As dictated by the “Organization and Guidelines of the DF” and as 
laid out in the operational manuals specific to the equipment in use. 
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V) The adapted SOP (Standard Operating Procedure) for the DF 
 
a) Pre-screening cell (and potential mycoplasma) expansion and DNA 
isolation 
 
All arriving cells or cell lines have to be tested upon arrival (not compulsory for commercially 
purchased cells or cell lines that are routinely tested and certified mycoplasma-free by the supplier, 
e.g. ATCC, ECACC, DSMZ, …). 
For mycoplasma screening culture cells (if applicable in BSL2 incubator) for more than 1 week in your 
medium of choice. 
 
Extract DNA from 1-2*106 cells (in culture > 1 week after thawing) with NucleoSpin Blood acc. to 
manufacturers protocol (see Appendix B for the “Protocol at a glance rev04” page 2). 
Store eluted DNA acc. to NucleoSpin Blood recommendations (e.g. -20°C). 
 
Prepare and include all proper PCR controls to assure DNA integrity and PCR functionality, so you will 
have a minimum set of 4 PCR reactions to test 1 cell line as follows: 
1. DNA control: test DNA plus a set of genomic DNA control primers 
2. mycoplasma positive control: mycoplasma positive DNA sample plus mycoplasma primers 
3. mycoplasma negative control: mycoplasma negative DNA sample plus mycoplasma primers 
4. mycoplasma test: test DNA plus mycoplasma primers 
 
 
b) Screening by genomic PCR 
 
Reaction mix 
10x ThermoPol buffer (NEB, B9004S) 2 μl 
10x (2mM) dNTP 2 μl 
Primer 10μM each 1 + 1 = 2 μl 
H2O 12.8 μl 
Template 1 μl 
TaqPol (NEB, M0267L) 5000U/ml 0.2 μl (see Appendix C for TDS) 
Total volume 20μl 
 
 
Mycoplasma PCR 
95°C 5’ 
95°C 40’’ ⎫ 
60°C 40’’ ⎬ 30 ? 
72°C 40’’ ⎭ 
72°C 5’ 
4°C pause 
 
 
Primers tested 
5’ Myco_9 5’ CGC CTG AGT AGT ACG TTC GC 3’ 
3’ Myco_3 5’ GCG GTG TGT ACA AGA CCC GA 3’ 
product size: 500bp 
 
 
Primers not yet tested 
Primer fwd 5’ ACA CCA TGG GAG CTG GTA AT 3’ 
Primer rev 5’ CTT CAT CGA CTT TCA GAC CCA AGG CAT 3’ 
product size: ~300 – 400bp 
 
KB013 Myco_F1 5’ ACA CCA TGG GAG CTG GTA AT 3’ 
KB014 Myco_R1 5’ CTT CAT CGA CTT CCA GAC CCA AGG CAT 3’ 
product size: ~500bp (16S-23S rRNA spacer)
 
 
Run gel (usually 1% agarose) of PCR reaction(s). 
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c) Post-screening (if mycoplasma-positive) attempt to eliminate the 
contamination(s) 
 
For mycoplasma contaminated cells (if applicable in BSL2 incubator) try to cure with 25 μg/ml Plasmocin 
for 2 weeks in your medium of choice (see Appendix D for manufacturer’s protocol and TDS). 
Retest cells according to the SOP directly after Plasmocin treatment and another time more than 2 weeks 
after the end of the treatment to assure the cells remain mycoplasma-free. 
Use and freeze cells only after second mycoplasma-negative test. 
 
 
d) Concluding remarks and further suggestions 
 
Do not forget to clean up the liquid nitrogen from mycoplasma-positive freezing batches. 
Use Plasmocure (Invivogen) instead of Plasmocin (Invivogen). 
 
 
 
VI) References 
 
The reference papers to the mycoplasma detection method used in the Experimental Immunolgy Lab of 
the DF are 
• Hopert A et al.: J Immunol Methods. 1993 Aug 26;164(1):91-100. 
• Hopert A et al.: In Vitro Cell Dev Biol Anim. 1993 Oct;29A(10):819-21. 
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VII) Appendices 
a) Mycoplasma_wiki_20070227.pdf 
 
The reference was taken from http://en.wikipedia.org/wiki/Mycoplasma the 27th of February 2007 (note 
that only part of the wikipedia entry is printed below). 
 
Mycoplasma is a genus of bacteria that lack cell walls. They can be parasitic or saprophytic. Several 
species are pathogenic in humans, including M. pneumoniae, which is an important cause of pneumonia 
and other respiratory disorders, and M. genitalium, which is believed to be involved in pelvic inflammatory 
diseases. They are unaffected by antibiotics that target cell wall synthesis, such as penicillin. 
The genus Mycoplasma is one of several genera within the class Mollicutes. Mollicutes are bacteria which 
have small genomes, lack a cell wall and have low GC-content (18-40 mol%). There are over 100 
recognized species of the genus Mycoplasma. Their genome size ranges from 0.6 - 1.35 megabase-
pairs. Mollicutes are parasites or commensals of humans, other animals including insects, and plants; the 
genus Mycoplasma is by definition restricted to vertebrate hosts. Cholesterol is required for the growth of 
species of the genus Mycoplasma as well as certain other genera of mollicutes. Their optimum growth 
temperature is often the temperature of their host if warmbodied (e.g. 37 degrees Celsius in humans) or 
ambient temperature if the host is unable to regulate its own internal temperature. Analysis of 16S 
ribosomal RNA sequences as well as gene content strongly suggest that the mollicutes, including the 
mycoplasmas, are closely related to either the Lactobacillus or the Clostridium branch of the phylogenetic 
tree (Firmicutes sensu stricto). 
Mycoplasmas are often found in research laboratories as contaminants in cell culture and come from 
careless handling; due to their small size, they are difficult to detect under a microscope and their 
presence can skew experimental results. 
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b) NucleoSpin Blood (MN) GenomicDNABlood_R04 p2.pdf 
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c) Taq M0267_NEB.pdf 
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d) Plasmocin (Invivogen)_TDS.pdf 
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